Diagnosis and Treatment of Small Bowel Disorders by unknown
 Diagnosis and Treatm
ent of Sm
all Bow





of Small Bowel 
Disorders
Printed Edition of the Special Issue Published in 
Journal of Clinical Medicine
www.mdpi.com/journal/jcm
Anastasios Koulaouzidis and Wojciech Marlicz
Edited by
Diagnosis and Treatment of Small 
Bowel Disorders






MDPI • Basel • Beijing • Wuhan • Barcelona • Belgrade • Manchester • Tokyo • Cluj • Tianjin
Editors
Anastasios Koulaouzidis
The Royal Infirmary of Edinburgh
UK
Wojciech Marlicz






This is a reprint of articles from the Special Issue published online in the open access journal
Journal of Clinical Medicine (ISSN 2077-0383) (available at: https://www.mdpi.com/journal/jcm/
special issues/small bowel disorder).
For citation purposes, cite each article independently as indicated on the article page online and as
indicated below:




c© 2020 by the authors. Articles in this book are Open Access and distributed under the Creative
Commons Attribution (CC BY) license, which allows users to download, copy and build upon
published articles, as long as the author and publisher are properly credited, which ensures maximum
dissemination and a wider impact of our publications.
The book as a whole is distributed by MDPI under the terms and conditions of the Creative Commons
license CC BY-NC-ND.
Contents
About the Editors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . vii
Wojciech Marlicz and Anastasios Koulaouzidis
Small Bowel—Key Player in Health and Disease
Reprinted from: J. Clin. Med. 2019, 8, 1748, doi:10.3390/jcm8101748 . . . . . . . . . . . . . . . . . 1
Johanna K. Larsson, Konstantinos J. Dabos, Peter Höglund, Johan Bohr, Andreas Münch,
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Karolina Skonieczna-Żydecka, Mariusz Kaczmarczyk, Igor Łoniewski, Luis F. Lara,
Anastasios Koulaouzidis, Agata Misera, Dominika Maciejewska and Wojciech Marlicz
A Systematic Review, Meta-Analysis, and Meta-Regression Evaluating the Efficacy and
Mechanisms of Action of Probiotics and Synbiotics in the Prevention of Surgical Site Infections
and Surgery-Related Complications
Reprinted from: J. Clin. Med. 2018, 7, 556, doi:10.3390/jcm7120556 . . . . . . . . . . . . . . . . . 39
Masanao Nakamura, Takeshi Yamamura, Keiko Maeda, Tsunaki Sawada, 
Yasuyuki Mizutani, Takuya Ishikawa, Kazuhiro Furukawa, Eizaburo Ohno, Hiroki 
Kawashima, Ryoji Miyahara, Anastasios Koulaouzidis, Yoshiki Hirooka 
and the Nagoya University Crohn’s Disease Study Group
Validity of Capsule Endoscopy in Monitoring Therapeutic Interventions in Patients with 
Crohn’s Disease
Reprinted from: J. Clin. Med. 2018, 7, 311, doi:10.3390/jcm7100311 . . . . . . . . . . . . . . . . . 67
Alka Singh, Atreyi Pramanik, Pragyan Acharya and Govind K. Makharia
Non-Invasive Biomarkers for Celiac Disease
Reprinted from: J. Clin. Med. 2019, 8, 885, doi:10.3390/jcm8060885 . . . . . . . . . . . . . . . . . 79
Samuel Ortega, Himar Fabelo, Dimitris K. Iakovidis, Anastasios Koulaouzidis 
and Gustavo M. Callico
Use of Hyperspectral/Multispectral Imaging in Gastroenterology. Shedding
Some–Different–Light into the Dark
Reprinted from: J. Clin. Med. 2019, 8, 36, doi:10.3390/jcm8010036 . . . . . . . . . . . . . . . . . . 97
v
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Over the last two decades, remarkable progress has been made in understanding the etiology
and pathophysiology of diseases. New discoveries emphasize the importance of the small bowel
(SB) ‘ecosystem’ in the pathogenesis of acute and chronic illness alike. Emerging factors, such as
microbiome, stem and progenitor cells, innate intestinal immunity, and the enteric nervous system,
along with mucosal and endothelial barriers, play a key role in the development of gastrointestinal (GI)
and extra-GI diseases. The results of other studies point also towards a link between the digestive tract
and common non-communicable diseases, such as obesity and cancer. These discoveries unravel novel
dimensions of uncertainty in the area of clinical decision-making motivating researchers to search for
novel diagnostic and therapeutic solutions.
Recent studies unravel the role of the poorly-understood complexity of the SB. Insights into
its critical physiologic and pathophysiologic role in metabolic homeostasis and its potential role as
a driver of obesity, insulin resistance, and subsequent type 2 diabetes mellitus (T2DM) have been
revealed [1]. For example, bypassing the proximal small intestine by means of bariatric surgery results
in a significant metabolic benefit to an individual undergoing such a procedure. Moreover, endoscopic
procedures aimed at placing devices separating luminal contents from the duodenal mucosa result in
modest weight loss and improvement in glucose homeostasis [1].
Another endoscopic treatment which aims at resurfacing duodenal mucosa (DMR, duodenal
mucosal resurfacing), leads to improvement in glycemia and insulin resistance in patients with
T2DM [2]. It is not surprising when we recall that SB endocrine cells secrete glycemia-regulating
incretin hormones (e.g., glucagon-like peptide, GLP-1), and this process is dependent on food content
in the intestinal lumen. Moreover, bile acids with various targets in the liver and small intestine (e.g.,
farnesoid receptor, FXR) together with a plethora of other small signaling molecules act in concert in
regulating metabolic and digestive GI function.
The human digestive tract and enteric nervous system (ENS) communicate with the central nervous
system (CNS) through the gut-brain axis (GBA). This bidirectional communication involves diverse
neural networks through the X cranial vagal nerve—dorsal roots of the sympathetic/ parasympathetic
nervous system. Important roles in the regulation of the gut-brain axis are played by: (i) the
hypothalamus-pituitary-adrenal axis (HPA), (ii) the stress hormones (cortisol), (iii) the short-chain fatty
acids (SCFAs), and (iv) the gut microbiota. The intestinal barrier, another important part of GBA, is
composed of: (i) goblet cells derived mucus, (ii) microbiota, (iii) epithelial cells, (iv) endothelial cells,
(v) lymphatic vessels, and v) enterocytes’ tight cellular junctions. Of interest, the structure and function
of the intestinal barrier resemble that of the blood-brain barrier (BBB). The gut-brain communication is
mediated via blood, portal/hepatic circulation, and the bone marrow [3].
Recently, it has been described that the alterations of the intestinal barrier play a crucial role in the
pathology of several human inflammatory and autoimmune diseases. Mohanan et al. documented
the crucial role of the C1orf106 inflammatory bowel disease (IBD) susceptibility gene in stabilizing
intestinal barrier function and intestinal inflammation [4]. Manfredo Vieira et al. evidenced the role of
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pathobionts in the process of intestinal barrier alterations, which were followed by their translocation to
lymph nodes and the hepatic portal system, triggering systemic lupus erythematosus (SLE) [5]. Thaiss
et al. reported that hyperglycemia leads to disruption of the intestinal barrier followed by intestinal
inflammation and systemic infection [6]. Spadoni et al. recently documented that the presence of
the gut-vascular barrier (GVB) in the small intestine controls the dissemination of bacteria into the
bloodstream [7]. The authors reported a decrease of the wnt/beta catenin-inducible gene Axin2 (a
marker of stem cell renewal) in gut endothelium under the presence of Salmonella typhimirum in the
SB. The GVB was modified in patients with coeliac disease (CD) with altered serum transaminases,
which suggests that GVB deterioration may be responsible for liver damage in CD patients [7]. It has
been shown that disruption of epithelial and vascular barriers in the intestine were early events in
non-alcoholic steatohepatitis (NASH), and GVB leakage marker could be identified in colonic biopsies
in patients with NASH [8]. Of importance, SB epithelial and vascular barriers are FXR-controlled, which
opens avenues to clinical trials aimed at investigation of novel FXR-agonists as future therapeutics [9].
Of interest, intestinal barriers could be monitored in vivo with the aid of confocal laser endomicroscopy
(CLE) [10,11].
Therefore, the SB is considered a key player in metabolic disease development [12], including
diabetes mellitus and NASH, and other diet-related disorders such as coeliac and non-coeliac
enteropathies. Another major field is drug metabolism and its interaction with small bowel
microbiome [13]. Moreover, the emergence of gut-brain, gut-liver, and gut-blood barriers point
towards the important role of the SB in the pathogenesis of previously unthought and GI-unrelated
conditions such as neurodegenerative and cardiovascular disease [14,15]. The SB remains an organ
that is difficult to fully access and assess and accurate diagnosis often poses a clinical challenge.
Undoubtedly, the therapeutic potential remains untapped. Therefore, it is now time to direct more
of our interest towards the SB and unravel the interplay between the SB and other GI and non-GI
related diseases.
In this Journal of Clinical Medicine Special Issue, “Diagnosis and Treatment of Small Bowel
Disorders”, several groups of investigators contributed their knowledge to the field of SB research by
presenting original papers and reviews.
Enaud et al. [16] describe original observations by utilizing next-generation sequencing (NGS),
that intestinal inflammation in children with Cystic Fibrosis (CF) was associated with alterations of
microbiota similar to those observed in Crohn’s disease (CrDs). Authors for the first time applied novel
CrDs Microbial-Dysbiosis index in CF patients and pointed towards the importance of gut-lung axis
in CF prognosis [16]. Of interest, intestinal inflammation was associated with previous intravenous
antibiotic courses for CF [13]. This observation is important as global awareness of antibiotic resistance
rises. Nakamura et al. [17] sought to evaluate the validity of using capsule endoscopy (CE) to monitor
the effect of medical treatment on SB mucosal healing in post-operative CrDs patients, regardless of the
presence of clinical symptoms. Although the significance of endoscopic monitoring has been widely
accepted in CrDs, to date, only a few studies looked at the validity and effectiveness of escalating
treatment for patients in clinical remission but with endoscopically visible active mucosal lesion.
The authors demonstrated that CrDs patients in clinical remission with ongoing intestinal inflammation
at the time of the CE could benefit from additional treatment. This study motivates physicians to
optimize treatment plans for asymptomatic CD patients.
Several characteristics of SB lesions (e.g., mucosal disruption, bleeding, irregular surface, polypoid
appearance, color, delayed passage, white villi, and invagination) have been described to better predict
SB lesions, such as intestinal bulges, masses, and tumors. The lack of precise features in characterizing
these lesions places a limitation on the accuracy of CE diagnosis. Therefore, Min et al. [18] in their
retrospective study, evaluated the utility of an additional morphologic criterion, the mucosal protrusion
angle (MPA), which was defined as the angle between a SB protruding lesion and its surrounding
mucosa. The authors documented that MPA was a simple and useful tool for differentiating between
2
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intestinal true masses and non-significant bulges [18]. Their observation creates a useful extra tool for
those who are faced with the question of ‘mass or bulge?’
SB microbiota alterations have also been implicated in the pathogenesis of surgical site infections
(SSIs) and surgery-related complications (SRCs). Skonieczna-Żydecka et al. [19] conducted a systematic
review with meta-analysis and meta-regression of randomized clinical trials investigating the efficacy
of probiotics and synbiotics to counteract SSIs and SRCs in patients under various surgical treatments.
The authors aimed to determine the mechanisms behind probiotic/synbiotic action. Their meta-analysis
revealed that probiotics/synbiotics administration prior and at a time of major abdominal surgery, leads
to a reduction in the incidence of SSIs and SRCs (e.g., abdominal distension, diarrhea, pneumonia, sepsis,
urinary tract infection, postoperative pyrexia). Furthermore, probiotics/synbiotics were associated
with shortening of the duration of antibiotic therapy and hospital stay. Based on current evidence, the
action of probiotics/synbiotics in surgical patients seems to be exerted via modulation of gut-immune
response and production of short-chain fatty acids (SCFAs) [19].
Included also in this special issue, Singh et al. [20] comprehensively reviewed the pros and cons of
biomarkers in coeliac disease and summarized the current status of coeliac disease screening, diagnosis,
and monitoring. The review could guide clinicians in diagnosis and monitoring of patients with
coeliac disease. As biomarkers allow for smart targeted-screening, similarly imaging spectroscopy (a
combination of digital imaging and spectroscopy, also known as hyperspectral/multispectral (HS/MS)
imaging (HSI/MSI) technology) allows for smart tissue visualization beyond the limitations of the
human eye. HSI has been utilized for various research purposes including: (i) food quality inspection,
(ii) optimization of the recycling process, (iii) art painting renovations, (iv) geology and minerals
inspection, (v) soil evaluation and (vi) plant response to stress. HSI has also been evolving in the field
of medical research in gastroenterology, pathology, and surgery. This modality was used to generate
alternative visualization of tissues, abdominal organ differentiation, identification of surgical site
resection, and abdominal ischemia to name a few. Ortega et al. [21] in their thorough review provided
a detailed summary of the most relevant research work in the field of gastroenterology using HSI.
Last but not least, Skonieczna-Żydecka et al. [22] in a narrative review published in this issue of
Journal of Clinical Medicine, discussed involvements of GBA deregulation in the origin of brain-gut
disorders. The authors hypothesized that stem cell-host microbiome cross-talk was potentially involved
in GBA disorders. Interestingly, patients with inflammatory bowel disease (IBD) have an elevated
risk of mental illness, and depression increases the risk of IBD. Of key interest, are observations
that multiple drugs are known to induce metabolic malfunctions, possibly through alterations of SB
milieu. These alterations result in body weight gain, metabolic disturbances, and suppression of
metabolic resting rate. The authors in their comprehensive review presented the current state of the art
knowledge of the role of GBA in GI and psychiatric comorbidities. The current evidence supports
the notion that an injury to the intestinal mucosa can result in significant, though delayed, metabolic
consequences that may seriously affect the health of an individual. Future investigations [23] into the
pathophysiology of host-microbe interactions should focus on the small bowel [24,25], which is still
relatively inaccessible. Therefore, the research is challenging but necessary to pave the way to new
findings and solutions in the clinical area of the small bowel [26] and beyond [27].
Dr Marlicz and Dr Koulaouzidis are Guest Editors of this Special Issue of the Journal of
Clinical Medicine (ISSN 2077-03830), which belongs to the journal’s section Gastroenterology and
Hepato-Pancreato-Biliary Medicine.
Conflicts of Interest: The authors declare that there is no conflict of interest.
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Abstract: Data on malignancy in patients with collagenous colitis (CC) is scarce. We aimed to determine
the incidence of cancers in patients with CC. In a two-stages, observational study, data on cancers in
patients diagnosed with CC during 2000–2015, were collected from two cohorts. The risk was calculated
according to the age-standardized rate for the first cohort and according to the standardized incidence
ratio for the second cohort. The first cohort comprised 738 patients (394 from Scotland and 344 from
Sweden; mean age 71 ± 11 and 66 ± 13 years, respectively). The incidence rates for lung cancer (RR 3.9,
p = 0.001), bladder cancer (RR 9.2, p = 0.019), and non-melanoma skin cancer (NMSC) (RR 15, p = 0.001)
were increased. As the majority of NMSC cases (15/16) came from Sweden, a second Swedish cohort,
comprising 1141 patients (863 women, mean age 65 years, range 20–95 years) was collected. There were
93 cancer cases (besides NMSC). The risk for colon cancer was decreased (SIR 0.23, p= 0.0087). The risk
for cutaneous squamous cell carcinoma was instead markedly increased (SIR 3.27, p = 0.001).
Keywords: colon cancer; cancer risk; collagenous colitis; lung cancer; microscopic colitis; skin cancer;
squamous cell carcinoma
1. Introduction
Microscopic colitis (MC) is an inflammatory disorder of the colon that causes chronic, watery and
non-bloody diarrhoea, occasionally associated with abdominal pain and weight loss. With a predilection
for those ≥60 years of age and for females, MC has an incidence rate of approximately 10/100.000 per
year [1–3]. Macroscopic findings are rare and the diagnosis is confirmed through histopathology [4–6].
MC comprises two main histologic subtypes; collagenous colitis (CC) and lymphocytic colitis (LC).
Histopathological features of CC include a continuous, thickened sub-epithelial fibrous band (>10 μm)
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and associated chronic mucosal inflammation. The collagen band contains entrapped capillaries,
red blood cells, as well as inflammatory cells. Moreover, damaged epithelial cells appear flattened,
mucin-depleted, and irregularly-oriented. Focally, small strips of surface epithelium may lift-off the
basement membrane [7]. Patients with CC are considered to have a more symptomatic and long-lasting
disease course than those with LC [8].
Chronic inflammation is considered a risk factor for cancer development. Moreover, chronic
inflammation may result in cancer development in sites other than the affected organ/system.
For instance, the risk of lymphoma in rheumatoid arthritis (RA) is increased by 60% [9]. In patients
with inflammatory bowel disease (IBD), there is an increased risk of colorectal cancer (CRC), at least in
some subgroups, as well as extra-intestinal cancers such as haematological, bladder, lung as well as skin
cancers [10–12]. Patients with coeliac disease have a reported increased risk of non-Hodgkin lymphoma,
small-bowel cancer, CRC and basal cell carcinoma (BCC) [13]. Helicobacter pylori itself contributes to
many neoplasias, but studies have shown that the inflammatory response per se contributes to the
carcinogenesis as well [14].
Data on the incidence of metachronous cancer(s) in MC is scarce. Although the inflammation is
limited as compared to classical IBD the condition may be active for several years; furthermore, it often
affects elderly individuals who have already an increased cancer risk. Additionally, many patients
with CC smoke [15]. Chan et al described an increased risk of lung cancer in a small cohort of patients
with CC with a mean follow-up time of 7 years. The study included 117 patients, and no cases of
CRC were described [16]. A negative association has actually been suggested between CRC and MC
(including both CC and lymphocytic colitis) in a cohort comprising 647 patients with MC and a mean
follow-up time of five years. Twelve MC patients had CRC compared to 27 in a control group of
similar size (p = 0.015) [17]. Therefore, the aim of the present study was to determine the incidence of
metachronous cancer in patients with CC.
2. Patients and Methods
The investigation was carried out as a two-stage, observational, international, multicentre,
cohort-study, comprising two sizeable cohorts of patients diagnosed with CC. See Figure 1.
 
Figure 1. Participating centres: Series 1: 1 = Edinburgh, Scotland, 2 =Malmö; Series 2: 3 = Linköping,
4 = Örebro, 5 = Skåne region.
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2.1. First Stage—Scotland and Sweden
In an international, retrospective, two-centre observational study; data on extra-colonic cancer
in patients with CC were collected for a 14-year period (2000–2013) from Edinburgh, Scotland and
Malmö, Sweden. The CC diagnosis was set according to established criteria i.e., symptoms of
chronic, non-bloody diarrhoea and histopathological findings of thickened sub-epithelial collagen layer
≥10 μm, associated with chronic inflammation in the lamina propria and with an increased number of
intraepithelial lymphocytes [18]. Data were obtained from the pathology department, Edinburgh and
Malmö with a catchment area of 750,000 and 320,000 inhabitants, respectively. The records of those
with CC were manually searched for data on metachronous, extra-colonic cancers.
2.2. Second Stage—Sweden
Due to an unexpectedly skewed distribution of cancer cases in the first stage of the study we
decided to re-do the study and focus on Swedish data. Patients with CC in three different regions
(Skåne, Linköping and Örebro) were included. In Sweden, all patients that are diagnosed with CC
according to the established criteria are registered at the Departments of Pathology and are given a
specific code number. All specimens taken during colonoscopy in the three regions are regularly sent
to specific Pathology Departments. All patients with a CC diagnosis from 2000 in Skåne and Örebro
and from 2008 in Linköping until the end of 2015 were included.
For each patient with CC, the follow-up period began at the time of CC diagnosis and continued
until whichever of the following occurred first: death or the end of the observation period (31st December,
2015). Patients were not excluded after their first diagnosis of cancer, since we wanted to examine
incidence risk for all cancers developed during follow up. The CC cohort was linked up with the




Person-years at risk was calculated according to age-specific categories up to 85 years. The standard
error (Se) was calculated using the Poisson approximation. Confidence interval (CI) of the age-standardised
rate (ASR) was compared to public data, available from UK´s National Cancer Intelligence Network.
The relative risk (RR) for ASR was calculated and compared to ASR in Lothian region, Scotland.
The standardised cancer incidence rates (IR) were also compared to the ones of Lothian under the
assumption that populations at the same latitude share the same IR.
2.3.2. Second Stage
Person-years at risk were calculated by gender and 5-year age groups, separately for the 3
geographical areas (Skåne, Linköping, and Örebro). Standardized incidence ratios (SIR) were calculated
for each of the reported cancers. Because patients in this cohort came from three different Swedish
regions and in light of the known national variations of cancer incidence, the expected numbers of
cancers were calculated by pooling the patients and linking each area to existing cancer registries.
The expected numbers of cases of cancers and specific cancer types were calculated by multiplying
the number of person-years for each gender, age and area group by the corresponding specific cancer
incidence rates in the respective areas. SIR and their 95% CI were calculated assuming that the observed
number of cases followed a Poisson distribution. Mid-P exact test was applied and values below
0.05 were considered significant. For non-melanoma skin cancer (NMSC), both BCC and cutaneous
squamous cell carcinoma (cuSCC) that can occur several times in one individual, the number of
tumours was recorded—instead of individual cases—in both the CC cohort and in the control group.
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This study was approved by the institutional review board at Lund University (The local Ethics
Committee at Lund University, date: 6th November 2013; decision LU 2013/650 and date: 27th October,
2016; decision LU 2016/788) and Lothian NHS. Since it was a retrospective registry study the Ethical
Board approved that written informed consent was not necessary to obtain prior to the collection of
data. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki as
reflected in a priori approval by the institution’s human research committee.
3. Results
3.1. First Stage
The demographics of the first cohort can be seen in Table 1. Of the 738 included, 71 (50 women
and 21 men) were affected by some form of extra-colonic, metachronous malignancy following the
diagnosis of CC. The remainder of this cohort (n = 667) did not develop any extra-colonic cancer
during the follow-up period. The average follow-up duration was 7 years (range 2–15 years), while the
average time interval between CC and cancer diagnosis was 3 years (range 0–11 years). Of these
71 cases, 14 developed any cancer during the first year, 25 during the following two years and 32 from
the third year.
Table 1. Characteristics of the collagenous colitis (CC)-cohort in Scotland and Sweden (Series 1).
Edinburgh Malmö Total
N 394 344 738
Age, median (IQR) 68 (57–76) 69 (59–77) 68 (58–77)
% women (n) 68% (268) 83% (285) 75% (553)
IQR = interquartile range
The RR for all cancers, lung, bladder cancer and NMSC, as well as the ASR in patients with
CC were higher compared to those of the general population. The RR for lung cancer was 3.88
(CI: 1.62–9.31), for bladder cancer 9.23 (CI: 1.14–75.03) and for NMSC 14.96 (CI: 2.57–87.08). See Table 2.
Table 2. Observed and expected cancers in the Scottish/Swedish cohort (series 1). RR, relative risk.
Cancer Type Cases Exp RR P-Value
Skin (NMSC) 16 1 15.0 0.001
Bladder 6 1 9.2 0.019
Lung 18 2 3.9 0.001
NMSC = non-melanoma skin cancer.
The cases with bladder and lung cancer were evenly distributed, but in contrast 15/16 cases with
NMSC were addressed from the Malmö cohort. Because of this a decision was taken to proceed to
a second stage by including more regions in Sweden. Furthermore, in most countries the number
of NMSC is difficult to determine because BCC and cuSCC cases are not reported to national cancer
registries, or they are reported as one heterogeneous group [19]. However, in Sweden these cancer
types are reported separately and consequently it is possible to obtain data on the occurrence of BCC
and cuSCC.
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3.2. Second Stage
In this stage, a total of 1141 patients with diagnosis of CC were identified. It should be noted that
344 out of those from Skåne were included also in stage one. The characteristics of the patients are
shown in Table 3. The average follow-up duration was 8 years (range 2–15 years), while the average time
interval between CC and cancer diagnosis was 4 years (range 0–14 years). Of the 93 solid cancers 17
were diagnosed during the first year, 25 during the following two years and 51 thereafter. The expected
and observed cancer cases are presented in Tables 4 and 5. The risk of lung cancer was increased in
Skåne (SIR 1.85 CI: 1.053–3.029, p = 0.034) but since there were no other cases of lung cancer in the
other two Swedish regions, this did not become significant in the whole group. The total number of
cancer cases besides NMSC was 98. However, five rare cancer cases were considered not applicable
for data calculation and thus excluded, leaving 93 cancer cases (61 women and 32 men). The total
number of NMSC was 140. The mean time interval between CC diagnosis and cuSCC was 5.4 years,
range 0.6–12.1 years. Of the 46 cases of cuSCC, four developed cuSCC during the first year, eight during
the following two years, and 34 after three years or more.
Table 3. Characteristics of the CC-cohort Sweden, three regions (Series 2).
Linköping Örebro Skåne Total
N 130 133 878 1141
Age, median (IQR) 66 (57–75) 64 (53–74) 68 (58–76) 67 (57–76)
% women (n) 75% (98) 84% (112) 74% (653) 76% (863)
IQR = interquartile range
Table 4. Observed and expected cancers in the Swedish cohort, divided into Skåne, Linköping and
Örebro (Series 2).
Cancer site Skåne Linköping Örebro
obs exp SIR obs exp SIR obs exp SIR
Eye 1 0.13 7.64 0 0.023 0.00 0 0.011 0.00
Oesophagus 3 0.65 4.60 0 0.066 0.00 0 0.068 0.00
Cervix 2 0.46 4.33 0 0.07 0.00 0 0.079 0.00
CuSCC 36 11.58 3.11 6 1.44 4.18 4 1.060 3.78
Vulva 1 0.29 3.46 0 0.033 0.00 0 0.049 0.00
CNS 2 1.29 1.55 2 0.19 10.30 0 0.17 0.00
r 3 1.3 2.31 1 0.19 5.14 0 0.20 0.00
Stomach 1 1.27 0.79 1 0.14 7.14 1 0.14 7.27
Bladder/Ureter 8 4.29 1.87 0 0.5 0.00 2 0.38 5.30
Rectal/Anus 1 3.20 0.31 4 0.39 10.19 2 0.44 4.55
Pancreas 3 1.50 2.00 0 0.25 0.00 0 0.21 0.00
Lung 14 7.57 1.85 0 0.89 0.00 0 0.84 0.00
Prostate 8 7.56 1.06 1 1.56 0.64 1 0.56 1.78
Leukemia/Myeloma 3 2.93 1.02 0 0.37 0.00 1 0.40 2.52
Melanoma 3 3.92 0.76 2 0.63 3.18 0 0.55 0.00
BCC 83 82.08 1.01 7 7.62 0.92 4 6.19 0.65
Breast 11 17.61 0.62 3 1.89 1.59 2 1.98 1.01
r 1 2.47 0.40 0 0.30 0.00 1 0.26 3.78
Uterus 2 2.76 0.72 0 0.38 0.00 0 0.52 0.00
Colon 2 7.11 0.28 0 0.84 0.00 0 0.86 0.00
SIR = Standard Incidence Ratio, BCC = Basal cell carcinoma, cuSCC = Cutaneous squamous cell carcinoma.
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Table 5. Observed and expected cancers in the whole Swedish cohort in a forest plot (Series 2).
BCC = Basal cell carcinoma, cuSCC = Cutaneous squamous cell carcinoma.
4. Discussion
This is the largest study published to date on the risk of metachronous malignancies in patients
diagnosed with CC. In the first stage, it was noted that the risk for lung and bladder cancer was
increased in patients with CC diagnosis. Furthermore, the risk of NMSC was also increased in this
cohort. In the second stage of this observational, multicentre study comprising a large Swedish cohort
we could confirm the decreased risk of colon cancer in patients with CC, as reported in previous
studies [16,17]. However, previous studies either included prevalent cases of CRC (15) or comprised a
fairly limited number of CC-patients (14). Analysis of the current large cohort from three counties in
Sweden indicated that the risk of getting colon cancer was reduced at least four times (from 8.8 expected
cases to two observed). Since we do not have information about previous colonoscopies in this elderly
population with gastrointestinal complaints it cannot be excluded that this reduced risk hypothetically
could be due to pre-emptive polypectomies preceding the diagnostic endoscopy. However, in patients
with longstanding albeit low-grade, inflammatory response in the colon, one would instead expect to
observe an increased risk of colon cancer. Nevertheless, not only the inflammation is modest, but it
may also be protective. For instance, frequent watery diarrhoea reduces the transit time and likely any
potential impact from toxic agents. Yen et al. suggest that elevated intraepithelial lymphocytes in the
colonic mucosa in patients with MC may have a protective function against carcinogenesis through
recruiting delta-gamma T-cells that kill cells undergoing DNA-damage or cell stress [17].
Data from the second series revealed a more than three-fold increase in cuSCC in patients with CC.
Except UV-light exposure and immunosuppressive treatment related to organ transplantation, little is
known about risk factors contributing to cuSCC [19–21]. Evidence that glucocorticoids enhance the risk
of cuSCC is limited, but has been described previously [22,23]. The incidence of NMSC (both cuSCC
and BCC) is increased in patients with IBD, but likely related to the exposure of immunosuppressive
treatment (thiopurines and biologics) [24]. However, Singh et al. also described an increased risk
of BCC in men with Crohn’s disease not treated with immunosuppression [25]. Therefore, not only
immunosuppressive treatment is related to an elevated risk of NMSC but also the inflammation per se,
probably as a result of dysregulation of the immune system. In CC, Günaltay et al have described a
decreased production of IL-37 in such patients, indicating a disturbed immune response [26,27]. Thus,
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the elevated risk of cuSCC in CC may be related to a malfunctioning immune system caused by the
disease itself, medication or other not yet known procarcinogenic factors.
The incidence rate of lung cancer was increased in the first stage cohort but not in the second.
However, the incidence was increased also in the second series in Skåne but not for the whole Swedish
cohort. In Skåne 878 out of the 1141 cases with CC were identified and 14 cases with lung cancer was
found (7.57 expected). In contrast to this large cohort the expected incidence of lung cancer in the cities
Örebro and Linköping (based on 150,000 inhabitants in each location) were one case in each location.
Consequently, the observed incidence with no cases in these two minor cities must be interpreted with
caution. The incidence rate in Skåne with around 1.3 million inhabitants is of course more reliable.
The risk of urinary bladder and/or ureteric cancer was increased in the first cohort and showed a
positive trend in the second, something that strengthens this observation. The association between
CC and smoking habits is already well described [15]. Smoking is related to cancer in both lung and
bladder which is probably the reason why these incidence rates are elevated in our CC cohort [28,29].
The risk of cancer in oesophagus also showed a positive trend in the second series. Risk factors of
oesophagus cancer are among others, smoking, alcohol, hot liquids and HPV-infection [30]. As can
be seen, some of the risk factors are shared with CC such as smoking and alcohol [31]. Furthermore,
oesophageal cancer is often of squamous cell origin just as in the skin. In this study we did not get
detailed information if the oesophagus cancer cases were of squamous cell or adenomatous origin.
However, in view of the low number of cases with oesophageal or bladder cancer, despite a fairly
large number of CC patients, a definitive conclusion cannot be drawn regarding putative relationship
between CC and cancer in oesophagus or bladder.
Some strengths and limitations should be noted; this is the largest study to date concerning the risk
of metachronous cancer in patients with a previous diagnosis of CC. In the second cohort, 1141 patients
could be included. The studied regions are well defined, and patients are referred to specific hospitals
within these regions. All common cancers types in the western world were represented in the present
study. In other words, no common cancer type was totally absent. The control group in the Swedish
cohort consisted of all cancer cases in the same regions as our cohorts, adjusted for year of onset,
gender and age group. This procedure is necessary in order to obtain more reliable results. Furthermore,
the cancer registry at the National Board of Health and Welfare covers more than 96% of the cancer
cases in Sweden [32]. Since we wanted to investigate if CC can be considered as a risk factor for
cancer, we included only incident cases of cancer diagnosed after the CC diagnosis. The outcome of
cancer was assessed from day one after the CC-diagnosis. This may cause a risk of including prevalent
cancers, but since we know that the time lapse between disease onset and diagnosis of CC may be
long, we believe that these factors level out. A majority of the cancers was diagnosed after more than
three years making detection bias less probable.
This study also has some limitations that merit consideration. First, nationwide registers do not
contain information about lifestyle habits like smoking, alcohol consumption, family history, exercise or
other possible confounding factors. We neither had detailed data of disease severity nor medication in
our study population. Information about sun exposure and consequently also about the location of
the skin tumours would have been valuable. Furthermore, the associations found are not necessarily
causal; one disease could lead to another or a not yet known factor besides the studied could lead to
both CC and cancer. The retrospective design also limits the conclusions that can be drawn, although a
study with a prospective design would have been difficult to finalize.
Consequently, this study could confirm the previously described negative association between CC
and colon cancer, an observation of unknown cause. Even though significance was not achieved for
cancers in lung, bladder and oesophagus there was a trend indicating that there could be a correlation
anyway. A new, so far, unknown association between CC and cuSCC has also been revealed. There are
reports about an increase incidence of BCC in coeliac disease and of NMSC in IBD. Consequently,
we have to be extra cautious when examining patients with gastrointestinal inflammation in order to
reveal any incident skin cancers.
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Abstract: Cystic fibrosis (CF) is a systemic genetic disease that leads to pulmonary and digestive
disorders. In the majority of CF patients, the intestine is the site of chronic inflammation and
microbiota disturbances. The link between gut inflammation and microbiota dysbiosis is still poorly
understood. The main objective of this study was to assess gut microbiota composition in CF children
depending on their intestinal inflammation. We collected fecal samples from 20 children with CF.
Fecal calprotectin levels were measured and fecal microbiota was analyzed by 16S rRNA sequencing.
We observed intestinal inflammation was associated with microbiota disturbances characterized
mainly by increased abundances of Staphylococcus, Streptococcus, and Veillonella dispar, along with
decreased abundances of Bacteroides, Bifidobacterium adolescentis, and Faecalibacterium prausnitzii.
Those changes exhibited similarities with that of Crohn’s disease (CD), as evidenced by the elevated
CD Microbial-Dysbiosis index that we applied for the first time in CF. Furthermore, the significant
over-representation of Streptococcus in children with intestinal inflammation appears to be specific
to CF and raises the issue of gut–lung axis involvement. Taken together, our results provide new
arguments to link gut microbiota and intestinal inflammation in CF and suggest the key role of the
gut–lung axis in the CF evolution.
J. Clin. Med. 2019, 8, 645; doi:10.3390/jcm8050645 www.mdpi.com/journal/jcm17
J. Clin. Med. 2019, 8, 645
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1. Introduction
Cystic fibrosis (CF) is a genetic disorder caused by mutations in the Cystic Fibrosis Transmembrane
Conductance Regulator gene (CFTR), leading to viscous secretions accumulating on epithelial surfaces
in both the lungs and the gastrointestinal tract [1]. In recent decades, improved patient care in
the management of pulmonary disease has led to an older CF population with new complications,
including intestinal disorders [2]. However, some CF gastrointestinal complications such as chronic
inflammation, gut microbiota disruption, and increased risk of gastrointestinal malignancies remain
poorly understood [3–6].
Gut microbiota has been recently shown to be associated with the human health and diseases
including CF [7]. Its composition is clearly different in CF patients, with a decrease in specific
bacteria such as Bifidobacterium spp., Eubacterium spp., Clostridium spp., and Faecalibacterium prausnitzii,
and the emergence of opportunistic pro-inflammatory bacteria such as Escherichia coli and Eubacterium
biforme [4,8–11]. In CF, this disturbed microbiota, usually named “dysbiosis”, stems from multiple
factors including hydro electrolytic disruptions of the intestinal secretions, slower gastrointestinal
transit time [12], drug uses, impaired innate immunity in the gut [13,14], and hypercaloric diet [15,16],
and appears to be correlated with the severity of the CFTR mutations [11].
Furthermore, chronic intestinal inflammation is present in the majority of CF patients, even in the
absence of digestive symptoms [17]. Inflammation is characterized by an infiltrate of the lamina propria
by mononuclear cells expressing inflammation markers (such as ICAM-1, CD-25, IL-2, IFNγ) associated
with Crohn’s-like endoscopic lesions of the mucosa (edema, erythema, or ulcerations) [3,18,19].
To better assess intestinal inflammation, Bruzzese et al. have adapted in CF the fecal calprotectin
measurement, previously used as a non-invasive digestive inflammation biomarker in inflammatory
bowel disease (IBD) [20]. Fecal calprotectin level is significantly higher in CF patients compared to
healthy subjects [20–22].
The pathophysiology of intestinal inflammation is still unclear in CF. Very few studies have
focused on the link between intestinal microbiota composition and inflammation in CF, while this link
is well documented in IBD [23]. To our knowledge, only one study using next-generation sequencing
(NGS) of microbiota was dedicated to this issue and showed a positive correlation between E. coli
abundance and intestinal inflammation in CF children [24]. A recent study focused on the evolution
of intestinal microbiota and inflammation in CF patients treated with ivacaftor, a CFTR-modifying
therapy. An absence of intestinal inflammation was significantly associated with an increased
Akkermansia abundance [25].
As previous studies focused on mucosal inflammation and microbiota in the gastrointestinal tract
of CF patients were highly limited [22,24], our aim was to investigate links between gut microbiome
and intestinal inflammation using NGS approach plus fecal calprotectin measurements, in a pediatric
CF population.
2. Materials and Methods
2.1. Study Design, Sample Collection, and Ethics Statement
Our observational prospective study took place at the Children’s Hospital of Bordeaux from
November 2015 to May 2018. The inclusion criteria were patient over 3 years of age with
well-documented CF associated with exocrine pancreatic insufficiency. The exclusion criteria were an
ongoing enrollment in therapeutic protocols, antibiotics, or probiotics courses during the two months
prior the inclusion or patients after organ transplantation.
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At the inclusion visit patients’ stool samples were collected and stored at −80 ◦C until use.
In parallel, patient clinical status was documented using demographic data, nutritional status
assessed by the Body Mass Index expressed as percent of the standard normalized by age (%BMI),
respiratory capacity measured by Forced Expiratory Volume in 1s expressed as percent predicted
(%FEV1), and microbial pulmonary colonization along with previous intravenous (IV), oral, or inhaled
antibiotic courses.
In addition, questionnaires focused on standardized assessments of quality of life (PedsQLTM 4.0
Generic Core Scale) and of digestive symptoms (PedsQLTM—Gastrointestinal Symptoms Scales 3.0)
were provided at no charge via the ePROVIDE™ online distribution process and filled for each child.
These questionnaires, validated for different age groups, include a self-assessment and a parental
evaluation. A score negatively correlated with the presence of symptoms was assigned from 0 to
100 to each item based on the collected responses. An average score was calculated for the main
questionnaire sections.
Finally, long-term evolution based on clinical monitoring two years after inclusion was recorded
for each child, based on %BMI and %FEV1 values at the follow-up visit, plus the corresponding
variations (estimated by the difference between %BMI or %FEV1 measures at two years and inclusion),
and the number of antibiotic courses during this period (IV, oral, inhaled, or any mode of administration
combined) (Table 1 and Supplementary Table S1).
Table 1. Characteristics of patients with and without intestinal inflammation.
No Inflammatory Group Inflammatory Group
Patient 13 (65%) 7 (35%)
Fecal calprotectin level 122 (91.0–149.0) 459 (324.5–925.0)
Age in years 9 (7.0–11.0) 8 (7.5-11.5)
Female 7 (53.9%) 3 (43%)
Mutations
- F508del homozygous 10 (77%) 4 (57%)
- F508del heterozygous 2 (15%) 3 (43%)
- Others 1 (8%) 0
%BMI † 97.6 (94.0–108.0) 98.3 (88.5–97.7)
%FEV1
†† 81(71.0–91.0) 76 (71.5–93.5)
Chronic pulmonary colonization
- P. aeruginosa 1 (8%) 0
- S. aureus 11 (85%) 7 (100%)
Previous IV antibiotic courses * 0 (0–2) 5 (0.5–10)
Quality of life
- Parents’ report 81.9 (76.5–88.4) 89.0 (86.7–90.4)
- Child’s report 83.9 (71.9–89.2) 85.1 (76.8–88.6)
Digestive symptoms ••
- Parents’ report 83.2 (80.6–90.7) 94.5 (93.6–95.0)
- Child’s report 84.5 (79.4–95.1) 91.2 (88.7–98.1)
Follow-up at 2 years
- %BMI † 96.6 (90.6–105.9) 97.6 (92.3–102.6)
- %BMI variation −0.5 (−3.8–1.5) −0.3 (-1.0–3.0)
- %FEV1 †† 84.0 (71.2–95.2) 83.5 (69.5–85.5)
- %FEV1 variation 1 (−21.0–8.5) 9 (-4.7–14.5)
- IV antibiotics 2.5 (0.0–5.2) 6.5 (5.2–9.2)
- Oral antibiotics 1.5 (0.0–3.2) 2 (2.0–2.7)
- Inhaled antibiotics + 1 (1.0–1.2) 2 (2.0–2.7)
- Total antibiotics + 5 (3.7–8.2) 11.5 (10.2–12.7)
Data are presented as n (%) or median (interquartile interval); Abbreviations: BMI, body mass index; FEV1, Forced
Expiratory Volume in 1s; IV, intravenous; + p < 0.05; † expressed as percent of the standard normalized by age;
†† expressed as percent predicted; * Evaluated using PedsQLTM Generic Core Scale 4.0; •• Evaluated using PedsQL™
Gastrointestinal Symptoms Scales 3.0.
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The present study was approved by the regional ethical committee “CPP Sud-Ouest et Outremer
III” (DC 2015/129). Informed consent was sought from study participants and their parents.
2.2. Measurements of Fecal Calprotectin
The fecal calprotectin assay was carried out using the GHSA kit (Eurobio, Courtabœuf, France).
In the absence of a specific threshold in CF, we applied a cut-off of 250 μg/g, recently validated to
predict an inflammatory flare associated with endoscopic lesions in IBD [26,27].
2.3. Microbiota Analysis
DNA extraction was performed using DNeasy Blood & Tissue kit (Qiagen, Hilden, Germany)
according to the manufacturer’s protocol. The DNA samples were the used for V4 region of the
16S rRNA gene sequencing as previously described [28]. For specific analysis of S. oralis and total
bacteria population, droplet digital PCR (ddPCR) on the fecal DNA was performed, as described in the
Supplemental Information.
2.4. Sequencing and Bioinformatics Analysis
Next-generation sequencing was performed using Illumina MiSeq sequencer, and bioinformatic
analysis as described previously [28]. Alpha and beta diversity indexes were assessed using raw
Operational Taxonomic Unit (OTU) occurrence counts and a Non-Metric Multidimensional Scaling
(NMDS) ordination method with Bray-Curtis distance metric implemented by R package phyloseq,
respectively. Subsequent OTU filtering and analyses were performed with MicrobiomeAnalyst
(http://www.microbiomeanalyst.ca) [29]. OTUs were normalized by total sum scaling. Two groups
of patients were defined with low (<250 μg/g) and high (>250 μg/g) fecal calprotectin level and used
for DESeq2 [30] (Supplementary Table S2) and LEfSe [31] (Supplementary Table S3) analyses to find
differentially present taxa and microbiota markers, respectively. Raw data have been deposited in the
European Nucleotide Archive (ENA) sequence read archive (ENA accession number PRJEB28609).
2.5. Microbial Dysbiosis Index Evaluation
We estimated the Microbial Dysbiosis index (MD-index; Supplementary Table S4), a ratio between
relative abundance of increased and decreased bacteria recently proposed in Crohn’s disease (CD) [32].
2.6. Statistical Analysis
Differentially present taxonomic nodes between groups of patients were calculated using DESeq2
approach and a False Discovery Rate (FDR) < 0.05. LEfSe method was used to identify metagenomic
biomarkers [31]. Nonparametric Wilcoxon–Mann–Whitney test was used to compare quantitative
variables between groups. Correlations were calculated using Spearman method. Statistical analysis
was performed with R studio program (version 1.1.453 for WindowsTM); a p-value< 0.05 was considered
indicative of statistical significance.
3. Results
Intestinal inflammation is associated with more previous intravenous antibiotic courses in CF.
Twenty children with CF between 6 and 14 years of age were included; their main demographic
characteristics, clinical and microbiological data are summarized in Table 1. Among them, we identified
seven (35%) children (mean of age at 8.0± 3.0 years old, Table 1) with significant intestinal inflammation
(fecal calprotectin > 250 μg/g, with levels ranged from 300 to 1800 μg/g). Age of patients, mutation
severities, %BMI and %FEV1 were not significantly different between children without and with
intestinal inflammation (Table 1). In addition, no complaint recorded in questionnaires could
discriminate inflammatory status of children (Table 1). However, children with intestinal inflammation
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have received significantly more intravenous antibiotic courses before inclusion (p = 0.04 adjusted
with age, Table 1).
CF children with intestinal inflammation are distinguished by their intestinal microbiota
composition. The microbiota composition from 20 fecal samples was estimated using targeted 16S
rRNA gene sequencing. After bioinformatic analysis, the median number of high-quality reads
per patient was 421,720 (from 69,534 to 2,500,796). Taxonomic assignment was used to compare
the profiles of patients’ microbiota (Figure 1). At the phylum level, the proportion of Firmicutes
was significantly higher in microbiota profiles of children with intestinal inflammation (on average
81% vs. 65% respectively for children with and without intestinal inflammation, FDR = 0.0078)
(Figure 1A). To evaluate species diversity in patients’ microbiome we calculated alpha diversity indices.
The Shannon and Simpson indices are two complementary approaches to alpha diversity, sensitive to
changes in abundance of the rarest or the most abundant OTUs, respectively. Alpha diversity indexes
were not significantly different between children with and without intestinal inflammation (Figure 1B).
However, the beta diversity analysis (NMDS) reflecting the variation of microbiome between samples,
showed partial separation of the patients with intestinal inflammation (Figure 1C).
Figure 1. Microbiota composition in the Cystic Fibrosis (CF) cohort. (A) Proportions of bacteria
from the five most abundant phyla colored according to the legend. Calprotectin measurements per
patient are shown in boxes below the bar plot. The proportion of Firmicutes was significantly higher in
microbiota profiles of children with intestinal inflammation (gray boxes). (B) Alpha diversity values
for all patients (n = 20) are shown as points and summarized as boxplots for each group. Both Shannon
and Simpson alpha indices measure microbial diversity within sample, and they were not significantly
different between children with and without intestinal inflammation (Wilcoxon—Mann–Whitney test).
(C) Beta diversity (NMDS), which assesses differences in microbial composition between samples using
a NMDS ordination method with Bray–Curtis distance metric, showed a partial separation of samples
of patients with intestinal inflammation.
21
J. Clin. Med. 2019, 8, 645
Differential expression (DESeq2) analysis revealed 80 distinctive OTUs that belonged to 25 unique
taxonomic nodes differentially present between patients according to their intestinal inflammation
status (Figure 2A, Supplementary Table S2). Among them, increased abundances of Acidaminococcus
spp., Staphylococcus spp., Streptococcus spp., and Veillonella dispar, along with decreased abundances of
Bacteroides spp., Ruminococcus spp., Coprococcus spp., Dialister spp., Parabacteroides spp., Bifidobacterium
spp., Dorea formicigenerans, and Faecalibacterium prausnitzii were observed in children with fecal
calprotectin higher than 250 μg/g (Figure 2A).
Figure 2. The composition of the microbiota differs according to the inflammation status of CF
patients. (A) Differential abundance analysis (DESeq) assessing OTU significantly changed in the
microbiome of patients with intestinal inflammation, compared with patients without intestinal
inflammation. Each circle represents one of 80 significant OTUs colored by a phylum according to the
legend. OTUs are collapsed to 25 taxa represented on x axis and ordered by decreasing log of fold
change. For full results see Supplementary Table S2. (B) LEfSe analysis showing OTUs distinguishing
patients without and with intestinal inflammation (p-value < 0.01) and confirming DESeq2 results.
For full results see Supplementary Table S3.
Using LEfSe analysis (Supplementary Table S3), we identified numerous taxonomic nodes that
can predict intestinal inflammation in our young CF population. It confirmed the results of DESeq2 at
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genus levels regarding Staphylococcus, Streptococcus, Bacteroides, Ruminococcus, Coprococcus, Dialister,
and Parabacteroides, and at the species level regarding Veillonella dispar, Bifidobacterium adolescentis,
Dorea formicigenerans, and Faecalibacterium prausnitzii. In addition, some OTUs belonging to the families
Lachnospiraceae and Ruminococcaceae appear to be differentially correlated to the inflammatory
patient status (Figure 2B, results with p-value < 0.01).
CF intestinal inflammation and microbiota exhibit similarities with IBD. In order to analyze
deeper the CF intestinal microbiota changes in our cohort, we applied the MD-index, recently designed
and validated in CD [32]. This index is based on a ratio between given bacterial taxa known to
be increased or decreased in CD listed in Figure 3A. The MD-index was significantly higher in the
CF children with intestinal inflammation compared to the group without inflammation (p = 0.03)
(Figure 3B and Supplementary Table S4). It was not correlated to age, %BMI, or %FEV1 in our cohort.
Figure 3. MD-index distribution in CF cohort according to the intestinal inflammation status.
(A) Bacterial taxa contributing to the MD-index according to [32]. (B) Boxplot of MD-index values for
patients separated into groups according to calprotectin level. Patients with CF intestinal inflammation
have a significant higher MD-index (Wilcoxon–Mann–Whitney test, p = 0.03). For full results see
Supplementary Table S4.
However, Streptococcus genus, increased in our inflammatory patient group, is not usually
associated with IBD and is not included in the MD-index. Given the role of Streptococcus mitis group in
CF lung disease evolution [33,34] and difficulties in distinguishing this group from other Streptococci
by NGS, we assessed the presence of mitis group species by using ddPCR that specifically targeted
Streptococcus oralis. We observed a non-significant increase log ratios of S. oralis per total bacteria in
children with intestinal inflammation, compared to children with low calprotectin levels (ratio median
−5.8 and −6.8, respectively, p = 0.24) (Figure 4).
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Figure 4. Relative abundance of S. oralis assessed by ddPCR according to the inflammation status
of CF patients. Boxplot of values representing relative proportion of S. oralis in patients’ microbiomes,
separated into groups according to calprotectin level. Among Streptococcus found in CF children,
there was a notable proportion of S. oralis but without significant difference between children with or
without intestinal inflammation (Wilcoxon–Mann–Whitney test, p = 0.24).
Intestinal inflammation at the inclusion is associated with increased antibiotic use over the
next two years. We compared the clinical evolution at two years between children without and with
intestinal inflammation. While intestinal inflammation was not predictive of evolution of %FEV1 or
%BMI at two years (Table 1), children with intestinal inflammation at the inclusion had more antibiotic
treatments over the next two years, all routes of administration combined (p = 0.02). Surprisingly,
this discrepancy appears to be more related to inhaled antibiotic courses (p = 0.02) than to intravenous
(p = 0.06) or oral (p > 0.05) antibiotic therapies (Table 1).
4. Discussion
Intestinal microbiota disturbances and intestinal inflammation are now widely accepted as an
integral part of CF. With the increased life expectancy of patients, the management of these digestive
disorders is becoming a topical subject, even if the corresponding physiological mechanisms are not
yet well understood. In fact, links between intestinal microbiota and inflammation in CF have been
suggested directly or indirectly by a limited number of studies [5]. In one of the few CF studies
analyzing gut microbiota by NGS according to inflammation, intestinal inflammation was associated
with an increase of E. coli abundance [24]. In another study, gastrointestinal mucosal lesions recorded
by capsule endoscopy was positively correlated with Firmicutes and negatively correlated with
Bacteroidetes [3]. Indirectly, probiotic intake or antibiotic courses in CF patients were able to decrease
intestinal inflammation [20,35].
In order to refine the relationships between intestinal microbiota composition and inflammation
in the CF, we compared intestinal microbiota profiles from young CF patients, according to their
intestinal inflammatory status evaluated by fecal calprotectin. Despite the limited number of children
included (n = 20) and their young age (mean of age at 8.0 ± 3.0 y.o. in Table 1), we identified a notable
proportion of children (35%) with significant intestinal inflammation and microbiota disturbances
(Figures 1 and 2). In this group, fecal calprotectin levels ranged from 300 to 1800 μg/g, rates comparable
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to those seen in IBD [26]. We observed increased abundances of Staphylococcus spp., Streptococcus
spp., and Veillonella dispar, along with decreased abundances of Bacteroides spp., Ruminococcus spp.,
Coprococcus spp., Dialister spp., Parabacteroides spp., Bifidobacterium adolescentis, and Faecalibacterium
prausnitzii in children with fecal calprotectin higher than 250 μg/g (Figure 3). We did not find significant
increased E. coli abundances, as previously reported in a cohort of younger CF children (median
age at 10 months) [24]. Our results were confirmed using LEfSe (Supplementary Table S3). On the
whole, these microbiota disturbances exhibited numerous similarities with the well described IBD
microbiota [23,32,36]. Interestingly, the MD-index, which is positively correlated with the clinical
disease activity of CD [32], was significantly higher in our group of CF children with high fecal
calprotectin levels.
Decrease of B. adolescentis and F. prausnitzii in group of children with intestinal inflammation
confirm the results recently published in CF [22] and are congruent with data exploring in vitro
anti-inflammatory proprieties of bacteria. Bifidobacterium adolescentis inhibits inflammatory responses
in intestinal epithelial cells, by limiting the lipopolysaccharide-induced inflammatory response and
the TNF-α production [37]. Furthermore, the intestinal inflammation in our cohort was associated
with an under-representation of F. prausnitzii (Figure 2B), a strain well investigated in IBD for its
anti-inflammatory properties and considered as a viable marker of health [36].
Taken together, these results raise the question of the causal relationship between microbiota
composition and inflammation: does a decrease of anti-inflammatory bacteria lead to inflammation or
does it result from this inflammation as a basic consequence of anti-inflammatory bacteria decrease?
The answer to this question is still a matter of debate in CF as well as IBD [38]. Keeping in mind that the
causal relation is probably bidirectional, few published data suggest the existence of a pro-inflammatory
microbiota. Experiments using a murine model of colitis showed that disease can be transmitted from
a genetically modified mouse to a wild mouse by a microbiota transfer [39]. In CF, oral antibiotic or
probiotic exposures were shown to reduce intestinal inflammation [20,35]. A higher MD-index in
our inflammatory subpopulation lets us suggest that these patients may have a more pronounced
“pro-inflammatory” microbiota (Figures 2A and 3B). This subpopulation exhibited also significantly
more Firmicutes and had previously received more IV antibiotics, which is a known factor leading to
an increase of Firmicutes (Table 1 and Figure 1A) [8]. Moreover, the young age of our cohort together
with the microbiota disturbances observed in CF from the first weeks of life [9,40] seem to indicate that
CF gut microbiota changes is inherent to the disease rather than a basic consequence of inflammation
and/or antibiotic use.
More recently, the human microbiome (which includes the gut microbiome but also the other body
sites) has emerged as a complex interconnected entity leading to the popularization of the concepts of
gut–brain and gut–lung axes [41,42]. The gut–lung axis is of major interest in CF, as patients colonize
their digestive tract with microorganisms from oral or respiratory tracts by sputum swallowing [43].
Bacteria found in gastric fluid were correlated with CF sputum microbiota composition, especially
regarding Streptococcus abundance [43]. Streptococcus isolates are naturally present in the digestive
tract [9] but their proportion seems to be higher in CF patients [9]. We identified a significant
over-representation of Streptococcus spp. in CF children with intestinal inflammation (Figure 3A), with a
notable proportion of S. oralis (Figure 4). Streptococcus strains may contribute to the inflammatory
process by synergistic interactions with other commensal microorganisms such as Candida albicans or
Veillonella spp., both being increased in IBD flares [23,44,45]. Overall, these data support the relationship
between respiratory and digestive microbiomes.
This CF “gut–lung axis” is poorly described. It appears to be bidirectional with intestinal microbiota
changes predicting pulmonary colonization of Pseudomonas aeruginosa [40] and oral probiotics decreasing
pulmonary exacerbations [46]. Interestingly, we found that intestinal inflammation at the inclusion
was associated with an increase in short-term antibiotic cures, especially with an increase over the next
two years in inhaled antibiotic courses (Table 1). However, in the absence of repeated fecal calprotectin
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measurement during these two years, we cannot affirm that non-inflammatory patients at baseline
remain without intestinal inflammation during this period.
Short-term intestinal inflammation may affect the nutritional status of CF patients, as demonstrated
by significant correlations between fecal calprotectin level and both weight z-scores and height z-scores
of CF patients [47]. As previously recorded [21], we did not find a significant correlation between
intestinal inflammation and BMI. BMI evolution is recognized as multifactorial and is now part of the
nutritional management, fully integrated into CF disease treatment [21].
Long-term inflammation could impact morbidity and mortality, especially regarding the increased
risk of small intestine and colon cancers in CF patients compared with the general population [48].
The pathogenesis of digestive cancers in CF remains unclear. It has been shown that chronic intestinal
inflammation is associated with this malignancy risk [49]. Furthermore in IBD, risk factor for colorectal
cancer is correlated with the intensity and duration of the inflammation [50]. CF inflammation is present
even at an early age, as well demonstrated in our pediatric cohort than in previous studies [51,52],
which may be a key factor in developing digestive malignancy later on.
Microbiota composition has also been associated with digestive cancer, due to a decrease in
bacteria protecting against cancer and changes in the corresponding metabolite production, such as a
decrease in butyrate production, also observed in CF patients with intestinal inflammation [49,53,54].
We and others [10,22,40,54,55] showed that Bacteroides—known as protective bacteria against
malignancy [53]—are decreased in CF.
5. Conclusions
To conclude, with more CF patients surviving into advanced adulthood we need to improve our
understanding and management of this systemic disease, including the chronic intestinal inflammation.
Few studies including ours reinforce the relation between intestinal inflammation and microbiota
disturbance. Further in vitro and in vivo studies are warranted given the limited understanding of
the CF physiopathology. Even well-documented probiotic strains, such as Bifidobacterium adolescentis
identified in this study to be significantly decreased—that inhibits inflammatory responses in intestinal
epithelial cells [37]—will require further clinical trials to decipher their potential ability to reduce the
short-term intestinal inflammation and the long-term cancer risk.
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Abstract: The diagnosis of small-bowel tumors is challenging due to their low incidence, nonspecific
presentation, and limitations of traditional endoscopic techniques. In our study, we examined
the utility of the mucosal protrusion angle in differentiating between true submucosal masses
and bulges of the small bowel on video capsule endoscopy. We retrospectively reviewed video
capsule endoscopies of 34 patients who had suspected small-bowel lesions between 2002 and 2017.
Mucosal protrusion angles were defined as the angle between the small-bowel protruding lesion and
surrounding mucosa and were measured using a protractor placed on a computer screen. We found
that 25 patients were found to have true submucosal masses based on pathology and 9 patients had
innocent bulges due to extrinsic compression. True submucosal masses had an average measured
protrusion angle of 45.7 degrees ± 20.8 whereas innocent bulges had an average protrusion angle of
108.6 degrees ± 16.3 (p < 0.0001; unpaired t-test). Acute angle of protrusion accurately discriminated
between true submucosal masses and extrinsic compression bulges on Fisher’s exact test (p = 0.0001).
Our findings suggest that mucosal protrusion angle is a simple and useful tool for differentiating
between true masses and innocent bulges of the small bowel.
Keywords: small-bowel mass; small-bowel bulge; video capsule endoscopy
1. Introduction
The diagnosis of small-bowel tumors is challenging due to their low incidence, nonspecific clinical
presentation, and the limitations of traditional endoscopic techniques. Video capsule endoscopy (VCE)
has dramatically improved our ability to detect small-bowel tumors by enabling the visualization
of portions of the small-bowel that are not accessible by colonoscopy or upper endoscopy [1]. VCE
was able to diagnose small-bowel tumors in 8.9% of the 562 patients in a single-center retrospective
study who underwent VCE for occult gastrointestinal bleeding, abdominal pain, and a variety of other
indications [2]. Furthermore, VCE missed only 10% of small-bowel tumors compared to a collective
miss rate of 73% by double balloon enteroscopy, small-bowel series, colonoscopy, and ileoscopy [3].
J. Clin. Med. 2019, 8, 418; doi:10.3390/jcm8040418 www.mdpi.com/journal/jcm31
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One of the major limitations of VCE is its inability to biopsy lesions identified during passage
through the small bowel. Though double balloon enteroscopy can potentially be used to visualize the
entire small intestine, reported rates for total enteroscopy are widely variable (ranging between 20 and
90%) and are highly user-dependent [1]. A group of experts at the 2006 International Conference on
Capsule Endoscopy identified several major and minor characteristics of small-bowel lesions that are
predictive of tumors, including mucosal disruption, bleeding, irregular surface, polypoid appearance,
color, delayed passage, white villi, and invagination [4]. However, in the absence of these features,
it can be challenging to differentiate between true submucosal masses and benign bulges arising from
extrinsic compression by adjacent structures.
In order to address this challenge, Girelli et al. developed the “smooth, protruding lesions
index at capsule endoscopy” (SPICE) and examined its utility through a single-center, prospective
study of 25 patients [5]. SPICE score was calculated by adding one point for each of the following:
(1) Well-defined boundary with surrounding mucosa, (2) diameter less than height, (3) visible lumen,
and (4) image of lesion lasting more than 10 min. A SPICE score >2 was found to be 83.3% sensitive
and 89.4% specific for identifying true submucosal masses, therefore supporting a novel system for
differentiating true from false masses on VCE. Through our retrospective study, we will evaluate the
utility of an additional morphologic criterion, the mucosal protrusion angle. We have defined this
as the angle between the small-bowel protruding lesion and surrounding mucosa. We hypothesize
that false masses arising from extrinsic compression will create more obtuse protrusion angles >90◦
compared with true submucosal masses, <90◦. By determining the utility of the mucosal protrusion




Patient demographics, indication for VCE, findings on VCE, radiographic studies, endoscopic
and surgical interventions, pathology results, and survival following VCE were all collected
retrospectively. Only those patients who were found to have a small-bowel protruding lesion on
VCE were included in the study. Small-bowel protruding lesions were defined as any masses seen
on VCE, including suspected submucosal masses and benign bulges. In total, we analyzed the
VCEs of 34 patients. All VCEs were performed with the M2 A, PillCamTM SB2 or SB3 (Medtronic,
Minneapolis, MN, United States) and were analyzed using RAPIDTM version 8.3 (Given Imaging LTD,
Yoqneam, Israel). This study was approved by the UMass Medical School Institutional Review board
on December 2, 2015.
2.2. Angle Measurement
All angles were obtained through VCE images on RAPIDTM software version 8.3 (Given Imaging
LTD, Yoqneam, Israel). The mucosal protrusion angle was defined as the angle between the protruding
lesion and surrounding mucosa. Mucosal protrusion angles were measured using a protractor placed
on the computer screen. We categorized lesions as having a protrusion angle of either >90◦ or <90◦
and hypothesized that an angle >90◦ suggests an external protrusion or bulge while an angle <90◦
suggests a submucosal mass. The frame for protrusion angle measurement was selected independently
at each user’s discretion based on the frame in which they felt the protrusion angle could best be
measured. A sample image with angle measurement technique was provided to each operator
(see Figure 1). Angles were measured independently by two novice users and one expert user to assess
for interobserver agreement. Both novice users performed <10 VCEs prior to this study and the expert
user performed >1000 VCEs.
32
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Figure 1. (a) Demonstration of acute angle measurement on RAPIDTM. (b) Demonstration of obtuse
angle measurement on RAPIDTM.
2.3. SPICE Calculation
SPICE scores were calculated for each patient as outlined in Girelli et al. [5]. Lesions were given
1 point for the following: (1) Sharp boundary with surrounding mucosa, (2) height larger than diameter,
(3) visible lumen in the frames in which the lesion appears, and (4) image of the lesion lasting more
than 10 min. Any lesion with greater than two of the four SPICE criteria were predicted to be true
submucosal masses per the findings in Girelli et al. A ruler placed directly on the computer screen was
used to determine exact height and diameter of the small-bowel lesions.
2.4. Statistics
We calculated the sensitivity, specificity, positive predictive value (PPV), and negative predictive
value (NPV) of both SPICE and protrusion angle. Fisher’s Exact Test was performed to assess the
association between protrusion angle and true vs. false submucosal mass. All Fisher’s tests were
one-tailed and the cutoff for significance was set at a p-value of <0.05. Interobserver agreement
(kappa statistic) was assessed by comparing angle measurements of two novice VCE users and
an expert user. We ran a logistic regression on capsule angle measurements for expert and novice users
combined using a cutoff value of <90 degrees for a true mass and fit the data to a receiver operating
characteristic (ROC) curve. We also ran a logistic regression on SPICE scores using a cutoff of >2 for
true mass and fit the data to an ROC curve. Statistical analysis was performed using Stata Statistical
Software: Release 13 (College Station, TX, USA).
3. Results
3.1. Demographics
We retrospectively reviewed the charts of 289 patients over the age of 18 who had undergone VCE
for suspected small-bowel protruding lesions between January 2002 and March 2017. Of the patients,
241 were excluded because no protruding lesion was identified between the pylorus and ileocecal
valve. Five patients were excluded because they were later identified as having true submucosal
masses but did not have available pathology reports in our medical records. Nine patients were
excluded because either the protrusion angle or SPICE score could not be determined due to poor
image quality or limited visualization of the protruding lesion. In total, we analyzed the VCEs of
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34 patients. The average age was 73.0 ± 16.6 years. There was a larger proportion of female patients
(67.6%) compared with male patients (32.4%) (see Table 1)






Location Imaging c Endoscopy c Surgery Final Diagnosis
F 65 OGB 42.5 20.0 Jejunum CTE + ASBE + Yes GIST
M 52 OGB 16.0 10.0 Ileum CT + ASBE + Yes GIST
M 81 OGB 50.0 30.0 Ileum CT − ASBE − Yes Carcinoid
F 56 Carcinoid a 20.0 10.0 Ileum CT ± Colo + Yes Carcinoid
F 77 IDA 27.5 20.0 Ileum CT − RSBE + Yes Carcinoid
F 56 CD 55.0 50.0 Ileum CTE ± RSBE + Yes Carcinoid
F 58 AP 10.0 20.0 Ileum CT ± Colo + Yes Carcinoid
F 62 AP 100.0 10.0 Ileum CT + Colo − Yes Carcinoid
M 38 AP 72.5 30.0 Jejunum CT + ASBE − Yes InflammatoryPolyp
F 73 OGB 35.0 110.0 Jejunum ND ASBE + No Lymphangiectasia
M 53 OGB 25.0 30.0 Ileum CT − Colo − Yes DLBCL
F 30 Peutz-Jeghers a 45.0 30.0 Jejunum ND RSBE + Yes Peutz-Jeghers
F 39 Peutz-Jeghers a 47.5 30.0 Ileum ND RSBE + No Peutz-Jeghers
F 36 Peutz-Jeghers a 45.0 50.0 Duodenum ND ASBE + Yes Peutz-Jeghers
M 37 IDA 27.5 40.0 Jejunum ND ASBE + Yes Peutz-Jeghers
F 49 OGB 50.0 20.0 Jejunum ND ASBE + No Peutz-Jeghers
F 58 OGB 52.5 15.0 Jejunum CT − ASBE + No InflammatoryPolyp
M 37 Crohn’s a 65.0 20.0 Jejunum CT − ASBE + No InflammatoryPolyp
F 76 OGB 40.0 40.0 Jejunum CTE + ASBE + Yes Hamartoma
F 57 OGB 45.0 10.0 Duodenum ND ASBE + No Hamartoma
M 78 BO 60.0 20.0 Ileum MRE ± ASBE − Yes Lipoma
F 83 AP 82.5 >90 Duodenum ND ASBE + No Tubular Adenoma
F 41 OGB 35.0 10.0 Ileum ND Colo − Yes Leiomyoma
F 48 OGB 47.5 10.0 Jejunum ND ASBE − Yes Hemangioma
M 47 AP 30.0 60.0 Duodenum CT + ASBE + No Hyperplastic Polyp
F 70 AP, OGB 130.0 70.0 Jejunum CT − ASBE − No Bulge
M 51 Leukemia a 95.0 50.0 Jejunum PET CT + NA No Bulge
F 61 AP/CD 115.0 20.0 Duodenum ND ND No Bulge
F 29 AP 105.0 110.0 Ileum CT − Colo − No Bulge
F 55 OGB 75.0 20.0 Jejunum NA NA No Bulge
M 85 AP 122.5 130.0 Ileum ND Colo − No Bulge
M 29 AP 105.0 30.0 Ileum CT − Colo − No Bulge
F 54 OGB 125.0 130.0 Ileum CT − Colo − No Bulge
F 73 IDA 102.5 130.0 Ileum CT − ASBE − No Bulge
AP, abdominal pain; ASBE, anterograde small-bowel enteroscopy; BO, bowel obstruction; CD, chronic diarrhea;
Colo, colonoscopy; CT, CT abdomen/pelvis; CTE, CT enterography; DLBCL, diffuse large B cell lymphoma; GIST,
gastrointestinal stromal tumor; IDA, iron deficiency anemia; MRE, magnetic resonance enterography; NA, not
available; ND, not done; OGB, obscure gastrointestinal bleeding; PET CT, positron emission tomography CT; RSBE,
retrograde small-bowel enteroscopy. a Video capsule endoscopy performed for screening or surveillance. c Novice
angle represents an average of measurement of 2 novice users. b Signs (+), (−), and (±) indicate positive, negative,
and equivocal findings, respectively.
3.2. Diagnosis
The most common indication for VCE was obscure gastrointestinal bleeding (41.2%), followed
by abdominal pain (29.4.%). Twenty-five patients were found to have true submucosal masses based
on pathology report (6 carcinoid, 2 gastrointestinal stromal tumor, 1 diffuse large B-cell lymphoma,
1 leiomyoma, 5 Peutz-Jeghers, 1 tubular adenoma, 1 hyperplastic polyp, 3 inflammatory polyps,
2 hamartomas, 1 lipoma, 1 cavernous hemangioma, 1 lymphangiectasia) and 9 patients had innocent
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bulges due to extrinsic compression (see Table 1). None of the patients with bulges had available
pathology data because no mass was seen on follow-up studies such as enteroscopy or repeat
capsule endoscopy.
3.3. Protrusion Angle and SPICE Calculations
True submucosal masses had an average measured angle of protrusion of 45.7◦ ± 20.80 whereas
innocent bulges had an average protrusion angle of 108.6◦ ± 16.3◦ (p < 0.0001; unpaired t-test).
When compared with SPICE scores, a mucosal protrusion angle <90◦ had a higher sensitivity
(92.0% vs. 32.0%), PPV (96.0% vs. 88.9%), and NPV (66.7% vs. 32.0%). Both protrusion angle and
SPICE scores had the same specificity of 88.9%. Acute angle of protrusion accurately discriminated
between true submucosal masses and extrinsic compression bulges on Fisher’s exact test (p = 0.0001).
Interobserver agreement between the two novice users and the expert user was good (κ = 0.67; 95% CI,
0.50–0.84). The area under the curve for mass angle using a cutoff value of <90 degrees for true mass






Figure 2. (a) The area under the receiver operating characteristic (ROC) curve for combined expert and
novice mucosal protrusion angle using a cutoff of <90◦ for true mass. (b) The area under the ROC curve
for smooth, protruding lesion at capsule endoscopy (SPICE) index using a cutoff of >2 for true mass.
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4. Discussion
VCE has emerged as a convenient way to identify small-bowel tumors because it is non-invasive
and allows for visualizuation of the entire length of the small bowel. Over the past several decades,
its role in detecting malignancies has become more important as the incidence of small-bowel tumors
has increased from 11.8 cases per million in 1973 to 22.7 cases per million in 2004. It is unclear how
much of this increase can be attributed to improved diagnosis with the advent of VCE, however
Bilimora et al. pointed to the rising incidence of carcinoid tumors as a major driving factor [6].
Prior studies have cited VCE malignant tumor detection rates as high as 63–83% [7,8]. In our study,
we found a lower but still significant proportion of malignant tumors (45% of true submucosal masses)
after excluding patients with Peutz-Jehgers.
Though VCE has significantly improved our ability to detect small-bowel tumors, it has also
opened up what Pennazio et al. describes as a “Pandora’s box” of findings including both malignant
and benign lesions [9]. Bulges are among one of the most problematic benign findings on VCE, as they
can often mimic the appearance of small-bowel tumors and contribute to false-positive outcomes [10].
False-positive outcomes may lead to further invasive and costly procedures, therefore highlighting
the importance of differentiating bulges from true submucosal masses. Though “alarm” features,
including bleeding, mucosal disruption, irregular surface, polypoid appearance, and white villi,
have been described based upon expert consensus for malignant small-bowel masses, there are few
studies available to support the use of these findings on VCE [4,11]. There have been prior attempts
to use of automatic detection methods based on textural alterations on VCE, however none of these
methods have been validated in clinical practice for diagnosing submucosal masses [12,13].
The SPICE score described by Girelli et al. was the first scoring system developed to distinguish
between submucosal masses and bulges on VCE [5]. This study showed that a SPICE score >2 was
highly sensitive (83.3%) and specific (89.4%) for detection of true submucosal masses. A validation
study by Rodrigues et al. showed a lower sensitivity (66.7%) but high specificity (100.0%) for the
SPICE score [14]. In our study, we found that a SPICE score >2 had an equally high specificity
when compared with the mucosal protrusion angle but a significantly lower sensitivity of 32.0%.
The discrepencies in our results may in large part be due to differences in study design, as the
Girelli et al. study was prospective whereas ours was retrospective. Additionally, we included patients
with Peutz-Jehgers and patients with “alarm” features outlined by Shyung et al., all of whom were
excluded by Girelli et al. [5,11]. None of our true masses had a length time >10 min, criteria 4 on the
SPICE scale, which made SPICE less sensitive in our patient population.
We evaluated the utililty of a new, simpler measure, the mucosal protrusion angle, in differentiating
true masses from bulges. We found that an angle <90◦ accurately discriminated between true masses
and extrinsic compression bulges (p = 0.0001). Acute protrusion angle also had a high sensitivity (92.0%)
and specificity (88.9%) for distinguishing between true masses and bulges. It should be noted that we
used both novice and expert users in our study, whereas the Girelli et al. study utilized only expert users.
Discrepencies in angle measurements between the novice and expert users in our study were likely due
to differences in the frames of the lesion on RAPIDTM chosen by each user. Despite these discrepencies,
we found that there was good interobserver agreement between the novice and expert users when using
mucosal protrusion angle (κ = 0.67; 95% CI, 0.50–0.84). This suggests that mucosal protrusion angle has the
potential to be utilized by a wide range of users regardless of their VCE experience level.
5. Study Limitations
There are several limitations of this study that are important to note. First, this is a retrospective
study and therefore is subject to both confounding and selection bias. As mentioned above, one
potential source of bias is the variation in frame selection on VCE, as there was no way to ensure that
all users would select the same image for angle measurement. In the future, it would be valuable
to assess the degree of variability in frame selection between observers as this was not evaluated in
our present study. An additional limitation of our study was that none of the bulges had pathologic
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confirmation due to our inability to visualize these transient lesions on subsequent interventions
and the unethical nature of performing surgery or further invasive workup in such patients. We felt
that long-term follow up provided an adequate surrogate but recognize this as a limitation. Finally,
the number of patients in our study is comparatively small.
6. Conclusions
Mucosal protrusion angle is a novel and simple tool for differentiating between true masses
and innocent bulges of the small bowel. To our knowledge, there are no prior studies examining the
utility of this index. We found that small-bowel protruding lesions with a protrusion angle >90◦ are
more likely to represent bulges and may not warrant any additional workup, whereas lesions with
angle <90◦ are more likely to be true masses that should be evaluated for malignancy with enteroscopic
or surgical interventions. Further prospective studies are still needed to validate our results.
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Abstract: Intestinal microbiota play an important role in the pathogenesis of surgical site infections
(SSIs) and other surgery-related complications (SRCs). Probiotics and synbiotics were found to
lower the risk of surgical infections and other surgery-related adverse events. We systematically
reviewed the approach based on the administration of probiotics and synbiotics to diminish
SSIs/SRCs rates in patients undergoing various surgical treatments and to determine the mechanisms
responsible for their effectiveness. A systematic literature search in PubMed/MEDLINE/Cochrane
Central Register of Controlled Trials from the inception of databases to June 2018 for trials
in patients undergoing surgery supplemented with pre/pro/synbiotics and randomized to the
intervention versus placebo/no treatment and reporting on primarily: (i) putative mechanisms of
probiotic/symbiotic action, and secondarily (ii) SSIs and SRCs outcomes. Random-effect model
meta-analysis and meta-regression analysis of outcomes was done. Thirty-five trials comprising
3028 adult patients were included; interventions were probiotics (n = 16) and synbiotics (n = 19 trials).
We found that C-reactive protein (CRP) and Interleukin-6 (IL-6) were significantly decreased (SMD:
−0.40, 95% CI [−0.79, −0.02], p = 0.041; SMD: −0.41, 95% CI [−0.70, −0.02], p = 0.006, respectively)
while concentration of acetic, butyric, and propionic acids were elevated in patients supplemented
with probiotics (SMD: 1.78, 95% CI [0.80, 2.76], p = 0.0004; SMD: 0.67, 95% CI [0.37, −0.97], p = 0.00001;
SMD: 0.46, 95% CI [0.18, 0.73], p = 0.001, respectively). Meta-analysis confirmed that pro- and
synbiotics supplementation was associated with significant reduction in the incidence of SRCs
including abdominal distention, diarrhea, pneumonia, sepsis, surgery site infection (including
superficial incisional), and urinary tract infection, as well as the duration of antibiotic therapy,
duration of postoperative pyrexia, time of fluid introduction, solid diet, and duration of hospital stay
(p < 0.05). Probiotics and synbiotics administration counteract SSIs/SRCs via modulating gut-immune
response and production of short chain fatty acids.
J. Clin. Med. 2018, 7, 556; doi:10.3390/jcm7120556 www.mdpi.com/journal/jcm39
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1. Introduction
One of the most challenging health care issues worldwide are surgical site infections (SSIs) [1,2].
Timely administration of effective preoperative antibiotics along with other perioperative quality
control interventions recommended by various guidelines [3–5] have resulted in a significant reduction
of the rate of SSIs. Despite these efforts, globally SSIs occur in 9–22% of procedures, with a direct
correlation with the human developmental index [1]. SSIs result in prolonged hospitalizations,
unscheduled re-admissions, extended duration of antibiotic therapy, increase mortality rate, and pose
high costs to healthcare systems. Therefore, it is of priority to look for other effective, evidence-based
interventions capable of reducing the incidence of life-threatening SSIs [6–8].
There is increasing evidence that human intestinal microbiota play an important role in the
pathogenesis of SSIs. Although historically, gut flora has been considered as a pathogen in human
infections [9], recent studies show that alteration of the human microbiome (dysbiosis) may play a role
in the pathogenesis of SSIs and other surgery-related complications (SRCs) [10–12]. Human gut
microbiota composition fluctuates on a daily basis depending predominantly on diet, but also
exercise, medications, and exposure to stressful events [13–16]. The general health status of a patient
scheduled for surgery is of particular interest, and the make-up of the microbiota could be of
particular interest, because it is believed that the majority of hospital infections originate from the
patient’s own microbiota, in part due to noxious and stressful surgical preparatory procedures [2].
Supporting the role of microbiota, it has been shown that mechanic bowel preparation (MBP) before
gut resection, accompanied by oral antibiotic therapy, reduces the number of infectious complications,
including anastomotic leakages by almost half [17]. However, multiple studies have reported vast
disturbances in microbial counts and diversity following these procedures that may itself create
microbiota disturbances with health consequences [18,19].
The surgical procedure itself and other pathology not even related to the gastrointestinal tract
may be a major cause of alterations in the intestinal microbiota. There are numerous examples in
the literature. Dysbiosis has been described in the excluded colon after small bowel stoma [20].
Major burn injury was described to reduce two major phyla within the human gut and to increase
Gammaproteobacteria class involved in SSIs [21]. Significant changes of gut flora with increased virulent
Escherichia coli, Pseudomonas aeruginosa, and Enterococcus faecalis counts have been described with surgical
procedures [21–23]. Surgical reconstructions of the gastrointestinal (GI) tract may delay the microbiota
refaunation [24,25], and result in enhanced virulent phenotype expression [26]. In severe injuries, more
virulent pathogens may predominate in the intestinal ecosystem [27], disrupt the intestinal barrier structure
and function, which facilitates the bacterial translocation, and may result in SSIs.
It thus appears that manipulating gut microbiota composition to a healthier variety could be
promising. Administration of beneficial microbes (probiotics), fiber (prebiotics), or both (synbiotics)
could be an attractive strategy to diminish the incidence of SSIs [28]. There are randomized,
double-blind, placebo-controlled trials and meta-analyses that support the efficacy of this strategy [28–33].
A recently published meta-analysis aimed to find evidence on prebiotics, probiotics, and synbiotics
supplementation on postoperative complications (mostly infective) in surgical patients [28,29,32,34].
Additionally, Wu et al. [29] estimated the efficacy of probiotics and antibiotics combination in the
prevention of SSIs and the decrease of antibiotics usage in colorectal surgery, and Kasatpibal et al. [28]
conducted a network meta-analysis (NMA) to evaluate the efficacy of probiotics, prebiotics,
and synbiotics in reducing SSIs as well as other postoperative complications. Although probiotics have
already been used as prophylaxis against SSIs, to the best of our knowledge, none of the guidelines
recommend their use. Among the reasons could be lack of data on the precise mechanisms of such
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interventions in lowering the risk of SSIs and the fact that studies aimed at elucidating the effect of
probiotic action on mucosal and stool microbiota lack correlation with clinical outcomes [35].
Therefore, this systematic review was performed to study the role of probiotics and synbiotics in
the prevention of SSIs and SRCs. In particular, our study aimed to evaluate:
a. The mechanism of action of probiotics and synbiotics in prevention of SSIs;
b. The influence of probiotics on gut microbiota alterations related to the surgery;
c. A possibility to establish recommendations concerning strain(s), dose, and mode of administration of
probiotic in the prevention of SSI and SRCs.
A random-effect model meta-analysis to determine putative mechanisms associated with such
intervention was also performed. The meta-analysis (MA) evaluated all available data on the usefulness
of probiotics in the prevention of SSIs/SRCs in patients undergoing abdominal surgery. The findings
could result in a call to determine the appropriateness of implementation probiotics into clinical
practice and consideration for inclusion in guidelines as a potentially cost-effective and life-saving
therapy. Finally, a meta-regression was performed in order to try to identify a particular probiotic
strain of formula, dose, and duration of the probiotic supplementation, which could be recommended
as treatment to prevent SSIs.
2. Materials and Methods
2.1. Search Strategy and Inclusion Criteria
Two independent authors (K.S.-Z., M.K.) searched PubMed/MEDLINE/Cochrane Central
Register of Controlled Trials from the inception of databases until 1 June 2018 in English for human
trials assessing the efficacy of pre/pro/synbiotic administration in reducing the incidence of SSIs and
SRCs. The following search terms with medical subject headings (MeSH–bold font) Supplementary
Concept Record terms (SCR italic font) and free text terms were used: (“probiotics” OR probiotic
* OR “prebiotics” OR symbiotic * OR fiber OR “dietary fiber” OR microbiota *) AND (operation
OR “surgical procedure” OR “surgical procedures, operative” OR “general surgery” OR surgery OR
transplantation OR “surgical operation” OR surgery OR “abdominal surgery” OR “colorectal surgery”
OR “colectomy” OR “small bowel surgery” OR hepatectomy OR “biliary surgery” OR “pancreas
surgery” OR proctology * OR proctocolonic surgery * OR intestine surgery *) AND (readmission
OR “readmission rate” OR mortality OR morbidity OR sepsis OR procalcitonin OR calcitonin OR
leakage OR “surgical infection” OR “surgery site infection” OR leakage OR “anastomotic leakage”
OR SSI OR post-operative wound infection * OR postoperative wound infection * OR complication
OR peritonitis OR abscess OR translocation OR lactulose OR zonulin OR calprotectin OR ileus OR
“postoperative ileus”). Apart from the electronic search, a manual review of reference lists from existing
meta-analysies and relevant reviews was performed.
We used the following inclusion criteria:
1. treatment with pro-/pre-/synbiotics;
2. randomisation to pre/pro/synbiotic versus placebo/monotherapy/standard care; and
3. available meta-analyzable endpoint/change score data on outcomes placed below.
4. if a study contained more than two arms, the data were abstracted separately for each comparator.
2.2. Data Abstraction
Two authors (K.S.-Z., M.K.) independently, in accordance with the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA) [36], abstracted information from each study,
including details of the study (e.g., study design, treatment protocol, duration, number of subjects,
gut barrier and SRCs parameters, and risk of bias), intervention (e.g., pre/pro/symbiotic, agent name,
dosage, and duration of treatment), and primary patient characteristics (e.g., age, sex, and reason for
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the surgery). In case of missing data, a request letter for additional information was sent to authors.
Any inconsistencies were referred by the senior author (W.M.).
2.3. Outcomes
The primary outcomes that were extracted from each study were the gut-related parameters
associated with the putative mechanism of pre/pro/symbiotic action: bacterial translocation,
lactulose/mannitol ratio, short chain fatty acids production, zonulin, calprotectin, gut microbiota
composition, diamine oxidase (DAO) activity, as well as non-specific indices of inflammation such as
C-reactive protein (CRP), interleukin-6 (IL-6) plasma concentration and white blood cells (WBC) count.
To update the data reported by other authors on the effectiveness of pre/pro/synbiotics evaluating
such interventions in the prevention of SSIs/SRCs the following secondary outcomes were evaluated:
abdominal distention, anastomotic leakage, diarrhea, intraabdominal abscess, mortality, methicilin
resistant staphylococcus aureus infection, peritonitis, pneumonia, re-operation, sepsis, SSIs, superficial
incisional SSIs, deep organ/space SSIs, urinary tract infections, blood loss, duration of antibiotic
therapy, duration of postoperative pyrexia, the time of implementation of fluid and solid diet, hospital
and intensive care unit stay duration, and operating time.
2.4. Data Synthesis and Statistical Analysis
A random effects meta-analysis [37] of outcomes for which at least three studies contributed
data was conducted using software (Comprehensive Meta-Analysis, version 3.3.070; http://www.
meta-analysis.com). The between-study variance (τ2) was estimated using the method of moments
(DerSimonian and Laird) and the assumption of homogeneity in effects was tested using the Q statistic
with a k-1 degree of freedom (k—the number of studies). Pooled standardized mean difference (SMD)
in change score/endpoint scores was used to analyze group differences in case of continuous variables.
For nominal outcomes the summary risk ratio (RR) was calculated. A two-tailed Z test was used
to test the null hypothesis that the summary effect is zero. In addition to classical meta-analysis,
a meta-regression was performed under the random-effects model for both continuous and nominal
study level covariates. The regression models with single covariates were fit. Funnel plots were
inspected to quantify whether publication bias could have influenced the results. The Egger’s
regression intercept test for asymmetry of the funnel plots was used. The statistical significance
was adopted at two-side p value < 0.05.
2.5. Risk of Bias
Two authors (K.S.-Z. and M.K.) independently assessed the risk of bias using the Cochrane
Collaboration’s tool for assessing risk of bias [38]. When a discrepancy occurred, a third author (I.Ł.)




The initial search yielded 2872 citations. Of these, 2822 were duplicates and/or removed
after title/abstract evaluation. Five manuscripts were identified using a manual search.
Forty-seven articles underwent a full-text review, and some were excluded because they were
reviews/meta-analysis/systematic review (N = 8), in the Chinese language (N = 2), mice model (N = 1),
and contained no meta-analyzable infectious related data/end-points (N = 1). Eventually, 35 studies
were included in the meta-analysis [39–73] (Figure 1).
42
J. Clin. Med. 2018, 7, 556
Figure 1. Study flow chart.
3.2. Study, Patient and Treatment Characteristics
Of the 35 studies included, the majority were double-blind trials (N = 17) [39,42,45–47,49–52,56,60,61,
64,71–74]. The mean study duration was 14.5 ± 5.58 (range: 3–28) days. In 16 studies [39,41,42,46,49–54,56,
63–65,69,70], probiotic intervention was used, while synbiotics were administered in 19 trials [40,43–45,47,
48,55,57–62,66–68,71–73]. There were two major groups per surgery performed: hepatopancreatobillary
(N = 15) [40,43,46,51,54,58,63,64,66–68,70–73] and colorectal (N = 11) [31,41,47,49–52,56,61,62,65]. In seven
studies [42,44,45,48,53,55,60] the procedure was not specified. Two trials involved oesophagectomy [57,59].
The most commonly utilized comparator was placebo (N = 15) [31,42,43,45,47,49–52,56,60,63,64,69,70].
There were 3028 patients included, with a male predominance (n = 1748, 57.73%). Details are given in
Table 1.
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3.3. Microbiota and Putative Mechanism of Probiotic/Synbiotics’ Action in SSIs/SRCs
Prevention—Primary Outcomes
Gut microbiota analyses were present in 14 studies [40–44,52,55–59,64,65,67]. The results
confirmed postoperative microbiome alterations in study groups compared to controls. Most studies
identified Lactobacillus (phylum Firmicutes) and Bifidobacterium (phylum Actinobacteria) as beneficial
for the outcomes. Nine studies [40–42,55–57,59,67] reported elevations in Bifidobacterium genus (or
its particular species) including patients supplemented with microbial agents, but did not reach
statistical significance for a benefit. Lactobacillus concentrations were elevated post-surgery in six
studies [40,57,59,64,67,75]. In contrast, decreased numbers of beneficial microbes and increased
abundance of harmful species (Enterobacteriaceae, Pseudomonas, Staphylococcus, and Candida) were
reported in a few no-intervention groups [40,42,44,57]. One study [56] reported a Bifidobacterium/E. coli
ratio. In two studies [43,58], there were no significant differences in bacterial species abundance
between the groups. For example, Usami et al. [58] concluded that two weeks after the surgery
microbiota composition resembled that of before the surgery regardless of the intervention.
However, changes of fecal microbiota composition observed by Usami et al. [58] were not consistent
with results reported by other authors [67]. Reasons for this discrepancy might be associated with
the difference in intestinal microbiota between liver cirrhosis and biliary surgery patients and/or no
administration of enteral nutrition in their study [40,67]. Details are given in Table 2.
Putatively factors associated with the mechanism of pro/synbiotic action were searched with
a focus on gut barrier integrity. These included: (i) bacterial translocation, (ii) lactulose/mannitol
permeability test, and (iii) short chain fatty acids (butyrate, acetate, propionate) concentration, as well
as non-specific markers of inflammation: (iv) C-reactive protein, (v) IL-6, and (vi) WBC counts.
Diamine oxidase (DAO) activity was analyzed in two studies only [40,58], therefore excluded from
metanalysis. CRP and IL-6 were significantly decreased (SMD: −0.40, 95% CI [−0.79, −0.02], p = 0.041;
SMD: −0.41, 95% CI [−0.70, −0.12], p = 0.006, respectively) and short chain fatty acids (SCFAs)–acetic,
butyric and propionic acids–were elevated (SMD: 1.78, 95% CI [0.80, 2.76], p = 0.0004; SMD: 0.67, 95% CI
[0.37, 0.97], p = 0.00001; SMD: 0.46, 95% CI [0.18, 0.73], p = 0.001, respectively) in patients supplemented
with probiotics. No other statistically significant results were found. Results are presented in Table 3
and Figures 2–9.
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Figure 2. The effect size (standardized mean difference) for the concentration of CRP in patients taking
probiotics (intervention) vs. no probiotics (control).
Figure 3. The effect size (standardized mean difference) for the concentration of IL-6 in patients taking
probiotics (intervention) vs. no probiotics (control).
Figure 4. The effect size (standardized mean difference) for the concentration of WBC in patients taking
probiotics (intervention) vs. No probiotics (control).
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Figure 5. The effect size (standardized mean difference) for the lactulose/mannitol (L/M) ratio in
patients taking probiotics (intervention) vs. no probiotics (control).
Figure 6. The effect size (standardized mean difference) for the concentration of butyrate ratio in
patients taking probiotics (intervention) vs. no probiotics (control).
Figure 7. The effect size (standardized mean difference) for the concentration of acetic ratio in patients
taking probiotics (intervention) vs. no probiotics (control).
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Figure 8. The effect size (standardized mean difference) for the concentration of propionic ratio in
patients taking probiotics (intervention) vs. no probiotics (control).
Figure 9. The effect size (risk ratio) for the overall effects of probiotics in the prevention of
bacterial translocation.
3.4. Surgery Related Complications (SRCs) and Secondary Outcomes
To evaluate the effectiveness of pro/synbiotic interventions in reducing the incidence of SSIs/SRCs,
data was extracted from common surgery-related clinical outcomes. Consequently, meta-analyses were
conducted on parameters reported in at least three studies and the data confirmed that microbial
supplementation was associated with a significant reduction in the incidence of SSIs and SRCs including:
(i) abdominal distention, (ii) diarrhea, (iii) pneumonia, (iv) sepsis, (v) superficial incisional infection,
(vi) urinary tract infection, (vii) duration of antibiotic therapy, (viii) duration of postoperative pyrexia,
(ix) time of fluid introduction and (x) solid diet, and (xi) duration of hospital stay. Data are given in
Supplementary Table S1. Representative forest plots of secondary outcomes are presented in Supplementary
Figures S1 and S2. Other forest plots are available upon request.
To obtain data useful for drawing clinical recommendations and new guidelines a meta-regression
was conducted (Table 3). Based on the analysis of the selected studies, it was not possible to find a
particular probiotic formula or strain, its dose or duration of the probiotic supplementation that could
be recommended to manage either primary or secondary outcomes analyzed in this study (p > 0.05).
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An inverse correlation was only found for propionic acid concentration. For every increase of one
unit (day) in treatment duration, the SDM for propionate decreased by 0.0355 (p = 0.049). Also effect
sizes were found to be independent of the timing of the intervention (pre + post vs. only post-surgery).
It was not possible to show whether the quality of the trial could have influenced its results (p > 0.05).
3.5. Risk of Bias
An analysis of the overall risk of bias from the studies included in the meta-analysis was limited
by restricted information being provided. For example, random sequence generation bias could
not be determined in 15 studies and allocation concealment bias could not be studied in 13 papers.
The unclear risk of bias in performance, detection, short-term outcomes, and reporting sections were
reported in 9, 11, 3, and 12 studies, respectively. It was not possible to determine other risks of bias
in 24 papers. Overall, 14 studies were of high quality and 21 of low quality. One study achieved
maximum points of low risk assessments (i.e., 7 points) and only two studies achieved no low risk of
bias assessments points (i.e., 0 points). The results are in Table S2 (Supplementary Material).
4. Discussion
To the best of our knowledge this meta-analysis of 35 trials and 3028 patients is the first one to
exclusively investigate the effect and possible mechanism of action of pro-/synbiotics to lower the
risk of SSIs and SRCs. The study shows that microbial agents administered perioperatively have the
potential to increase the abundance of beneficial bacteria within the gut, elevate the synthesis of short
chain fatty acids and thus reduce the immune response. Consequently, it appears to indicate that
pro-/synbiotics may serve as preventive strategy toward SSIs and SRCs.
The data are mounting that the host complex of bacteria, fungi, viruses, and Archaea contribute
to human biology [76]. In patients scheduled for elective abdominal surgery, the gut microbiota
might undergo alterations that have an impact on surgery outcomes. In this study in patients
not treated with any microbial agents perioperatively, the predominance of beneficial microbes
was decreased, but the counts of potentially harmful ones were elevated. Eubiosis and a proper
abundance of protective bacteria in the gut may protect the host against pathogens [75]. In this
meta-analysis, the majority of the studies showed that pro-/synbiotic treatment reduced the
number of Enterobacteriaceae. However, Mangel et al. [52] showed opposing results and observed
increased abundance of Enterobacteriaceae in patients undergoing colon resection who received a
probiotic. The explanation of this phenomenon is not clear. One reason might be too short of a
probiotic administration to reduce potential pathogen counts, while another could be associated
with oatmeal used as a prebiotic, which could act as a substrate for intestinal bacteria, and the third
one is that lactobacilli given orally did not survive the passage through the gastrointestinal tract.
Another explanation is a different response of Enterobacteriaceae genera to probiotic administration
(reduction in the numbers of one genera by the probiotic may result in an expansion of another).
This is also of interest as lipopolysaccharide (LPS) attached to the membrane surface of Gram-negative
microbes [77,78] may result in enhanced virulence phenotype expression [26]. In severe injuries, more
virulent pathogens may predominate in the intestinal ecosystem [27], disrupt the intestinal barrier
structure, and function and facilitate bacterial translocation resulting in SSIs and SRCs.
The steady state composition of gut microbiota is crucial in maintaining gut homeostasis [79].
The mechanisms that are implicated in the pathogenesis of complications in patients in the
perioperative period are complex. Initially, a healthy microbiota produces lactic acid, which
is metabolized to short chain fatty acids (SCFAs), the latter ones are directly related to fecal
Bifidobacterium count [66]. SCFAs, predominantly butyrate, are crucial for proper gut barrier
structure and function [80,81]. After abdominal surgeries and in the course of multiple nonsurgical
diseases, beneficial butyrate, acetate, and propionate concentration diminish as a consequence of
the deterioration of lactic acid metabolism, as well as fasting [82]. Butyrate, apart from being an
energy source for colonocytes, stimulates mucus production and tight junction proteins synthesis [75].
57
J. Clin. Med. 2018, 7, 556
It has been found to inhibit the expression of virulence genes [83] and restrict the growth of
Pseudomonas aueroginosa, a collagenase producer, implicated in the pathogenesis of anastomotic
leakage [84,85]. Butyrate controls the function of regulatory T cells in a microbe-associated context [86]
and suppresses inflammation via nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB)
signaling [87]. It also stabilizes the hypoxia inducible factor involved in the augmentation of the barrier
function [88]. This meta-analysis shows that the concentrations of acetic, butyric, and propionic acids
were elevated in patients supplemented with probiotics. Surprisingly, a meta-regression indicated
that the longer duration of probiotic intervention, the smaller the effect size for propionic acid.
This seems to be in contrast with mechanistic studies in which propionic acid was discovered to
act as an immunosuppressant [89]. This metabolite possesses anti-fungal and anti-bacterial effects [90]
responsible for the inhibition of invasion genes in Salmonella typhimurium. Propionic acid is able to
diminish the synthesis of eicosanoids via lowering the activity of cyclooxygenase [91,92]. Although the
acid may inhibit mitogen-activating lymphocytes proliferation, different studies found that the
inhibitory effects may be positively correlated with its concentration [93–95]. The discrepancies
between concentrations inside and outside the visceral compartment may at least partly explain the
observed results. It should be pointed out that this data was extracted from four studies, so the results
need to be interpreted with caution [40,44,55,67]. More studies evaluating SCFAs concentration in
surgical patients are needed to confirm this finding.
It was also found that in patients supplemented with pro-/synbiotics, the concentration of
CRP and IL-6 were significantly decreased in comparison to non-treated patients. As antigens flow
through the disrupted intestinal barrier, the activation of the immune response in lamina propria
and the production of inflammatory mediators take place. IL-6 and CRP were found to be at
higher serum concentrations in patients with low DAO activity following the surgery [58]. This is
crucial as DAO being produced at the tip of the villi reflects the integrity of the small intestine
barrier. The enzyme serum concentration is of small bowel origin [96–98] and its activity was found
to be diminished following major hepatectomy [40,58,67]. This study shows that pro-/synbiotic
intervention significantly lowered the concentration of IL-6 and CRP. The body of evidence states that
IL-6 signaling plays a pivotal role in epithelial stem cells and intraepithelial lymphocytes proliferation
and may be involved in wound healing [99]. Recently, Kuhn et al. [100] discovered that intraepithelial
lymphocyte-derived IL-6 served positively toward barrier function via claudin-1 protein expression
and increased mucus thickness [100]. Although CRP production in hepatocytes was found not to be
influenced by medical therapies [101], the most recent meta-analysis by Mazidi et al. proved that
probiotic administration may significantly reduce serum CRP with a weighted mean difference (WMD)
of −1.35 mg/L; however, that study was not limited to surgical patients only [102].
Gut-derived bacteremia is a result of elevated intestinal permeability which further makes antigens
flow through the epithelium, elevate serum inflammatory mediators [58], and enhance bacterial
translocation to mesenteric lymph nodes after interventions such as a hepatectomy [103] and an
esophagectomy [104]. In this study, it was not possible to demonstrate that microbial intervention
diminished the risk of bacterial translocation. However, studies evaluating the bacterial translocation
were based on culture-based methods and such methodology was valid to evaluate the presence of
well-cultured bacteria only [66]. Culture-independent molecular techniques and sophisticated bioinformatic
analyses should therefore be implemented in future trials to evaluate bacterial translocation and assess the
functionality of translocated microorganisms in patients in perioperative periods.
This updated systematic review found that patients treated perioperatively with pro-/synbiotics
had lower relative risk toward (i) abdominal distention, (ii) diarrhea, (iii) pneumonia, (iv) sepsis,
(v) superficial incisional infection, (vi) urinary tract infection, (vii) duration of antibiotic therapy,
(viii) duration of postoperative pyrexia, (ix) time of fluid introduction and (x) solid diet,
and (xi) duration of hospital stay, and supports other observations [28,29,32].
This study also shows that biochemical parameters associated with the gut barrier were
improved in patients treated with pro-/synbiotics, supporting the hypothesis that SSIs and SRCs
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are actually in large part sourced from the patient’s own gut flora. This is in line with a recent
SR by Lederer et al. [105] who reported that the gut microbiome was responsible for postoperative
complications including anastomotic leakage and wound infection. The data was not robust enough to
establish recommendations for the use of beneficial bacteria in SSIs/SRCs prevention. The limitations
of the available data did not allow us to determine which probiotics strain is the optimal choice,
particular clinical situations where they could prove beneficial, how long the intervention should last,
and the optimal dose of the supplement. The study was unable to establish that synbiotics should
be used first-line to reduce specific SSIs and SRCs, which contrasts with the network meta-analysis
by Kasatpibal et al. [28]. Apart from different methodological approach, this study included more
patients (2952 vs. 3028) but excluded studies in a non-English language that may partly explain the
discrepancies. Therefore, on the basis of the results of this study, microbial supplements in general,
without strain recommendation in perioperative period, could be advocated. Taking into account the
documented stability and safety of probiotics available on the market, the findings could explain the
lack of current implementation of probiotics/synbiotics into SSIs/SRCs prevention clinical guidelines.
More high-quality studies are needed to draw detailed protocols to evaluate particular probiotic strains,
optimal duration of their supplementation, objective outcomes measurements, and maybe even stratify
by surgery types to understand the roles. Nevertheless, the evidence is strong to already support dietary
supplementation with probiotics in patients undergoing major abdominal surgeries. This topic seems to
be of high priority as Berrios-Torres et al. [4] in their recent Centers for Disease Control and Prevention
Guideline for the Prevention of Surgical Site Infection stated that antimicrobial prophylaxis should be
administered only when indicated based on published clinical practice guidelines. The evidence is
mounting that the longer post-surgical antibiotic administration, the greater the frequency of SSIs [1].
Antibiotic administration was found to elevate the risk toward inflammatory disorders, predominantly
due to commensal bacteria translocation through the gut barrier, thus disturbing the microecological
niche within the gut [106]. Also, antibiotic gut decontamination may activate dormant spores, which
consequently results in severe infectious complications [107]. Recently, the 6th National Audit Project
of the Royal College of Anaesthetists reported antibiotic-induced life-threatening anaphylaxis as
well [108]. However, one of the current widely agreed and recommended intervention to decrease the
incidence of SSIs/SRCs is perioperative antibiotic administration.
Postsurgical complications (PSCs) are currently one of the most challenging health care
issues worldwide [1,2]. Moreover, these unpredictable post-surgical events result in unscheduled
readmissions, extended antibiotic therapy, and elevated mortality rate, but importantly generate
additional costs of treatment. For example, Tanner et al., evaluated that in the U.K., SSIs secondary to
colorectal surgery generated an extra cost of more than £10.000 with only 15% met in primary care [109].
More recently, Straatman et al. [110] pointed that in Netherlands, complications following major
abdominal surgery may generate as much as 240% higher costs of treatment, depending on the clinical
course of PSC. In the USA, the mean cost for a hospital stay was found to be approximately twice as
high in patients with complications compared with those suffering from no PSCs. Consequently, total
profit margin was estimated to be about 5.7% lower in patients with complications [111]. On the
other hand, as reported by Keenan et al. [112], introducing a preventive strategy, e.g., SSI bundle in
colorectal surgery, may significantly diminish the incidence of SSIs, and consequently, health care costs.
As our paper provides evidence linking PSCs to host intestinal microenvironment, maintaining healthy
microbiota—at least during the hospital stay—to reducing the incidence of these life-threatening
events seems to be one of these cost-effective regimens [6–8]. Indeed, our study has shown that
probiotic intervention significantly decreased the duration of antibiotic therapy (SMD: −0.597, 95% CI:
−1.093, −0.10, p = 0.018) and overall length of hospital stay (SMD: −0.479, 95% CI: (−0.660, −0.297,
p = 0.0000002). The reduction of these variables, together with the lowest incidence of PSCs reported
in our study, extrapolate to a reduction in the cost of a patient’s stay in a hospital. This is in line with
the assumptions made recently by Wu et al. [34] who analyzed two studies of Liu et al. [50,51] and
reported a lower hospital charge concerning patients receiving probiotics in comparison to the placebo
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groups. Finally, it was concluded [34] that probiotic prophylaxis in surgery wards may decrease the
hospital costs.
Several limitations of this MA require underlining. These include (i) a small number of
double-blind clinical trials; (ii) heterogeneous study aims, patient groups, intervention characteristics,
and study targets; (iii) a limited number of reported outcomes; and (iv) meta-regression analyses
were conducted only for exploratory reasons due to different subsets of patients and treatments.
The overall moderate quality of the studies may have significantly influenced the study outcomes.
Nevertheless, despite these limitations, this is the first, comprehensive SR/MA that shows a beneficial
effect of pro-/synbiotics in reducing the incidence of SSIs/SRCs likely via modulating gut related
immune response and production of SCFA.
In conclusion, our MA supports that pro-/synbiotics as a class can have an effect on the outcome,
but more granular data on particular types and concentrations cannot be recommended. The effect
on SSIs/SRCs is complex, including the modulation of CRP and WBC counts, as well as alteration
of SCFAs synthesis and others that need further clarification. More high-quality studies are needed
to draw detailed protocols to evaluate particular probiotic strains and optimal duration of their
supplementation in patients undergoing surgical procedures. However, the evidence presented in
this systematic review strongly supports that dietary supplementation with probiotics in patients
undergoing major abdominal surgeries has a beneficial effect.
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Abstract: Mucosal healing in Crohn’s disease (CD) can be evaluated by capsule endoscopy (CE).
However, only a few studies have utilized CE to demonstrate the therapeutic effect of medical
treatment. We sought to evaluate the validity of using CE to monitor the effect of medical treatment
in patients with CD. One hundred (n = 100) patients with CD were enrolled. All patients had
a gastrointestinal (GI) tract patency check prior to CE. Patients with baseline CE Lewis score (LS) ≤ 135
were included in the non-active CD group and ended the study. In those with LS > 135 (active CD
group), additional treatment was administered, regardless of symptoms, as per the treating clinician’s
advice. Patients of the active CD group underwent follow-up CE assessment 6 months later. Out of
92 patients with confirmed GI patency who underwent CE, 40 (43.4%) had CE findings of active
inflammation. Of 29 patients with LS > 135 who received additional medications and underwent
follow-up CE, improvement of the LS was noted in 23 (79.3%) patients. Eleven patients were
asymptomatic but received additional medications; 8 (72.7%) had improvement of the LS. This study
demonstrated that additional treatment even for patients with CD in clinical remission and active
small-bowel inflammation on CE can reduce mucosal damage.
Keywords: capsule endoscopy; Crohn’s disease; mucosal healing; small bowel
1. Introduction
The main goal in the treatment for Crohn’s disease (CD) is mucosal healing (MH). MH is
predictive of reduced subsequent disease activity and clinical upset, and decreased need for further
active treatment [1–3]. Several modalities are used in assessing overall disease activity and MH
in CD. For instance, faecal calprotectin (FC) is a simple, non-invasive, and readily available tool;
however, its accuracy in evaluating active small-bowel (SB) mucosal lesions in CD has often been
debated [4]. Although cross-sectional imaging has been traditionally used in the evaluation of SB
CD [5,6], endoscopy remains the ‘gold standard’ for assessing SB MH because it provides direct and
clear observation of the SB mucosa.
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Capsule endoscopy (CE) enables physicians to visualize the SB in a non-invasive manner.
Hence, CE allows detection of SB mucosal lesions, as well as linear ulceration and luminal stenosis [7].
Recently, Esaki et al. [8] reported that CE enables the identification of SB damage in 88% of patients
with established SB CD. Capsule retention is a potentially serious complication of CE; however,
the rate of this complication decreases substantially if gastrointestinal (GI) patency is assessed prior to
performing regular CE [9,10]. Consequently, CE is recommended as the initial diagnostic modality for
SB assessment in patients with suspected CD and negative ileocolonoscopy [11].
To quantify/categorize SB inflammation, Gralnek et al. [12] developed a CE index, the Lewis
score (LS), comprising 3 parameters: villous oedema, mucosal ulcer(s), and luminal stenosis. A LS
< 135 indicates normal or insignificant mucosal inflammation, LS 135–790 indicates mild mucosal
inflammation, and LS ≥ 790 indicates moderate-to-severe inflammation. LS has been validated
in the diagnosis and follow-up of established CD [13]. Stratifying SB inflammatory activity at the
time of diagnosis has relevant prognostic value in patients with isolated SB CD [14]. A CE-based
assessment of SB MH is reported to be useful for predicting long-term clinical remission in CD [15].
Moreover, several retrospective studies have highlighted the potential effect of CE on the therapeutic
management of patients with established CD [16–18].
However, a high percentage of patients in clinical remission have findings suggestive of on-going
inflammatory activity, as evidenced by C-reactive protein (CRP) and FC levels, CE, and cross-sectional
imaging [19]. Kopylov et al. [20] demonstrated that a positive CRP level was found in 30.8% of patients
with CD in clinical remission, while a high LS on CE was found in 84.6%. Nevertheless, patients with
CD who are clinically asymptomatic may not wish to receive additional treatment, and/or physicians
may be reluctant to recommend additional treatment in such situations.
Therefore, the aim of this prospective study was to evaluate using CE additional treatment in
patients with inflammatory activity, regardless of the presence of clinical symptoms.
2. Patients & Methods
2.1. Patients
This prospective, multicenter study was conducted in hospitals affiliated with the Department of
Gastroenterology & Hepatology at Nagoya University Graduate School of Medicine. Key inclusion
criteria were patients with established CD who were >10-years-old and scheduled to receive a PillCam
patency capsule (PPC), and thereafter CE. For patients to be eligible for inclusion, the colon had to be
clear of any inflammation, as confirmed using a conventional colonoscopy. Key exclusion criteria were
the presence of any contraindications to anti-tumor necrosis factor (anti-TNF) agents and/or those
who were considered non-appropriate candidates by their physician.
2.2. Study Protocol
The study protocol involved two rounds of CE. Patients with CD referred for CE evaluation
were informed of the study, aims, and its protocol. Once consent was obtained, patients who
accepted to participate underwent the baseline CE at their local hospital. For every patient who
was considered for study inclusion, the absence of colonic inflammation, confirmed by a conventional
colonoscopy, was necessary. PPC was used before CE, including follow-ups, in all patients who
agreed to participate. The PPC consists of lactose and 10% barium, which dissolves when intestinal
fluids come into contact with them through a window at the edges of the PPC. PPC is similar to
the second-generation Agile patency capsule, with the only difference being that the radiofrequency
identification tag has been removed [10] (Figure 1). GI patency was evaluated either by confirming
excretion of an intact PPC or by obtaining a plain abdominal X-ray and/or computed tomography
(CT), generally between 30 and 33 h after PPC ingestion. The capsules used for CE were PillCam®SB2
or SB3 (manufactured by Medtronic, Minneapolis, MN, USA), which measure 26 × 11 mm and are
propelled by peristalsis. All subjects whose GI patency was confirmed underwent CE, at their earliest
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convenience, following an overnight fast without prokinetics or prior laxative bowel preparation.
Patients whose GI patency was not confirmed were excluded from further participation in this study.
Following anonymization, the CE videos were sent to Nagoya University Hospital via the Nagoya
network system, as described in References [21,22]. Two expert CE readers (MN, TY) independently
reviewed each CE and calculated the LS. They also read the second CE videos and remained blinded
to the treatment provided following the baseline CE reports. SB cleansing was evaluated in four
grades according to previous literature [23,24]. In cases of any discordance in LS results, the experts
discussed all relevant CE images and provided final LS by consensus agreement. The report of each
CE was then sent back to the local hospital and further clinical management was left with the treating
physician/team. Clinical data related to PPC and CE, including adverse events, were collected.
Figure 1. PillCam patency capsule.
Clinical remission was defined as a CD activity index (CDAI) score < 150. Since a LS < 135 can
occasionally be associated with the presence of aphtha(e) or villous/fold oedema on CE, only a LS =0
was defined as complete MH. If LS ≤ 135 on baseline CE, suggestive of normal or clinically insignificant
mucosal inflammatory change [25], the patient finished the study (non-active CD group). In the case
of LS > 135, the treating teams could proceed with additional treatment, regardless of the presence
of any clinical symptoms (active CD group). For patients of the active group, the follow-up CE was
scheduled 6 months later, and it was performed with the same protocol as the baseline one.
2.3. Evaluations
Comparison was made between the clinical background and the baseline CE findings between
the active and non-active groups. Additional therapeutic effects were evaluated in the active group,
especially in asymptomatic patients, who underwent follow-up CEs. Primary outcome was any
reported change in CE findings between the two CE procedures. Key secondary outcomes were
changes in the CDAI and CRP level at the time of follow-up CE (for the active group), as well as any
adverse events of PPC and CE procedures.
2.4. Statistical Analysis
The statistical software package SPSS for Windows (SPSS Inc., Chicago, IL, USA) was used for
data analysis. The Wilcoxon signed-rank test was used to compare the LS based on CE and changes
in each marker before and after any additional treatment. Patients’ demographic data at the baseline
examination was compared between the active and non-active groups using the Mann-Whitney U test
or χ2 test. In all analyses, a p value < 0.05 was considered statistically significant.
2.5. Ethical Considerations
This study was approved by the ethics Committee of Nagoya University Hospital. This study
was registered in the University Hospital Medical Information Network, a clinical trials registry
(UMIN000008486). Written informed consent was obtained from all participants.
3. Results
Between September 2012 and April 2016, 100 patients were referred for CE and approached for
inclusion in this study at the Nagoya University Hospital and its 5 affiliated hospitals, as shown in
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Figure 2. Of these patients, 92 had confirmed GI patency and were eventually included in this study.
Absence of colonic inflammation was confirmed, prior to study entry, with a conventional colonoscopy
which was performed at a median of 14 (range 1–29) months prior to inclusion in the study.
Figure 2. Flow chart of present study. Abbreviations PC, patency capsule; CE, capsule endoscopy; DBE,
double balloon enteroscopy.
In the 92 baseline CEs, the grades of SB cleansing (for the whole SB) were excellent, good, fair,
and poor in 19, 59, 12, and 2 patients, respectively. Of 92 patients, 40 (43.4%) had findings of active CD
(active CD group); clinically, 28/40 patients were symptomatic. Their symptoms were diarrhea (n = 20),
abdominal pain (n = 4), bloody stool (n = 3), and abdominal fullness (n = 1). The remainder (n = 52),
with LS < 135 on baseline CE, comprised the non-active CD group. CDAI scores were not significantly
different between the two groups; however, LS was significantly higher in the active group than in the
non-active CD group. Hemoglobin and serum albumin levels were significantly lower in the active
group than in the non-active CD group (Table 1).
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Table 1. Demographic data of the patients at the point of study inclusion.
Total Active Group Non Active Group p Value
N 92 40 52
Age, mean ± SD, years old 37.2 ± 12.3 37.5 ± 12.3 37.1 ± 12.9 0.8624
Gender, M/F 68/24 29/11 39/13 0.9751
BMI 21.3 ± 3.2 21.5 ± 3.6 21.1 ± 2.9 0.603
Duration of disease, mean ± SD, months 117.1 ± 96.7 93.9 ± 73.3 135 ± 108.8 0.093
Montreal classification
Age at diagnosis
<17 years 7 3 4
17–40 years 70 30 40
>40 years 15 7 8
Location
L1—ileal 38 17 21
L2—colonic 0
L3—ileocolonic 54 23 31
Behavior
B1—Non-stricturing, non-penetrating 72 28 44
B2—Stricturing 15 9 6
B3—Penetrating 5 3 2
p-perianal disease 9 6 3
History of GI surgery 53/92 25/40 28/52 0.5353
Ileo-colonic resection 26 12 14
Ileal resection 21 9 12
Ileo-colonic resection plus Ileal resection 4 3 1
Colonic resection 2 1 1
Any symptom 28/92 19/40 9/52 0.0038
CDAI 104 ± 56 116 ± 72 95 ± 39 0.277
Laboratory data
CRP (mg/dL), mean ± SD 0.36 ± 0.62 0.53 ± 0.75 0.24 ± 0.47 0.0761
Hb (g/dL), mean ± SD 13.3 ± 2.1 12.7 ± 2.5 13.8 ± 1.6 0.0201
Albumin (g/dL), mean ± SD 4.0 ± 0.5 3.9 ± 0.5 4.2 ± 0.4 0.0014
Indication of CE
Symptom(s) 28 19 9
diarrhea 20 15 5
abdominal pain 4 2 2
bloody stools 3 2 1
abdominal fullness 1 0 1
Monitoring 64 21 43
PPC and CE
PPC intact body excretion 62/92 26/40 36/52 0.8377
Gastric transit time (min.) 45.5 ± 42.4 45.6 ± 40.3 47.2 ± 44.3 0.9904
SBTT (min.) 248.8 ± 128.8 270.7 ± 149.5 231.7 ± 108.5 0.3042
Lewis score, mean ± SD 396 ± 706 844 ± 892 52.1 ± 66.1 <0.0001
Treatment
Anti TNF-α agent 54/92 23/40 31/52
5-ASA 78/92 35/40 43/52
Immunomodulator 14/92 5/40 9/52
Elemental diet 57/92 23/40 34/52
We defined as regular use of non-steroidal anti-inflammatory drugs (NSAIDs), the use of this
class of medications for more than 6 months irrespective of type and dose. This was clarified by review
of the medical charts and patient interview. None of the patients regularly had used NSAIDs before
and/or after CEs. Of 38/40 patients of the active CD group who received additional anti-inflammatory
treatment(s) (infliximab, n = 8; 5-aminosalicylic acid, n = 7; azathioprine, n = 6; adalimumab, n = 4;
elemental diet, n = 2; prednisolone, n = 1; and mercaptopurine, n = 1), 29/40 (72%) underwent
follow-up CEs to assess the therapeutic effect on MH.
Following additional treatment for 6 months, the mean LS improved from 691 ± 126 to 394 ± 99.
Villous oedema before and after treatment was detected in 20 and 11 patients, respectively. Of all
the 29 patients who had ulcers at baseline CE, 19 improved and 4 no longer had an ulcer. The LS of
4 patients who had a baseline LS > 1000 decreased; however, only 2/29 patients achieved MH (Table 2).
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The mean CDAI score and LS significantly improved 6 months after the start of additional treatment
(Table 3), although the mean CRP level did not improve dramatically.
Table 2. 29 cases where intervention.
Case Medicine Intervention
Lewis Score
Total Score Villous Edema Ulcer Stenosis
Pre Post Pre Post Pre Post Pre Post
1 Infliximab dose up 5 ⇒ 10 mg/kg 2914 2824 112 112 450 360 2352 2352
2 Infliximab introduction 5 mg/kg 2585 280 8 0 225 0 2352 280
3 Adalimumab introduction 160 mg 2140 600 340 0 1800 600 0 0
4 Azathiopurin introduction 50 mg 1012 337 112 112 900 225 0 0
5 mercaptopurine introduction 20 mg 900 1368 0 168 900 1200 0 0
6 5-ASA dose up 3000 ⇒ 4000 mg 712 712 112 112 600 600 0 0
7 Infliximab introduction 5 mg/kg 712 421 112 0 600 225 0 196
8 Adalimumab introduction 160 mg 654 0 204 0 450 0 0 0
9 Adalimumab introduction 160 mg 600 0 0 0 600 0 0 0
10 Infliximab dose up 5 ⇒ 10 mg/kg 562 196 112 0 450 0 0 196
11 5-ASA dose up 1500 ⇒ 2000 mg 562 225 112 0 450 225 0 0
12 5-ASA introduction 3000 mg 562 337 112 112 450 225 0 0
13 Infliximab introduction 5 mg/kg 562 233 112 8 450 225 0 0
14 Azathiopurin introduction 50 mg 504 180 204 0 300 180 0 0
15 Prednisolone introduction 20 mg 458 450 8 0 450 450 0 0
16 5-ASA dose up 2000 ⇒ 3000 mg 458 147 8 12 450 135 0 0
17 Azathiopurin introduction 50 mg 450 458 0 8 450 450 0 0
18 Adalimumab introduction 160 mg 436 225 136 0 300 225 0 0
19 Elemental diet dose up 429 225 204 0 225 225 0 0
20 Elemental diet dose up 412 225 112 0 300 225 0 0
21 Infliximab dose up 5 ⇒ 10 mg/kg 412 225 112 0 300 225 0 0
22 Infliximab introduction 5 mg/kg 337 135 112 0 225 135 0 0
23 Azathiopurin introduction 50 mg 300 278 0 8 300 270 0 0
24 Azathiopurin dose up 50 ⇒ 75 mg 300 180 0 0 300 180 0 0
25 Azathiopurin introduction 50 mg 233 143 8 8 225 135 0 0
26 Infliximab dose up 5 ⇒ 10 mg/kg 225 233 0 8 225 225 0 0
27 5-ASA dose up 2000 ⇒ 3000 mg 225 225 0 0 225 225 0 0
28 5-ASA dose up 1500 ⇒ 3000 mg 225 450 0 0 225 450 0 0
29 5-ASA dose up 2000 ⇒ 3000 mg 180 135 0 0 180 135 0 0
Table 3. Biomarker levels at baselines and 6 months later.
Pre-Treatment Post-Treatment p Value
CDAI 102 (5–253) 68 (0–231) 0.0057
Lewis score 458 (180–2914) 233 (0–2824) 0.0004
CRP level (mg/dL) 0.55 ± 0.80 0.30 ± 0.51 0.0652
WBC count (/μL) 6822 ± 2602 5920 ± 1807 0.1663
Hb level (g/dL) 12.7 ± 2.5 13.2 ± 1.9 0.7843
Plt count(×1000/mm3) 26.6 ± 6.1 26.7 ± 7.0 0.5014
Albumin level (g/dL) 3.9 ± 0.6 4.1 ± 0.5 0.1297
Data are presented as a mean ± standard deviation. CDAI, Crohn’s disease activity index; CRP, C-reactive protein;
WBC, white blood cell; Hb, hemoglobin; Plt, platelet.
All 7 patients who received additional treatment with biologics had improvement of LS on repeat
CE (Figure 3). Of the 11 patients who were asymptomatic, 4 received 5-ASA, 3 received biologics,
2 received immunomodulators, 1 received prednisolone, and 1 received elemental diet as additional
treatment (Figure 4). LS improvement was noted in 8/11 (72.7%) patients; however, none of them
achieved MH. No adverse events occurred throughout the study, as no retention of PPC or capsule
was noted. Of 29 patients who received additional treatment and underwent follow-up CE, 23 patients’
clinical course could be confirmed post-study in November 2017. During the median follow-up 36
months, 12 patients did not undergo change in treatment, although 10 patients were given additional
treatment and 1 underwent surgery.
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Figure 3. Changes in the Lewis scores in patients who received biologics as additional treatment.
Abbreviations Pre, pre-treatment; post, post-treatment.
Figure 4. Changes in the Lewis scores in asymptomatic patients before and after treatment.
Bio, biologic; IM, infliximab; 5-ASA, 5-aminosalicylic acid; PSL, prednisolone; pre, pre-treatment;
post, post-treatment.
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4. Discussion
Our study confirms LS improvement in 23/29 patients (79.3%), irrespective of symptoms status,
who received additional treatment for active CD based on the findings of baseline CE. Interestingly,
8/11 asymptomatic CD patients (72.7%) had improvement in their LS, regardless of the type of
additional treatment provided. These results underline a couple of key points. First, asymptomatic CD
patients may require additional treatment or simply increasing the dose of their existing therapeutic
regimen to achieve MH. Additional medication had a positive effect in both asymptomatic and
symptomatic CD patients, as shown in Figures 2–4. Second, CE is a valid tool in evaluating both
therapeutic effect, as well as confirming MH in patients with asymptomatic (active) CD.
In CD, it remains controversial whether the physician should set the therapeutic target at MH or
clinical remission. If the therapeutic goal is MH rather than clinical (symptoms) remission, this can
only be evaluated by endoscopy. The POCER study suggested that monitoring using early colonoscopy
and treatment step-up was better in preventing postoperative CD recurrence, than conventional drug
therapy alone [26]. On the other hand, Kim et al. reported that endoscopic monitoring did not
significantly contribute to the non-hospitalization rate associated with CD, compared with ulcerative
colitis [27]. However, the definition of MH remains unclear. Total disappearance of mucosal ulcerations
has the advantage of providing irrefutable evidence of MH, but this strict ‘black-and-white’ goal
may be difficult to achieve [28]. For instance, a patient with numerous deep mucosal ulcerations
in whom treatment leads to healing of all but a superficial mucosal ulceration will be classified as
a ‘non-responder’.
To date, only few studies have shown the necessity and effectiveness of additional treatment for
CD patients in clinical remission and endoscopically-confirmed active lesions, although the significance
of monitoring has been widely recognized. Once the therapeutic effects for such patients have been
clarified, physicians may recommend a change of the medication regimen. Under the notion of
treat-to-target, Ungar et al. suggested a significant association between serum levels of anti-TNF agents
and the level of mucosal healing as the therapeutic goal [29]. Physicians may modify the dose of
biologic treatment with reference to the serum levels even if patients have no symptoms. The CALM
study demonstrated the significance of tight control, including timely escalation with anti-TNF therapy.
Combining clinical symptoms with biomarkers in patients with early CD results in better clinical
and endoscopic outcomes than symptom-driven decisions alone [30]. This study also supported the
importance of tight control in CD by evaluating treatment outcomes in asymptomatic patients.
The development and introduction of a new, more effective drug will provide better CD
monitoring. Endoscopic findings may become the best way to evaluate MH in CD because endoscopy
provides direct visualization of the intestinal mucosa and enables physicians to detect even subtle
mucosal lesions. However, it is unclear whether small lesions affect the long-term clinical outcome in
CD. Moreover, it is questionable whether physicians can determine MH in patients with small lesions.
LS calculation does not include the evaluation of such lesions. Therefore, MH according to LS means
that there is no mucosal ulcer, but this does not preclude the presence of erosions or mucosal aphtha(e).
Niv score or CECDAI, on the other hand, classifies erosion and small ulcers <5 mm under the same
category [31,32]. It may be necessary to evaluate the outcome of patients with and without erosions.
If physicians can ignore small lesions to consider the long-term outcome of CD, abdominal
ultrasonography and magnetic resonance enterography (MRE) will also be excellent modalities to
evaluate MH. Koulaouzidis et al. reported that the LS appears to have only a fair correlation with
the FC level, as well as other serological markers of inflammation [33]. FC level does not seem to be
a reliable biomarker for significant SB inflammation. Nevertheless, an FC level ≥ 76 μg/g may be
associated with appreciable visual inflammation on SB CE in patients with a prior negative diagnostic
workup, and it may become the surrogate marker of CD.
This study has few limitations. The overall sample size of this study was small. This study
focused on the Lewis score for next treatment, and laboratory data or calprotectin was not collected on
follow-up. Of the patients with active CD based on CE, the percentage of patients who received an
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intervention was low because five patients had developed small-bowel stenosis, as demonstrated on
a CT scan. The others did not wish to receive additional treatment. The kind of intervention depended
on the physician and patients according to the protocol. Therefore, the balance between the degree
of CD activity and kind of medication may not always be suitable. In conclusion, this prospective,
multi-center study demonstrated that additional treatment regardless of clinical remission reduces
mucosal inflammation in CD.
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Abstract: Once thought to be uncommon, celiac disease has now become a common disease globally.
While avoidance of the gluten-containing diet is the only effective treatment so far, many new targets
are being explored for the development of new drugs for its treatment. The endpoints of therapy
include not only reversal of symptoms, normalization of immunological abnormalities and healing of
mucosa, but also maintenance of remission of the disease by strict adherence of the gluten-free diet
(GFD). There is no single gold standard test for the diagnosis of celiac disease and the diagnosis is based
on the presence of a combination of characteristics including the presence of a celiac-specific antibody
(anti-tissue transglutaminase antibody, anti-endomysial antibody or anti-deamidated gliadin peptide
antibody) and demonstration of villous abnormalities. While the demonstration of enteropathy is an
important criterion for a definite diagnosis of celiac disease, it requires endoscopic examination which is
perceived as an invasive procedure. The capability of prediction of enteropathy by the presence of the
high titer of anti-tissue transglutaminase antibody led to an option of making a diagnosis even without
obtaining mucosal biopsies. While present day diagnostic tests are great, they, however, have certain
limitations. Therefore, there is a need for biomarkers for screening of patients, prediction of enteropathy,
and monitoring of patients for adherence of the gluten-free diet. Efforts are now being made to explore
various biomarkers which reflect different changes that occur in the intestinal mucosa using modern
day tools including transcriptomics, proteomics, and metabolomics. In the present review, we have
discussed comprehensively the pros and cons of available biomarkers and also summarized the current
status of emerging biomarkers for the screening, diagnosis, and monitoring of celiac disease.
Keywords: celiac disease; biomarker; serology; enteropathy
1. Introduction
Celiac disease (CeD) is a systemic autoimmune disorder that is induced by the ingestion of gluten
protein present in wheat, barley, and rye in genetically predisposed individuals [1]. Once considered
to be limited to Western Europe, CeD has now emerged as a major public health problem globally.
A recent systematic review suggests that 0.7% (95% Confidence Interval (CI), 0.5–0.9%) of the global
population suffers from CeD [2]. With the global population of 6.4 billion, approximately 37–59 million
people are estimated to have CeD globally. While the global pool of patients is so large, the majority
of patients (83–95%) in developed countries, and possibly even a higher number in developing
countries, still remain undiagnosed [3]. This large pool remains unrecognized partly because of
the lack of classical gastrointestinal symptoms in approximately half of patients. The spectrum of
clinical manifestation of CeD is wide and includes both gastrointestinal symptoms such as chronic
diarrhea, dyspepsia, anemia, and failure to thrive and extra-gastrointestinal manifestations such as
short stature, dermatitis herpetiformis, infertility, and liver diseases. Recognition of wide spectrum of
CeD, simplification of the diagnostic criteria and widespread use of celiac-specific serological tests
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(anti-tissue transglutaminase antibody, anti-endomysial antibody or anti-deamidated gliadin peptide
antibody) have led to an increase in the recognition of CeD globally [4]. There is no single gold
standard test for the diagnosis of CeD, and the diagnosis of CeD is based on a combination of clinical
manifestations, presence of the celiac-specific serological test and demonstration of villous abnormality
on intestinal mucosal biopsies [5]. While the treatment of CeD at present time is life-long gluten-free
diet (GFD); a number of drugs including intraluminal gluten degrading enzyme therapies such as
latiglutenases, peptide vaccines such as NexVax 2, and zonulin antagonist such as larazotide are being
explored as an alternative or additive treatment for patients with CeD.
A biomarker is a defining characteristic that is measured as an indicator of normal biological
processes, pathogenic processes, or responses to an exposure or intervention, including therapeutic
interventions [6]. Since an ideal biomarker should provide a “signature” for a condition, the
development of biomarkers requires several rounds of controlled experimentations, and validation
before it can be used in clinical practice. In the present review, we have discussed comprehensively
the pros and cons of available biomarkers and we have also summarized the current status of
emerging biomarkers for the screening, diagnosis, and monitoring of the disease. For CeD, biomarkers
are required for multiple purposes including a) screening of the disease, b) detection/prediction of
enteropathy, c) markers of complications, d) monitoring of the disease, and e) assessment of adherence
to gluten free diet (GFD). Indeed, enormous efforts have been made in this direction; some of the
established and potential biomarkers are summarized in Table 1.
Table 1. Established and potential biomarkers for celiac disease




Anti-tissue transglutaminase (tTG)- TG2, TG6, TG3
Deamidated gliadin peptide (DGP)
Synthetic neo-epitopes tTG-DGP complex
Genetic marker HLA-DQ haplotyping
Biomarkers for the prediction of
enteropathy
Cytochrome P450 3A4 (CYP3A4)
Plasma citrulline
Intestinal-fatty acid binding proteins
Regenerating gene1α (Reg 1α)
Biomarkers to predict dietary adherence Gluten immunogenic peptide (GIP)
Mean platelet volume (MPV)
Miscellaneous Biomarkers miRNA Intestinal permeability
2. Serological Biomarkers
Serological tests are the first line investigation for the screening of patients suspected to have CeD.
Until the late 1950s, there was no biomarker for the diagnosis of CeD, and the diagnosis made was on
the basis of the presence of suggestive clinical symptoms and resolution of symptoms with a GFD [7].
The advent of methods for obtaining intestinal biopsies such as Crosby capsules and endoscopic
techniques, added villous atrophy as one of the most specific requirements for the diagnosis of CeD.
The discovery of anti-gliadin antibodies (AGA) in the 1960s was a landmark step in the evolution of
the modern-day diagnostic strategy for CeD. AGA remained the first line celiac-specific serological test
until the 1990s [8]. In the 1990s, anti-endomysial antibody (AEA) was discovered and a combination
of AGA with AEA testing became the standard diagnostic strategy for CeD [9]. With recognition
of the high false positive rate for AGA, the use of AGA fell both for the screening and diagnosis of
CeD. Further discovery of anti-tissue transglutaminase (tTG) as the substrate for AEA, tTG based
enzyme-linked immunoassays (ELISA) became the standard diagnostic test for CeD [10].
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2.1. Anti-Gliadin Antibodies
Anti-Gliadin Antibodies (AGA) is produced against gliadin, a prolamin found in wheat and
related cereals. Anti-Gliadin Antibodies are of two types IgA-AGA and IgG-AGA. Anti-Gliadin
Antibodies is no more used for the diagnosis of CeD because of the advent of more reliable serological
tests. However, there has been renewed interest in the utility of AGA. Immunoglobulin G (IgG) AGA
and IgA-AGA are now used to recognize other gluten-related disorders such as non-celiac gluten
sensitivity, gluten ataxia, and autism [11]. Anti-Gliadin Antibodies (more precisely, IgG dependent
AGA) is positive in approximately 50% of patients with non-celiac gluten sensitivity [12,13].
2.2. Anti-Endomysial Antibody
Chorzelski et al. discovered the AEA test, which revolutionized the diagnostic strategy for CeD [14].
Anti-Endomysial Antibody (AEA) is an antibody against the smooth muscle’s inter-myofibrillar
substance [9]. Earlier, a monkey esophagus was used as a substrate for AEA testing and the use of
human umbilical cord as a substrate has enhanced the sensitivity and specificity of AEA [15]. While
both sensitivity and specificity of AEA was reported to be >95%, a recent systematic review has
reported a lower pooled sensitivity, 73.0% (95% CI, 61.0% to 83.0%), based on the data of newer studies,
the specificity however still remains to be 99.0% (95% CI, 98.0% to 99.0%) [16]. While AEA is very
specific, detection of AEA requires indirect immunofluorescence, which is labor intensive and time
-consuming as compared to the estimation of tTG Ab by ELISA [17].
2.3. Anti-Tissues Transglutaminase Antibody
Transglutaminase (TG) is a calcium-dependent enzyme, which catalyzes the covalent bond and
cross-linking of proteins irreversibly [18]. Nine different types of the TG gene have been discovered in
mammals, eight codes for catalytically active enzymes and one for an inactive enzyme. These TGs play
different roles in different tissues in physiological and pathological conditions. Transglutaminase 1 (TG1)
(keratinocyte), TG3 (epidermal), and TG5 are involved in the formation of the cornified envelope during
keratinocyte differentiation, thus contribute to the cutaneous barrier function [19]. Transglutaminase
6 (TG6) and TG7 are expressed in testis, lung and brain, but their function is still uncertain [20].
Transglutaminase 2 (TG2) is ubiquitously present in cells and tissues—and hence TG2 is known as
“tissue” TG.
Autoantigen against TG2 was identified by Dieterich et al., who also suggested the role of TG2 in
the deamidation of the bond between glutamine and lysine, present in gluten [18]. Of all the serological
tests, IgA anti-TG2 Ab is the most widely used test both for the diagnosis and initial screening for
CeD because of its very high sensitivity and specificity, ease of use, and its quantitative capability. In a
recent systematic review, Chou R et al. reported a pooled sensitivity of anti-tTG Ab to be 92.8% (95%
CI, 90.3–94.8%); specificity 97.9% (95% CI, 96.4–98.8%); a positive likelihood ratio (LR) of 45.1 (95% CI,
25.1–75.5%) and negative LR of 0.07 (95% CI, 0.05–0.10%) [16]. Immunoglobulin A (IgA) tTG levels
also correlate with the degree of severity of mucosal damage, and a titer of 10 folds or higher over the
upper limit of normal (ULN) predicts presence of villous abnormality with very high specificity [21].
Antibodies against other TGs have been reported in extra-intestinal forms of gluten-related
disorders [22]. Anti-TG3 Ab has been reported in patients having dermatitis herpetiformis [23]. As
discussed above, TG6 is found in the brain and anti-TG6 Ab has been reported in gluten-induced
neurological diseases such as gluten ataxia [24,25]. The concentration of anti-TG6 Ab has been observed
to correlate with longer gluten exposure in them and the level of TG6 decreases after GFD [26]. In a
study, 73% of patients with idiopathic sporadic ataxia positive for AGA, were also positive for TG6
antibodies [27].
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2.4. Anti-Deamidated Gliadin Peptides
Anti-deamidated gliadin peptides Ab (DGP) is directed against deamidated gliadin peptides and
is another serologic marker for the diagnosis of CeD [28]. Initially, IgA DGP was reported to be equally
sensitive and specific as IgA tTG Ab, however recent studies have shown that tTG Ab is the most
trusted serological test for CeD [29,30]. A recent systematic review and meta-analysis reported the
pooled sensitivity of anti-DGP Ab to be 87.8% (95% CI, 85.6–89.9%), and of specificity 94.1% (95% CI,
92.5–95.5%) [16].
2.5. Point-of-Care Test
Point-of-care tests (POCTs) for the diagnosis and monitoring of CeD have been in use for the past
one decade, especially in Europe [31,32]. They are easy to perform, do not require a laboratory or
experienced laboratory staff, and have a quick turn-around time [33,34]. Therefore, POCTs have the
potential to increase CeD diagnosis rates worldwide, facilitate early diagnosis, and reduce cost. POCTs
have been shown to be successfully used in various settings including primary care, specialty clinics,
and endoscopy suites [35]. The majority of these POCTs are immunochromatographic tests and they
are performed in a similar way with whole blood/serum and buffer placed on a test field that diffuses
down a test strip [34]. If antibodies (tTG and/or DGP) are present, antigen-antibody complexes are
detected by labeled anti-human IgA and/or IgG antibodies. The test is visually read on site after a few
minutes as recommended by the manufacturer. A positive test is reflected by the presence of a solid
line in the test window and a negative test by the absence of a line in the test window [31–35].
In a recent systematic review and meta-analysis, we observed the pooled sensitivity and specificity
of all POCTs (based on tTG or DGP or tTG + anti-gliadin antibodies) for diagnosing CeD to be 94.0%
(95% CI, 89.9–96.5%) and 94.4% (95% CI, 90.9–96.5%), respectively. The pooled positive and negative
LR for POCTs were 16.7 and 0.06, respectively [36].
2.6. Limitations of Serological Tests
False positive results can occur due to a cross-reaction of antibodies in conditions such as enteric
infection, chronic liver disease, congestive heart failure, or hypergammaglobulinemia [37]. The
serological tests should ideally be conducted when the patient is on a gluten-containing diet, as being
on a low-gluten diet or gluten-free diet can lead to a false negative result [38]. False negative results
may also be due to IgA deficiency, which affects 2–3% of the general population [39]. In IgA deficient
patients, an IgG -based test such as IgG DGP or IgG anti-tTG antibodies should be performed [12].
A few studies have raised question about the sensitivity of these assays in clinical practice [40,41].
tTG antigens used in these commercial kits are variable, ranging from recombinant human tTG to
human tTG cross-linked to gliadin specific peptides [42,43]. In addition, commercial kits typically
provide sensitivity and specificity values that are calculated using small, poorly-defined populations,
which can be misleading. Several studies comparing different anti-tTG-ab based assays from different
manufacturers have revealed variable sensitivities and specificities for detecting CeD; however, most
of these studies were small in size and did not have the necessary sample size to accurately comment
on the diagnostic accuracies of the testing [22,43–46]. In addition to the possibility of inter-assay
variation in the diagnostic performance of commercially available IgA anti-tTG-ab assays, there might
be intra-assay variation in the diagnostic performance of these assays for different ethnic populations.
Studies from India suggest that the sensitivity of several tTG-ab ELISA assays might be lower in the
Indian population than that reported in the Caucasian population [33,36].
3. Genetic Markers
Human Leukocyte Antigen (HLA) DQ Haplotyping
Celiac disease is strongly associated with Human Leukocyte Antigen (HLA) and approximately
95% of CeD patients express HLA-DQ2 encoded by DQA1*05 and DQB1*02 and the rest 5% carry DQ8
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alleles encoded by DQA1*03 and DQB1*0302 alleles [47]. The HUGO Gene Nomenclature Committee
(http://www.genenames.org/) has shown HLA-DQA1 and HLA-DQB1 class II genes as CELIAC1 [48].
HLA alone accounts for about 40% of genetic heritability for CeD, while 60% genetic susceptibility
of CeD by non-HLA genes [49,50]. Other that HLA -DQ2/ DQ8, more than 40 candidate genes have
been discovered to be associated with CeD [51,52]. Interestingly, approximately 30% of the general
population have HLA-DQ2/DQ8 haplotype, only 3% of them ever develop gluten-related disorders [53].
Human leukocyte antigen typing is not sufficient for the diagnosis of CeD because of its modest
sensitivity (HLA-DQ2, 70–99.8%; HLA-DQ8, 1.6–38%) and specificity (HLA-DQ2, 69–77%; HLA-DQ8,
77–85%) [54]. Nevertheless, HLA-DQ typing test has a high negative predictive value that suggests
if an individual is negative for HLA-DQ typing, he or she is less likely to have CeD [49]. Human
leukocyte antigen (HLA)-DQ typing is mainly used for the exclusion of CeD and it is considered to
be an additional test especially in patients where no agreement exists between the serological and
histological results.
4. Biomarkers to Predict Presence of Enteropathy
Villous atrophy is the hallmark of CeD, which gets reverted after the institution of GFD. While the
clinical response to GFD is evident in weeks and months; reversal of mucosal changes takes months
and even years [2,54]. Furthermore, despite GFD, complete villous recovery may not be achieved. The
small intestinal mucosal biopsy is the cornerstone for the diagnosis of CeD. In addition to being the gold
standard for the initial diagnosis of CeD, periodic biopsies are also recommended for the monitoring
of the disease. However, obtaining biopsies is an invasive and expensive procedure (endoscopic
examination). Moreover, a correct assessment of biopsies requires an experienced pathologist and
well-oriented high-quality biopsy specimens. In fact, an active debate is going on amongst the celiac
disease scientific community, whether to do biopsies or skip biopsies in the making of a CeD diagnosis.
A relevant question is “can we demonstrate/predict villous atrophy by non-invasive means?”
Enterocytes are very specialized cells and they perform specific functions including absorption
of nutrients and secretion of enzymes. Because of the constant exposure of the gastrointestinal (GI)
tract to harsh mechanical and chemical conditions, the GI tract has evolved mechanisms to cope
with these assaults via a highly regulated process of self-renewal [55]. Most of the epithelial cells are
replaced every 3 to 5 days. According to the so-called “Unitarian hypothesis”, first proposed by Cheng
and Leblond, epithelial cell renewal is driven by a common intestinal stem cell residing within the
crypt base [56,57]. From their niche, intestinal stem cells (ISCs) give rise to transit-amplifying cells
that migrate upwards and progressively lose their proliferative capability and maturate to become
fully-differentiated villous epithelial cells (absorptive enterocytes or secretory cells which include
goblet cells, enteroendocrine cells, paneth cells, and tuft cells). Each adult crypt harbors approximately
5 to 15 ISCs that are responsible for the daily production of about 300 cells; up to 10 crypts are necessary
to replenish the epithelium of a single villus [58]. According to mathematical modeling, approximately
1400 mature enterocytes are shed from a single villus tip in 24 h (2 × 108 cells shed from small intestine
every day) [58].
All the changes that occur in the intestinal mucosa include intraepithelial lymphocytosis,
heightened apoptosis of enterocytes, heightened regeneration of enterocytes, imbalance in the rate of
apoptosis and regeneration leading to decrease in the villous height, enterocyte mass, and increase in
the inflammatory cells in the mucosa [59,60].
There are certain molecules which can serve as a biomarker of the enterocyte mass and enterocyte
function (citrulline, cytochrome P450 3A4), enterocyte injury (intestinal fatty acid binding protein),
and enterocyte regeneration (regenerating gene 1α).
4.1. Cytochrome P450 3A4
Like the liver, intestinal mucosa also has a drug metabolizing enzyme system along with the
crypt- villous axis. Cytochrome P450 3A4 is a drug-metabolizing enzyme system expressed abundantly
83
J. Clin. Med. 2019, 8, 885
at the tips of the villi, and less abundantly at the crypts [61]. Loss of intestinal villi because of any
cause including CeD can lead to a reduction in the activity of CYP3A4. Both the expression and
function of CYP3A4 can be assessed to estimate the function of enterocytes. Simvastatin is a lipid-
lowering agent that is metabolized by CYP3A4. Therefore, the function of CYP3A4 can be assessed
by pharmacokinetics and maximum concentration (Cmax) of orally administered simvastatin (SV) in
blood. While healthy people having normal enterocyte function should have a low level of SV and
higher levels of its metabolites in the blood; the levels of SV should be high and its metabolites level
should be low in those having enteropathy. Therefore, the assessment of the functional activity of
CYP3A4 may serve as a biomarker for enteropathy [62,63].
As a preclinical test of this hypothesis, we measured the plasma concentrations of SV and
its major metabolites in mice expressing the human CYP3A4 transgene in the small intestine,
in whom acute enteropathy had been induced using polyinosinic-polycytidylic acid (poly I:C).
In CYP3A4-humanized mice, a marked decrease in simvastatin metabolism was observed in response
to enteropathy. Encouraging results from these experiments motivated us to do a clinical study
involving untreated as well as treated patients with CeD along with healthy controls, in order to
determine the potential utility of using serum concentrations of SV and/or its metabolites as a tool
predicting enteropathy. We included 11 healthy volunteers, 18 newly diagnosed patients with CeD, and
25 patients with CeD who had followed a GFD for more than one year. The Cmax of orally administered
SV, plus its major non-CYP3A4 derived metabolite SV acid (SVeq Cmax) was measured, and compared to
clinical, histological, and serological parameters. Untreated patients with CeD displayed a significantly
higher SVeq Cmax (46 ± 24 nM) compared to treated patients (21 ± 16 nM, p < 0.001) or healthy subjects
(19 ± 11 nM, p < 0.005). SVeq Cmax correctly predicted the diagnosis in 16/18 untreated celiac patients as
well as the recovery status of all follow-up patients. Therefore, SVeq Cmax is a promising non-invasive
marker for the assessment of small intestinal health. Further studies are warranted to establish its
clinical utility for assessing the status of villous abnormality in patients with CeD.
4.2. Plasma Citrulline
Citrulline is a non-protein amino acid that is mainly synthesized by the enterocyte and hence the
level of citrulline in plasma can represent the synthetic function of the enterocytes [64]. The concept of
using citrulline as a marker of enterocyte mass was first provided by Crenn et al. [65]. They reported
lower citrulline levels in the plasma of patients with short bowel syndrome compared to controls
(20 ± 13 vs. 40 ± 10 μmol L−1, p < 0.001). Furthermore, the level of plasma citrulline also correlated
with the length of the residual intestine [66]. A lower level of plasma citrulline in comparison to healthy
controls has been observed in many small intestinal diseases including CeD, giardiasis, tropical sprue,
and small bowel lymphoma. Interestingly, a declining trend in the levels of plasma citrulline was
observed with increasing severity of villous atrophy i.e., concentration of citrulline <10 μmol L−1 in
patients with diffuse total villous atrophy, 10–20 μmol L−1 in patients with proximal-only total villous
atrophy, and 20–30 μmol L−1 for patients with partial villous atrophy. At an optimum cut-off value of
plasma citrulline of 20 μmol L−1, the diagnostic accuracy of predicting villous abnormality was 92%
with sensitivity and specificity of 95% and 90%, respectively [67].
In a recent study, we have shown that plasma citrulline of <30 μmol L−1 indicates the presence
of villous abnormality of modified Marsh grade more than 2 with a diagnostic accuracy of 89% with
sensitivity and specificity of 78.6% and 95.5%, respectively. Above mentioned statistics suggest that
it is possible to predict significant villous abnormality based on the citrulline level even without
obtaining duodenal mucosal biopsies in 78.6% patients with 95.5% specificity in patients suspected
to have CeD. Therefore, in a clinical context of a positive anti-tTG Ab, if the plasma citrulline is less
than 30 μmol L−1, one can predict that there is significant villous atrophy and one can choose to avoid
duodenal biopsy for demonstration of villous atrophy. (Under publication) A recent meta-analysis by
Fragkos et al. has shown that citrulline levels correlate with small bowel length in patients with short
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bowel syndrome (r = 0.76) while negatively correlate with the severity of intestinal disease such as
CeD, tropical enteropathy, Crohn’s disease, mucositis, acute rejection in intestinal transplantation [67].
4.3. Intestinal-Fatty Acid Binding Proteins
Fatty acid-binding proteins (FABPs) are small (14–15 KDa) cytoplasmic proteins involved in the
cholesterol and phospholipid metabolism, transport of long-chain fatty acids and maintenance of lipid
homeostasis [68]. Fatty acid-binding proteins was first discovered in 1972 and by now nine types of
FABP have been identified from the different organs where they are involved in active lipid metabolism.
Intestinal type (I-FABP) is specifically expressed in intestine and encoded by the FABP2 gene present
on chromosome 4 [69]. Intestinal fatty acid-binding proteins is expressed throughout the intestine,
most abundantly in the jejunum, and in greater abundance in enterocytes at the villous tip than in the
enterocytes at the crypts.
As I-FABP is expressed in enterocytes, the injury to enterocytes leads to the release of I-FABP
at the local sites, which are then absorbed and passes into the circulation. As the levels of I-FABP
get elevated in the serum in patients with enterocyte damage, I-FABPs has been considered to be a
potential biomarker for the detection of enteropathy [70]. Elevated levels of I-FABP are detected in
patients with necrotizing enterocolitis in preterm infants, mesenteric infarction, and intestinal allograft
rejection [71–75].
In a study including 96 biopsy-proven adult CeD patients, I-FABP levels were higher in untreated
CeD compared with controls (median 691 pg mL−1 vs. 178 pg mL−1, p < 0.001) and the level declined
with GFD [76]. Interestingly, in those patients with CeD, where the FABP levels remained elevated, the
biopsy showed persistent histological abnormalities. In another multicenter study, high FABP levels
have been shown to predict the diagnosis of CeD in 61/90 (67.8%) children [77].
In a study of treatment naïve patients with CeD, we observed that the optimal cut-off value of
plasma I-FABP is ≥1100 pg ml−1 in predicting villous abnormalities of modified Marsh grade 2 or more.
Using the ROC curve analysis, we observed a diagnostic accuracy of 78% with sensitivity, specificity
and odds ratio, LR+ and LR- of 39.7%, 95.5%, 13.9 (95% CI 5.8–33.1%), 8.7 and 0.63, respectively in
predicting villous abnormality of modified Marsh grade 2 or more (under publication). We believe that
I-FABP may be a good biomarker of enterocyte damage but it requires more studies around the world
to understand its consistent performance. There are inconsistencies in the performance of I-FABP as a
diagnostic marker as reported in earlier studies [74,76,78].
4.4. Regenerating Gene1α
Human Reg1α is a member of the multigene family and it plays a role in the regeneration of
cells [79]. There are four types of the Reg gene, Reg1α is one of them which is also known as
lithostathine-1-alpha or islet cell regeneration factor (ICRF) or islet of Langerhans regenerating protein
(Reg) [80]. In the GI tract, the highest levels of expression of Reg1α have been observed in the small
intestine and it is considered as a regulator of cell growth that is required to generate and maintain the
villous structure [81]. A high level of the Reg1α may denote the effort of the small intestinal mucosa
trying to compensate for the accelerated enterocyte injury/apoptosis/necrosis [82]. In patients with
CeD where there is excessive apoptosis of enterocytes, there is a higher expression of the Reg1α gene in
the intestinal crypts and the expression falls with GFD [83]. There is only one study showing elevated
levels of Reg1α in patients with CeD (n = 40) compared to healthy controls (n = 35) and the levels
declined after GFD [84]. There is a need for further study to prove whether Reg1α is a stable marker
or not.
5. High-Throughput Technologies for Biomarker Discovery
Several studies have employed high throughput genomics, transcriptomics, and proteomics
approaches to find out a panel of biomarkers to reveal the extent and status of small intestinal damage
by CeD.
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5.1. Transcriptomics Approaches
Since transcriptomics requires a lower amount of biological material such as intestinal mucosal
biopsies, this approach has been used to explore various aspects of small intestinal biology including
phenotypes and functions of T cells, as well as cytokine profiles within the small intestinal tissue [85].
In order to define the global cytokine gene expression network associated with CeD, one study
demonstrated higher expression of interleukin (IL)-15, IL-18, and IL-21 with gluten ingestion, which
could drive the inflammatory response in them [86]. In another study, a significant upregulation of 25
odd defense-related genes was observed, including IRF1, SPINK4, ITLN1, OAS2, CIITA, HLA-DMB,
HLA-DOB, PSMB9, TAP1, BTN3A1, and CX3CL1 in intestinal epithelial cells of patients having active
CeD in comparison with those treated with GFD [87]. Galatola M, et al. have explored the possibility
of the development of a non-invasive biomarker obtainable from peripheral circulation by carrying out
gene expression analysis using peripheral blood mono-nuclear cells (PBMCs) and they defined a 4
gene PBMC signature including NFKB, IL-21, LPP, and RGS1 for discriminating patients with CeD
from non-CeD individuals [88]. Although these genes were significantly differentially expressed in the
intestinal mucosa, their expression differences were much weaker in PBMCs. Subsequently the same
group demonstrated a set of 9 genes including KIAA, TAGAP (T-cell Activation GTPase Activating
Protein), and SH2B3 (SH2B Adaptor Protein 3), RGS1 (Regulator of G-protein signaling 1), TAGAP,
TNFSF14 (Tumor Necrosis Factor Superfamily member 14), and SH2B3 which could differentiate
patients with CeD from controls [89].
Two recent transcriptomics studies have made strides towards defining transcriptomics signatures
in CeD. In one of the studies, we analyzed the transcriptomes in the intestinal mucosa of HLA
DQ2/DQ positive asymptomatic first-degree relatives (FDRs) of patients with CeD and showed that
pre-symptomatic FDRs harbored a transcriptomic signature that was distinct from controls in spite of
the fact that these FDRs had no symptoms or enteropathy at the time of the study. This clearly suggests
that there are phenotypic differences in individuals without active enteropathy, which may be exploited
in order to develop a biomarker to predict intestinal damage. The second study demonstrated a CeD /
no CeD diagnosis based on transcriptomic profiles of duodenal biopsies which revealed a potential
biomarker subset consisting of CXCL10, GBP5, IFI27, IFNG, and UBD [90].
5.2. Proteomics Approach
Proteomics studies typically require a higher amount of biological material for studying the
proteome profile in tissues. Recent advances in label-free quantitative approaches have enabled whole
tissue proteomics of many tissues including small intestinal biopsies in patients with CeD [91]. In a
recent study, biopsy specimens collected from patients with CeD before and after 1-year treatment
with GFD showed differential expression of proteins such as Ig variable region IGHV5-51, which could
serve as a specific marker of immune activation in patients with CeD.
Proteomics approaches have also been used to identify autoantigens in patients with CeD. Stulík
J et al. used sera and intestinal biopsies from the patient with CeD and carried out 2D gel electrophoresis
of the intestinal proteome followed by immunoblotting of matched patient sera in order to identify
the repertoire of self-antigen in CeD patients [92]. This study detected 11 new self-antigen including
Adenosine tri-phosphate (ATP) synthase β, enolase α, and several other unannotated proteins. A major
limitation of this study was the limited use of proteomics to identify a very small number of autoantigens
and the use of a very limited sample size. However, this study suggests that several autoantigens like
tTG exist in patients with CeD against which serum antibodies may be developed.
5.3. Metabolomics Approaches
While there is a relative paucity of proteome-based studies, many metabolomic studies have
been done in patients with CeD to find metabolic markers of CeD, presumably due to the fact that
metabolites can be detected with greater sensitivity and with much lower requirement of biological
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material. Typically, mass spectrometric (MS) and nuclear magnetic resonance (NMR) methods are used
for metabolomics [93]. Nuclear Magnetic Resonance studies that have been carried out with urine and
sera of patients with CeD in comparison to those of healthy controls have revealed several metabolic
differences between the two study groups [94]. Sera of CeD patients have demonstrated lower levels
of amino acids, lipids, pyruvate, and choline and higher levels of glucose and 3-hydroxybutyric acid in
comparison to the healthy controls. Differentiation of patients with CeD from healthy controls was
done by 1H NMR studies using serum and urine metabolomics, where a pattern of metabolites was
observed [95].
Furthermore, using partial least squares-discriminant analysis of metabolites expressed in the
small intestinal mucosa, we observed a clear distinction in the pattern of metabolites in the intestinal
mucosa of patients with CeD and controls. There was a significantly higher concentration of isoleucine,
leucine, aspartate, succinate, and pyruvate, and a lower concentration of glycerol-phosphocholine in
the duodenal mucosa of patients with CeD patients compared with controls, suggesting abnormalities
in glycolysis, Krebs cycle, and amino acid metabolism in patients with CeD.
While studies based on metabolomic approach have provided a distinctive pattern of metabolites
which can differentiate patients with CeD from controls, such a pattern is based on a large panel of
metabolites, rather than based on a few metabolites. Hence, it is less likely that such a pattern of
metabolites can be tested individually in a clinical laboratory.
6. Biomarker to Predict Dietary Adherence
The mainstay of treatment of CeD is a life-long GFD with strict adherence. It is hard for the
patient to achieve the high adherence rate because of widespread use of gluten in the food industry [96].
Approximately one-third of patients with CeD are not able to comply with GFD very well and even
those who do, a persistence of enteropathy is observed in 20–40% of patients, which most likely
attributable to inadvertent use of gluten by cross contamination [97,98]. It is therefore important to
monitor the level of adherence to GFD by a biomarker which can detect ingestion of gluten by patients
with CeD.
6.1. Gluten Immunogenic Peptide
Gluten immunogenic peptide (GIP) are fragments of gluten which are resistant to digestion
and therefore eliminated in the urine and the stool [99]. The presence of gluten in the urine or stool
indicates recent consumption of gluten-containing food [100]. The α-gliadin 33-mer is the main
immunodominant toxic peptide that interacts with the immune system of patients with CeD and
a proportion of this peptide is absorbed in the GI tract and makes it way from blood to and partly
excreted in the stool [99].
The gluten peptide fraction has been detected in the stool of healthy subjects after consumption
of not only a normal gluten-containing diet but even in those who have consumed even
<100 mg gluten/day. The level of gluten peptides detected in the stool has been shown to be in
proportionate with the amount of gluten ingestion [101]. Gluten Immunogenic Peptide is also
detectable in urine, and a positive correlation was observed with the amount of gluten intake and
amount excreted in the urine. Gluten Immunogenic Peptide can be detected in the urine even with
25 mg of gluten ingestion.
Gluten Immunogenic Peptide is detected by anti-GIP immunochromatographic strips and the
conduct of the test is very simple and the test has high sensitivity and specificity [102]. The GIP
detection kit is similar to the pregnancy test, where GIP present in the sample, react with specific
antibody on the strips. As GIP is rapidly cleared through urine, the presence of GIP in the urine
suggests the ingestion of gluten within 20 h. Since the GIP stays longer in the intestinal lumen before
getting completely excreted, the detection of GIP in stool suggests the ingestion of gluten within
2–7 days. Approximately 17–80% of patients with CeD who are following GFD have been found to
have GIP in their stool [102].
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6.2. Mean Platelet Volume
Mean platelet volume (MPV) has been recognized as a marker of inflammation in various diseases
such as ulcerative colitis, acute pancreatitis and myocardial infraction etc. [103–105]. Purnak et al. have
shown significantly higher MPV in CeD compared to healthy subjects and significant decrease in MPV
in those showing good compliance to GFD compared to non-compliant individuals [106].
7. Miscellaneous Biomarkers
7.1. MicroRNAs
MicroRNAs (miRNAs) are small, endogenous noncoding RNAs that act as post-transcriptional
regulators of gene expression. Upon cell death, miRNAs are released into the surrounding environment
and then reach peripheral blood circulation or body fluids, hence detection of tissue- specific or
tissue-enriched miRNA in biofluids might be used as a biomarker for specific tissue damage and
specific tissue event. In a study, including untreated adult CeD patients, treated CeD patients and
control subjects without CeD showed dysregulation of seven miRNAs such as miR-31-5p, miR-192-3p,
miR-194-5p, miR-551a, miR-551b-5p, miR-638 and miR-1290 in patients with CeD compared to
those without CeD [107]. In another study, the expression pattern of miR-21 and miR-31 was
assessed in pediatric patients with CeD using qRT-PCR where significant up-regulation of miR-21
and down-regulation of miR-31 was observed in the untreated celiac patients in comparison with the
treated group (n = 25) and healthy controls (n = 20). Furthermore, there was a correlation between the
expression of miR-21 and the titer of anti- tTG Ab [108]. Many miRNAs including specifically miR-21
and miR-31 require further exploration.
7.2. Biomarkers for Assessment of Intestinal Permeability
Assessment of intestinal permeability is performed to assess the overall function of transport
through the intestinal epithelial paracellular route [109]. Urinary excretion of disaccharides and
monosaccharides and the ratio of their excretion is a basis for the measurement of intestinal
permeability. Intestinal permeability can be assessed using a variety of marker probes such as
lactulose, mannitol, rhamnose and cellobiose, polyethylene glycol (PEG) 400, PEG 1000, 51Cr-EDTA
and 99mTc-DTPA. The lactulose and mannitol ratio is the most commonly used test for assessment
of small intestinal permeability. The majority of treatment naïve patients with CeD have abnormal
intestinal permeability [109]. While the withdrawal of gluten improves both clinical and histological
abnormalities, it also normalizes the paracellular function and hence the intestinal permeability in them.
8. Conclusions
While many of the currently used biomarkers for the screening and diagnosis of CeD are quite
reliable, there is need for blood biomarkers which can predict presence of villous abnormalities even
without performing intestinal mucosal biopsies and biomarkers which can assist in the monitoring of
the disease. While initial data on the performance of biomarkers such as plasma citrulline and plasma
I-FABP in the prediction of the presence of villous abnormalities even without obtaining intestinal
mucosal biopsies is very promising, there is a need for further validation of these biomarkers before
they can be used reliably in the clinical practice. GIP detection in the stool or in the urine is now used in
the clinical practice for detection of gluten ingestion; a positive test however, only reflects ingestion of
gluten over the past few days, before the performance of the test. What really is required is a test which
can tell us the adherence to gluten ingestion over a longer period of time. In order to understand the
fundamental biology and in search of the clinically usable biomarker, a number of research laboratories
are exploring various approaches such as transcriptomics, proteomics, and genetics, and we hope that
these powerful technologies will provide us in the near future with clinically usable biomarkers for the
diagnosis, treatment, and monitoring of the diseases.
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Abstract: Hyperspectral/Multispectral imaging (HSI/MSI) technologies are able to sample from tens
to hundreds of spectral channels within the electromagnetic spectrum, exceeding the capabilities of
human vision. These spectral techniques are based on the principle that every material has a different
response (reflection and absorption) to different wavelengths. Thereby, this technology facilitates the
discrimination between different materials. HSI has demonstrated good discrimination capabilities
for materials in fields, for instance, remote sensing, pollution monitoring, field surveillance, food
quality, agriculture, astronomy, geological mapping, and currently, also in medicine. HSI technology
allows tissue observation beyond the limitations of the human eye. Moreover, many researchers are
using HSI as a new diagnosis tool to analyze optical properties of tissue. Recently, HSI has shown
good performance in identifying human diseases in a non-invasive manner. In this paper, we show
the potential use of these technologies in the medical domain, with emphasis in the current advances
in gastroenterology. The main aim of this review is to provide an overview of contemporary concepts
regarding HSI technology together with state-of-art systems and applications in gastroenterology.
Finally, we discuss the current limitations and upcoming trends of HSI in gastroenterology.
Keywords: hyperspectral imaging; multispectral imaging; clinical diagnosis; biomedical optical
imaging; gastroenterology; medical diagnostic imaging
1. Introduction
Hyperspectral/Multispectral (HS/MS) imaging (HSI/MSI), also known as Imaging Spectroscopy,
is a technology capable of overcoming the imaging limitations of the human vision based in white light
(WL). In fact, HSI combines the features provided by two technologies that have been, for decades
now, used separately i.e., digital imaging and spectroscopy. Digital imaging allows recording of the
morphological features of a given scene, extracting information of different objects in regards to shape
and textures. Spectroscopy deals with the interaction between the electromagnetic (EM) radiation and
matter. While the capabilities of the human vision are restricted to a certain region of the EM spectrum
(EMS), the visible spectrum that spans from 400 to 700 nm, most common HS commercial systems
expand this spectral range from 400 to 2500 nm. Although there are HS cameras able to cover the EM
up to 12 microns, such systems are restricted to certain applications that are out of the scope of this
manuscript. HSI provides information in regions of the EMS that the human eye cannot see, revealing
therefore substance properties that are normally unavailable to human beings. Furthermore, while the
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human eye is only capable of distinguishing three different wavelengths associated with the opsins of
the retina (Cianopsin sensitive to 430 nm -blue light-; Cloropsin sensitive to 530 nm -green light-; and,
Eritropsin sensitive to 650 nm -red light-), HS cameras can capture the EMS in hundreds of different
narrow wavelengths, largely increasing the resolution to over what humans can see. On the other
hand, MSI is based on the same principle of HSI with the main difference being that MSI is generally
characterized by a lower number of spectral channels [1].
An HS image is recorded in a data structure called HS cube, which contains both spatial and
spectral information from a given image. The information inside the HS cube can be visualized in
several different ways. If a single pixel from an HS image is selected, the spectrum related to this
pixel can be examined. Likewise, it is possible to visualize the entire spatial information for a given
wavelength. The observed information at various wavelengths represents different properties of the
matter. Figure 1 shows an HS cube, where both types of representations can be observed.
 
Figure 1. Example of an HS cube from in-vivo human brain surface and spectrum from the pixel in red
(left). Several images at different wavelengths obtained from the HS datacube (right).
The spectral signature (also called spectral fingerprint) is the curve that links the EM radiation
with a certain material. The key point of this concept is that each material has its own interaction
with the EMS, hence the spectral signature of any given material is unique. By analyzing the spectral
signatures contained in an HS image, it is possible to distinguish between the different substances
that are present in the captured image. Nevertheless, to properly differentiate materials by using
the spectral signature information, some issues have to be addressed. First, the measured spectral
signature from the same material can present subtle variations, i.e., inter-sample variability. Second,
there are materials that present spectral similarities among them, being extremely challenging to
perform an automatic differentiation of such materials based only on their spectral signatures.
Many researchers have employed HSI technology for different applications [1] such as
non-invasive food quality inspection [2,3], improving recycling processes [4], or examining paintings
for accurate identification of the pigments used in order to refine their restoration [5,6]. Geologists use
HSI to identify the location of different minerals [7]. Furthermore, in agriculture this technology has
been used to quantitatively characterize the soil [8] or to identify the stress levels of plants [9].
Figure 2 presents an example of the spectral signatures of different tissues [10], where the
differences between the spectral signatures of primary (glioblastoma and oligodendroglioma grade III)
and secondary brain tumors (metastatic lung, renal and breast) are evident. Just a visual inspection of
the shape of the reflectance curve reveals that it is possible to identify the type of tissue present at each
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pixel of the image. The measured spectral signatures are mainly affected by illumination, the mixture
of different substances, and/or by noise.
Figure 2. Spectral signatures of different brain tumor tissues in the VNIR (Visible and Near Infrared)
range [10]. The abscissa axis represents the different wavelengths, and the ordinate axis represents the
normalized reflectance. The continuous red line corresponds to Glioblastoma (GBM); the dashed blue
line corresponds to Oligodendroglioma grade III; the dashed black, green and cyan lines correspond to
a metastatic lung, renal and breast tumors, respectively.
In biomedical applications, the spectral signature is employed as an indicator of the different
biochemical constituents of different tissues [11]. The spectral signature is a useful tool to differentiate
among different tissues, and also to provide information useful to discriminate healthy from diseased
tissue [12]. Nevertheless, spectral signatures of the same tissue from different subjects present
differences due to biological variability. This fact is called inter-patient variability of data. Furthermore,
the spectral signatures measures from different parts of the same tissue also present subtle differences.
This is called intra-patient variability of data. Handling the intra- and inter-patient variability of data
is one of the most important challenges in biomedical HS image analysis.
Due to the large amount of information that HSI provides, it is necessary to process and analyze
the acquired HS images by using high-performance computational techniques, thus focusing on the
information that is more useful for a particular application. In this review, we briefly discuss the
different applications of HSI in the medical field and the HS systems and algorithms more commonly
used as well as the current investigations performed in the application of HSI to study and diagnostic
gastrointestinal (GI) diseases using in-vitro, ex-vivo and in-vivo samples.
2. Medical Hyperspectral Imaging
This section is intended to provide some context on the use of HS technology in the medical field
prior to analyzing details of the use on HS in GI medicine. However, for a deeper introduction about
the use of HSI in biomedical applications we strongly recommend the review articles published by
Li et al. [13], Lu et al. [14] and Calin et al. [15]. Furthermore, for a better understating about light
tissue interactions and how this information can be used in diagnostic applications, we recommend
the studies performed in [11,12].
In the first decade of the 21st century, HSI has attracted the interest of researchers in the medical
field for two main reasons. First, it has been proven that the interaction between the EM radiation
and tissues carries quantitative diagnostic information about tissue pathology [11,12]; and second,
because of the non-invasive nature of this technology. Recently, clinicians have started to use HSI in a
number of situations. Some aim to detect cholesterol by analyzing HSI of the face [16] or arthritis by
studying the skin reflectance [17]. HSI has also been used for detecting peripheral arterial disease [18],
99
J. Clin. Med. 2019, 8, 36
to enhance the visualization of blood vessels [19] or to achieve automatic differentiation between veins
and arteries during surgery [20]. This technology has also been used to measure the oxygenation levels
of retina [21], brain [22], or kidney [23].
In detection of neoplasia, the main aim of using HSI is to develop aid-visualization tools able to
accurately delineate the boundaries of the tumor in order to improve resection of cancerous lesions,
hence avoiding the unnecessary resection of healthy tissue. This technology has been successfully
applied in detecting prostate cancer [24], head and neck cancer [25,26] or breast cancer [27] in animal
models. In humans, this technology has been employed for the detection of tongue cancer [28], oral
cancer [29], skin tumors [30–32] or brain cancer [10,33].
In the field of histopathology, where the current diagnostic techniques are based on the
morphological analysis of tissue specimen slides, HSI can be employed as a complementary source
of information that may unburden the workload of the pathologists. Researchers have proven the
capabilities in detecting several diseases using this technology, such as examining retina sections for
the quantitative assessment and evaluation of the effect of medication [34], detecting cancer metastasis
in lung and lymph nodes tissue [35], identifying brain tumors [36] or lung cancer [37].
In the following sections, we briefly introduce the main concepts involved in medical HSI and the
use of HSI as a new technology for assessing the detection of GI diseases.
3. Hyperspectral Systems
HS acquisition systems present a challenge to engineers, who have to handle sophisticated optical
and electronic systems to generate an HS cube. There are several types of HS cameras, however
depending on how data are acquired the main categorization is in spatial scanning cameras and
spectral scanning cameras [38].
Spatial scanning cameras, based on the push-broom technique, are capable of acquiring
simultaneously a single spatial dimension (a narrow line of an image) and the whole spectral
information for a given scene. To capture an HS cube in this manner, it is necessary to perform
a spatial scanning, where either the camera or the captured object(s) shift their position while the
camera is capturing frames. The scanning can be also performed by using a mirror in front of the fore
optic, and moving the mirror to image the whole object. Although the use of mirrors allows developing
more compact instrumentation (hence more appealing in clinical circumstances), it is necessary to take
care regarding the geometric distortions mirrors can produce in the captured image. The core of these
cameras is an optical element that splits the incoming radiation into specific wavelengths values [39].
This type of camera has the advantage of capturing images with high spectral resolution, offering
also an excellent trade-off between spatial and spectral resolutions, compared to other HS cameras, in
the expense of performing scanning in order to acquire an HS cube. For this reason, in the medical
field these types of cameras are used in open surgical procedures, for in-vivo surface inspection or for
ex-vivo tissue analysis. It is not possible to directly attach this type of camera to medical apparatus,
like laparoscopes or intraoperative microscopes, due to their inability to perform spatial scanning.
Some examples of HS acquisition systems, based on push-broom cameras, can be found in Figure 3A,B,
while the intraoperative use of these systems are presented in [20,40]. Furthermore, it is possible to use
this kind of camera for registering pathological slides [41], as can be observed in Figure 3C.
On the other hand, spectral scanning cameras employ an optical element that filters the incoming
radiation, registering the entire spatial information of a single wavelength at each and every moment.
Capturing an HS cube requires change of the tuned wavelength of the filter in order to perform spectral
scanning. There are several types of spectral scanning cameras. The filter wheel cameras require the
manual shift of the optical filter, while the Liquid Crystal Tunable Filter (LCTF) or the Acousto-Optic
Tunable Filter (AOTF) are devices where the spectral transmission can be electronically controlled [42].
These cameras have lower spectral resolution than the push-broom cameras, and are not suitable
for applications where the captured object is moving, because the spatial information may vary for
different wavelengths. Nevertheless, these cameras can be easily attached to medical instruments and
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can offer high spatial resolutions. An example of HS acquisition system for medical applications using
these cameras is shown in Figure 3D [43].
 
Figure 3. HS acquisition system used in medical applications. (A,B) HSI acquisition systems based
on push-broom cameras for in-vivo human brain tumor detection [40] and in-vivo pig abdominal
surgery [20]; (C) Liquid crystal tunable filter camera attached to an endoscope for cancerous
tissue detection [43]; (D) Microscope coupled to an HSI push-broom camera for pathological slides
registration [36].
The remaining type of HS cameras is called snapshot [44]. Snapshot technology is intended
to deal with the main limitation imposed by the previously described HS technologies: real-time
acquisition. It is not possible to collect HS or MS data in real-time using the above-mentioned HS
technologies for the requirement of performing a scan (either spatial or spectral). These technologies
are restricted to static situations, or scenarios where the object that is moving has a slightly lower speed
compared to the scan speed. For these reasons, where necessary to obtain HS data of non-static scenes
(e.g., living cell imaging) a snapshot camera must be employed. Furthermore, snapshot cameras can
be directly attached to clinical instrumentation, such as endoscopes or laparoscopes. Nevertheless,
both the spectral and the spatial resolution of the snapshot cameras are lower compared to the other
HS technologies. To the best of our knowledge, there is no current research in GI using snapshot
cameras, mainly because all preliminary exploration of HS technology in GI is focused to prove the
capabilities of the technology for diagnosis, and hence it is necessary to evaluate each scenario using
high performance spectral and spatial instrumentation.
4. Hyperspectral Image Analysis
As mentioned in the previous sections, HSI data facilitates the identification of different materials.
However, to successfully retrieve useful information from HS images, the application of appropriate
image analysis techniques is necessary. In this section, a brief overview of such techniques is provided.
They include pre-processing algorithms, e.g., for noise removal (HS images carry noise that may affect
information extraction) [45,46], HSI system calibration (with respect to the camera spectral range
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and resolution) [47], feature extraction [48], dimensionality reduction [49], classification [50], spectral
unmixing [51], and Normalized Difference Index (NDI) estimation [52,53].
Data acquired using HS instrumentation is highly biased by both the instrumentation and the
environmental conditions. In order to remove the influence of instrumentation (mostly the wavelength
dependencies of the sensor and grating efficiency and transmission of the lens), is common to perform
a calibration. The typical calibration procedure in HS and MS imagery consist of capturing a reference
image using a material that has a flat spectral response (e.g., Spectralon). This reference image
captures the spectral dependencies of the instrumentation and is used to remove the influence of the
instrumentation in the captured HS images.
To ameliorate the challenges imposed by the high dimensionality of HS data, feature extraction
and dimensionality reduction approaches are usually employed. Firstly, feature extraction (or band
selection) methods are used to select a subset of the original spectral data that contains the most
useful information for data exploitation. This reduced set of spectral bands strongly depends on the
nature of the specimens under study. Secondly, dimensionality reduction approaches aim to find a
representation of HS image data with a lower dimensionality than the original data, while maintaining
the most significant information. In HSI, data reduction techniques are widely used for finding new
data representations prior to the application of other data analysis techniques (such as classification).
This procedure reduces the complexity of the classification task, and it can also contribute to better
data visualization or compression [54,55].
One of the key topics in HS image analysis is classification, which aims for the identification of
the materials depicted within an HS image. HS data classification methods can be categorized into
supervised and unsupervised. Supervised classifiers require training using prior information on the
materials to be classified; hence, a mathematical model is optimized using this information. Then,
this model is able to infer predictions about new data. A recent review article by Ghamisi et al. [56]
analyzes the mostly extended supervised classifiers employed by the HS community. Unsupervised
classification methods (also known as clustering methods [57]) have the goal of grouping pixels
according to some spectral similarity criteria. Although these kinds of algorithms provide useful
information about the materials that are present in a scene, it is not possible to relate these groups of
similar pixels with their class membership. Recent studies have shown that the joint exploitation of
the spectral and the spatial information in HS images improves the classification performance [58].
Finally, spectral unmixing and NDI estimation have been used for HS image analysis. On the
one hand, spectral unmixing techniques, such as those based on Linear Mixture Models (LMMs),
make the assumption that each pixel of an HS image can be modeled as the weighted sum of
pure spectra elements (called endmembers). This technique tries to overcome the limited spatial
resolution that generally characterizes MS and HS imaging compared to the traditional RGB imaging.
Unmixing algorithms first find the endmembers and then estimate the abundance (proportion) of
each endmember in a single pixel [51]. On the other hand, NDI-based approaches try to establish
a combination of spectral channels that reveal some characteristics of the subject under study.
For example, the Normalized Difference Vegetation Index (NDVI) aims to assess the presence of
live vegetation in HS satellite images [52]. In the context of medical applications, a Melanoma
Identification Index has been proposed in [53] for identification of skin lesions in dermoscopic HS
images. Additionally, there are some researches that make use of Light Transport Models in tissue to
retrieve useful information about tissue diagnosis [16,17,59,60].
5. Hyperspectral Imaging in GI Diagnosis
HSI is an emerging technology still at an early application stage in the medical field. Therefore, the
number of publications regarding the use of this technology in gastroenterology is limited. This section
summarizes the main research works performed in this field, structured following the taxonomy
presented in Figure 4. This taxonomy divides the gastrointestinal HSI applications categorized by
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the type of application, the type of subject to study and the type of sample (i.e., the organ where this
technology is applied).
 
Figure 4. Taxonomy of the current gastrointestinal HSI applications.
5.1. Surgical Assistance in Real-Time
One of the current target applications of medical HSI is in the field of surgical guidance. Such
applications are motivated by the non-invasive nature of HSI technology, and for its capability of
generating an alternative visualization of tissues, that can assist in the identification of several GI
diseases. In this section, we present the most important surgical guidance tools based on HSI developed
for GI use.
5.1.1. Abdominal Organs Differentiation
An illustrative use of HSI as a visual guide tool during surgery can be found in [61]. In this
research work, the authors collected and processed spectral signatures from various abdominal organs.
The experiment was performed during an open abdominal surgery on a pig. By processing the spectral
signatures of the small intestine, colon, peritoneum, bladder and spleen, a thematic map where each
organ is identified was generated. The results of this thematic map can be found in Figure 5, where
each organ is represented with a different color. The automatic identification of different tissues during
surgery may extend the surgeon’s visual capabilities, making possible examining larger areas of tissue,
and therefore saving surgical time.
Figure 5. Use of HSI for organs identification in pig’s abdominal surgery performed in [61]. (A) RGB
image from pig’s abdominal cavity and organs; (B) Segmentation map obtained after HS image processing
and analysis, where the different organs are identified using different colors.
5.1.2. Colorectal Surgery
Colorectal surgeries have also been studied using HSI as a guidance tool during tissue resections.
Schols et al. [62] presented an explorative study aiming to collect and automatically differentiate five
different tissue types within the human abdomen: colon, muscle, artery, vein and mesenteric adipose
tissue (Figure 6). This tool could help surgeons to avoid ureteral injuries, which may lead to severe
complications such as intra-abdominal sepsis, renal failure or loss of renal functions. Near-infrared
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(NIR) fluorescence imaging has been also used to enhance the visualization of the ureters and arteries.
However, this technique requires the use of a contrast agent. HS images from 10 human patients were
collected and analyzed to verify whether HS images were a suitable tool for identifying arteries and
ureters intraoperatively. Although the spectral signatures collected from various organs presented
similarities, the authors reached promising results in the automatic discrimination between different
tissues. Therefore, the foundations for a non-invasive optical guidance tool that could be used
during colorectal surgery, enhancing the visualization of critical anatomy, have been laid. The same
research group also studied an approach to automatically identify different tissue types that can be
observed during laparoscopic colorectal surgery procedures [63]. Five types of tissue were recorded
from ex-vivo human resected specimens, i.e., mesenteric fat, blood vessels, ureter, colonic tissue and
tumorous colonic tissue. The data acquisition was carried out by using a spectrometer working in the
spectral range 440–1830 nm. Based on the measured spectral signatures, the authors posed that the
differentiation between tissues is possible by exploiting the spectral fingerprints of each tissue.
Figure 6. Mean spectra per tissue type acquired during colorectal surgery in [62]. Average tissue
spectra for ureter (green), mesenteric adipose tissue (dark blue), artery (red), colon (light blue), muscle
(black), and vein (purple).
The above-mentioned research consisted on analyzing the capabilities of HSI to differentiate
between different types of tissue. Nevertheless, this technology has been also used for colon diagnosis
applications. Malignant colorectal tumors, adenomatous polyps and different types of colorectal
normal mucosa were analyzed in [64]. To collect in-vivo HS data, a contactless endoscopic diagnosis
support system was attached to an HS camera. The endoscopic system was able to capture HS images
in the wavelength range from 405 to 665 nm, acquiring 27 spectral bands using a filter wheel. A total of
21 HS cubes from 12 different patients were employed to assess an innovative band selection algorithm
based on Recursive Divergence Method (RDFS). In order to evaluate the performance of the proposed
algorithm, a supervised classification method based on a Support Vector Machine (SVM) classifier
was used, with the manually labeled spectral samples of the different types of tissue acquired, to
serve as a training set. Using only five bands from the original 27, the HSI system was able to identify
in real-time the colorectal tumors and outlining the region affected by the tumor with an average
accuracy of 92.9 ± 5.4%. Furthermore, only these five bands were sufficient for the enhancement of the
visualization of the microvascular network on the mucosa surface. Another approach for colonic cancer
detection using HSI can be found in [65], where the authors study the identification of esophageal
squamous neoplasm by using an HS endoscopic imaging system.
Finally, although the work performed by Beaulieu et al. [66] cannot be considered strictly as HSI
(they use a spectrometer, so there is no spatial information), they present an interesting discussion
about which spectral range provides a better discrimination between tumor and normal colon tissues.
After the analysis, they concluded that the inclusion of SWIR (Short-Wave InfraRed) spectral bands
contribute to a better discrimination of malignant and normal tissue.
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5.1.3. Bowel Anastomosis
The correct monitorization of oxygenation and blood volume fractions are key for success
in colorectal surgery. For this reason, some researchers have focused their attention on imaging
visualization tools that can prevent surgical complications such as intestinal anastomosis. In [67,68]
the authors proposed methods to derive both the oxygenation of tissue and the blood volume fraction
by using models for light transportation in tissue. The results are shown to surgeons as thematic
maps where these physiological parameters are presented (Figure 7A). The work presented in [69] go
beyond, and propose a method to suggest the optimal location of sutures for a better surgical outcome.
To generate such map (Figure 7B), the authors made use of the information about the blood-vessels
location and the tissue thickness (measured from a MS image). Although these research works have
been only tested in swine models, they show a promising methodology for improving colorectal
surgeries. Another interesting application of MSI in bowel anastomosis can be found on [70]. In
this research, authors noticed that the variations in the measured reflectance spectra using an MSI
laparoscope are coherent with biophysical changes during small bowel radiofrequency fusions.
  
(A) (B) 
Figure 7. HSI application in Bowel anastomosis. (A) Small bowel oxygenation estimation shown in [68];
(B) Suture map and recommendations about the location of the suture provided in [69].
5.1.4. Biliary Anatomy Identification
Currently, the technologies used to delineate the anatomy of the biliary tree, such as the
Intraoperative Cholangiography (IOC) or the routine intraoperative ultrasonography, are not
sufficiently accurate. For this reason, the biliary anatomy has been also investigated using HSI
to accurately identify the different parts of the anatomic structure. Concretely, in [71] and [55], Zuzak
et al. proposed to use HSI to develop a visualization system capable of identifying the biliary trees
that do not depend on any prior dissection. The authors developed an acquisition system consisting of
an HS camera coupled with a conventional laparoscope that was intended to enhance the visualization
of the biliary anatomy. The spectral range of this device covers the EM spectrum from 650 to 1100 nm.
This technology may achieve a reduction of bile duct injuries during surgery. In order to test the
ability of HSI in detecting the bile tree, a study visualizing intraoperatively the abdominal organs of
pigs during close cholecystectomy procedures was carried out. The authors found that the measured
spectra of several anatomic structures are unique, allowing the differentiation of arterial vessels, venous
structures and bile duct. In [55], the HS images were processed using PCA (Principal Component
Analysis), which proves a visual enhancement of the different observed anatomical structures, i.e.,
the gall bladder and the liver. The correct identification of the tissue types was assessed by using
the morphological structures of each tissue. This research work shows that the visualization of the
biliary tree could be safely performed during surgical procedures without the need for prior imaging.
The inclusion of this technology may lead to eliminating the risk of the bile duct injury during
cholecystectomy, avoiding also the current need of injecting radioactive contrast agents.
In addition, dual-mode imaging systems have been using for this goal. Mitra et al. [72] used
a system composed by a Indocyanine-green-loaded (IGC) micro-balloon and an HS camera. The
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goal of this study was to identify the surrounding anatomy during IOC in real-time. This imaging
technique was tested over ex-vivo swine tissues, showing an accurate identification of the biliary
anatomy. The advantages of this imaging modality over IOC are its low cost, its real-time response,
and its independence of radiation agents. This type of visualization tool can be used for guidance
during surgical procedures. Furthermore, it can be used as an additional input to surgical robots, such
as the Da Vinci robot [73].
5.1.5. Intestinal Ischemia Identification
The intestinal ischemia can be defined as an inadequate blood flow to the intestine, causing an
inability to absorb food and nutrients, bloody diarrheal, infection and gangrene. In this sense, HS
technology has been also used for this application. Akbari et al. [74] developed a intraoperative HSI
tool capable of obtaining spectral signatures of intestinal ischemia acquired during a pig abdominal
surgery. Two cameras were used, covering from 400 to 1700 nm. The methodology followed in this
paper to process the HSI data consisted in finding an optimal NDI that allows the discrimination of
intestinal ischemia over other kind of tissue. This article demonstrated that the HS image analysis
is suitable for visualizing intestinal ischemia during surgical procedures. However, although this
study was performed with a wide spectral range and presents good analysis of the capabilities of
HSI technology, the instrumentation based on push-broom cameras is extremely outsized, being
inappropriate for clinical environments.
5.1.6. Gastric Cancer Identification
Other relevant research where HSI is used to study GI diseases can be found in [75], where
the authors describe the use of HSI for detecting human gastric cancer. This study was carried
out over ten patients who underwent a total gastrectomy. The HS images were captured ex-vivo
after the resection of a tumor using an HS camera covering the range from 1000 to 2500 nm.
After pathologic diagnosis, the real diagnosis was compared with the image processing results.
Although the data acquisition system was not appropriate to be used for endoscopic diagnosis
(it consisted on a proof-of-concept demonstrator), the data analysis enabled the identification of
wavelengths improving the differentiation between healthy and tumor tissues. These wavelengths can
be employed as specifications in the development of future laparoscopic HSI systems optimized for
gastric cancer detection.
Another application of HSI as a guidance tool during surgical procedures can be found in [76].
In this research work, the authors processed the HS data aiming to determine a combination of
wavelengths, highlighting the presence of ulcer regions in gastric tissue. Using different spectral
components from different types of tissue, the authors generated a thematic map where the
visualization of ulcer and erythematous regions of the image were able to be differentiated with
respect to the surrounding tissue. Other research works have also studied the in-vivo identification
of gastric ulcers using HSI [77] or gastric cancer employing a customized MSI video endoscopy
system capable of capturing multispectral video composed by six bands located in the visual spectral
range [78]. These research works suggest that HSI and MSI can be used as a guidance tool both for
diagnosing, and for delimitating the gastric tumor margins accurately.
5.2. Pathological Assistance
The research works previously presented investigate methods aiming to automatic identification
and visualization of different types of tissues, in the context of clinical diagnosis, mainly to facilitate
surgical procedures in real-time. Nevertheless, HS images have been also applied to the pathological
diagnosis of colonic diseases. The following papers describe the use of HSI for the identification of
tumorous tissues from in-vitro and ex-vivo human colon pathology samples.
The work described in [79] presents a study performed on biopsy slides of colon tissue aiming to
distinguish between normal and malignant cells through exploiting HSI. A morphological analysis of
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the HS images of biopsy slides with several microdots belonging to different patients was performed
employing a dimensionality reduction and cellular segmentation to describe the shape, orientation
and other geometrical attributes, using ICA (Independent Component Analysis) and the k-Means
algorithm. The segmentation maps obtained after the application of k-Means clustering algorithm allow
differentiating the malignant and benign cells by their morphological features. These morphological
features were then used as input to a classification process that differentiates between normal and
malignant cells. For this purpose, LDA (Linear Discriminant Analysis) algorithm was used due to
its reduced computational cost and acceptable performance. The images were captured with an HSI
system based on a tunable light source and a CCD (Charge-Coupled Device) camera coupled to a
microscope with a magnification of 400×, covering the spectral range between 450 and 850 nm. An
accuracy of up to 84% was obtained in the classification experiments, demonstrating that the use of
HSI facilitates the discrimination between normal and malignant cells of colon tissue by using its
morphological features.
Furthermore, Rajpoot et al. [80] employed an SVM to classify in-vitro samples of normal and
malignant human colon cells. Archival Hematoxylin and Eosin (H&E) stained micro-array tissue
sections of normal and malignant (adenocarcinoma) colonic tissue image data cubes were acquired at
microscopic level. The spatial dimensions of each HS cube were 1024 × 1024 pixels, having 20 spectral
bands covering the wavelength range from 450 to 640 nm. Multiscale morphological features such as
area, eccentricity, equivalent diameter, Euler number, extent, orientation, solidity, major axis length,
and minor axis length, were obtained from the segmented maps to be used in the SVM classification
procedure. The experiments carried out in this study reveal that an accurate discrimination (99.72%)
between normal and malignant tissue can be achieved.
Colon biopsy samples have also been studied by Masood et al. [81], where the authors propose
an algorithm for the automatic classification of colon biopsies based on spatial analysis of HS images
captured from colon biopsy samples. The aim of their work was to distinguish between benign
and malignant tissue. Although the authors collected HS cubes with 128 bands, they only use a
single spectral band. To this end, the processing framework consisted on selecting a single band and
performing a spatial analysis of this image by using Circular Local Binary Patterns (CLBPs). Then this
information is used by different supervised classifiers in order to retrieve diagnostic information from
colon biopsies. The maximum accuracy obtained was 90.6% for the SVM classification, with 87.5%
sensitivity and 93.7% specificity. A clear advantage of performing the spatial analysis on a single band
is to save acquisition, storage, and computational costs, but it is difficult to state that this algorithm
really makes use of the richness of information contained in the HS images. Although authors reached
good discrimination between malignant and benign tissue, the discrimination capabilities may increase
if more spectral channels are used.
HSI technology was also evaluated for differentiating normal and cancerous gastric cells in H&E
stained pathological slides [82]. In this case, the main motivation to perform the study was to analyze
the differences in pH levels between cancerous and normal cells. These pH differences were reflected
in the spectral signature of the different cells, providing good discrimination between malignant
and normal cells using only the spectral information of cell nuclei. Conversely, the work presented
by Hidovic-Rowe et al. [59,60] aimed to extract histological parameters from ex-vivo colon tissues
using HSI. The measured parameters were the blood volume fractions, the hemoglobin saturation
levels and the size of collagen fibers or the thickness of the mucosa layer. These parameters were
computationally estimated by using a light transportation model over colon tissue, identifying both
normal and tumor tissues.
Some current technologies used to improve colorectal exams are the White Light Endoscopy
(WLE), the Chomoendoscopy, Autofluorescence Imaging and Narrow Band Imaging. Nevertheless,
these technologies present limitations that motivate the finding of new technologies to this end.
Motivated by this fact, the work presented in [83] evaluated the initial feasibility of using HSI for
colonic adenocarcinoma identification using HSI fluorescence excitation-scanning for measuring
107
J. Clin. Med. 2019, 8, 36
changes in fluorescence excitation spectrum. To this end, an ex-vivo and in-vitro analysis of colonic
tissue was carried out, in order to determinate if HSI fluorescence can be used as an additional
endoscopy technology. A total number of eight patients were enrolled in that study. Specimens were
imaged using a custom HSI fluorescence excitation-scanning microscope system. As it can be seen in
Figure 8A, at short excitation wavelengths, the fluorescence total intensity of adenocarcinomas was
lower than normal tissue. However, fluorescence resulting from excitation at higher wavelengths
was increased, and in the S4 sample was higher than normal tissue, Figure 8B,C. Transmission and
absorbance spectral data indicate that adenocarcinoma displayed increased optical absorbance, as
compared to surrounding normal tissue (Figure 8D,E). These preliminary data suggest that there are
significant differences in the spectral signature of cancerous and normal tissue. In this sense, the
same research group continued the investigations and presented new results in [84,85]. These results
could pave the way towards advanced classification systems than can automatically identify tissues
attending to their spectral signatures.
 
Figure 8. Spectral differences between normal and cancerous tissue for two specimen pairs: S4
and S5 presented in [83]. Preliminary data demonstrate the differences in spectral signature
between cancerous and normal tissue. Transmission and absorbance spectral data indicate that
adenocarcinoma displays increased optical absorbance, as compared to surrounding normal tissue,
with additional spectral differences that could be exploited to increase sensitivity and specificity for
tumor detection. Spectral scan types are as follows: (A) Fluorescence excitation scan from 390 to
450 nm; (B) Fluorescence excitation scan from 390 to 480 nm; (C) Fluorescence excitation scan from 390
to 550 nm; (D) Transmission scan from 390 to 700 nm; (E) Absorbance scan from 390 to 700 nm.
In addition to the studies presented before, there are other interesting and novel applications of
pathological assistance using MSI/HSI. For example, authors in [86] collected MS images from four
types of colorectal cells: viz. normal, hyperplastic polyps, tabular adenoma with low grade dysplasia
and carcinoma. After MSI analysis of different colorectal tissues, an accurate discrimination using
colorectal cells was achieved.
Finally, another less conventional approach, investigated in the context of HSI for GI pathological
assistance, presents a vocal synthesis model and its application to sonification of HS colonic tissue
images [87,88]. The authors state that sonification could be used as an intuitive means of representing
and analyzing high-dimensional and complex data. The high-dimensional data for sonification
have been obtained from HS scans of normal and abnormal colon tissue, the abnormal tissue being
potentially cancerous. The tissue images were collected in cooperation with the Department of Applied
Mathematics at Yale University. A series of slides were prepared from distinct patients, containing
more than 300 microdots each slide, and each microdot corresponding to a slice of colon tissue (roughly
0.5 × 0.5 mm in size). Each microdot may contain either normal or malignant colon tissue. A slide
was chosen and illuminated with a tuned light source (capable of emitting any combination of light
frequencies in the range of 450 to 850 nm), and the transmitted image was magnified 400× by a
Nikon Biophot microscope. An amount of 15 data cubes of normal colonic tissue and 46 data cubes
of abnormal colonic tissue were collected. Examples of pre-processed specimens are illustrated in
Figure 9. Initial experiments with a variety of vocal tract models suggest that human ability to easily
identify vowel-like sounds is promising for intuitive sonification.
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Figure 9. Samples of HS normal and abnormal colonic tissue images and the results obtained after
applying the pre-processing sonification presented in [87]. (A) Sample specimen showing normal
colonic tissue in gray-scale image; (B) Final three-dimension image that gives the probabilities that the
point in the specimen belongs to normal colon tissue; (C) Sample specimen showing abnormal colonic
tissue in gray-scale image; (D) Final three-dimension image that gives the probabilities that the point
in the specimen belongs to abnormal colon tissue.
5.3. HSI Application Summary
Finally, in Table 1 we provide a summary of the most relevant research work in the field of
gastroenterology using HSI. This table is organized attending to: (1) the disease that has been
investigated; (2) the type of tissue involved in each study; (3) the subject of the research; (4) the
HSI technology employed to acquire the images; and (5) the data processing methods applied to
extract useful information from HS data.









Data Analysis Methods (Category
*/Method ¥)
Reference(s)
Biliary tree visualization 650–1050 LCTF In-vivo Swine D, E/PCA [55]
Colon cancer detection 400–700 LCTF Ex-vivo Humans F, E/LPM [59,60]
Organs identification
during surgery 900–1700 Push-broom In-vivo Swine SA, P/DWT; C/SOM [61]
Identifying tissues during
surgery 350–1830 DRS In-vivo Humans SA, F/SGAD; C/SVM [62]
Tissue identification




405–665 Filter Wheel In-vivo Humans R/RDFS; C/SVM [64]
Colon cancer detection 300–1800 Spectroscopy Ex-vivo Humans C/LDA; C/SVM [66]
Oxygenation measurement
(small bowel) 400–720 LCTF In-vivo Swine Ex/Linear light model [67]
Oxygenation measurement
(small bowel) 470–700 Filter-based In-vivo Swine Ex/Non-linear light model [68]
Suture recommendation
(intestinal anastomosis) 470–770 LED-based Ex-vivo Swine
Ex/2D-filtering, SAM and composite




460–700 LCTF In-vivo Swine Ex/Linear light model [70]
Biliary trees identification 650–1100 LCTF In-vivo Swine D, E/PCA [71]
Biliary anatomy
visualization 650–700 LCTF Ex-vivo Swine S/LMM, R/PCA [72]
Intestinal ischemia
identification 400–1700 Push-broom In-vivo Swine I/Ischemia Index; C/SVM [74]
Gastric cancer detection 1000–2500 Push-broom Ex-vivo Humans I/Cancer Index; C/SVM [75]
Gastric ulcers 405–665 Filter Wheel In-vivo Humans R, E/DI [76]
Gastric cancer 400–800 N/A Ex-vivo Humans C/MDC [77,89]
Gastric cancer 400–650 Tunable Light Source In-vivo Humans C/SVM; C/RF; C/RobustBoost;C/AdaBoost [78]
Colon cancer detection 450–850 Tunable Light Source In-vitro Humans R/ICA; R/PCA; C/k-Means; C/LDA;C/SVM [79,80]
Colon cancer detection 440–700 Tunable Light Source In-vitro Humans F/CLBP; R/PCA; C/LDA; C/SVM [81]
Gastric cancer cell
identification 420–720 LCTF In-vitro Humans R/Manual band selection; C/ANNs [82]
Colonic adenocarcinoma
identification 390–700 LCTF Ex-vivo Humans SA [83]
Colon cancer detection 360–550 LCTF In-vitro Humans S/LMM; R/PCA [84,85]
Colorectal cell
differentiation 400–1700 LCTF In-vitro Humans F/LBP, C/RF [86]
Colon cancer detection 400–1000 Push-broom Ex-vivo Humans DR/SPA; C/LDA [90]
* Categories of data analysis methods: (P) Preprocessing; (F) Feature extraction; (C) Classification; (R) Data
Reduction; (S) Spectral Unmixing; (I) Normalized Difference Index; (E) Tissue Visualization Enhancement; (SA)
Spectral Signature Analysis; (Ex) Exploratory Data Analysis. ¥ Data analysis methods: (SGAD) Spectral Gradients
and Amplitude Differences; (SVM) Support Vector Machines; (DWT) Discrete Wavelet Transformation; (SOM)
Self-Organizing Maps; (CLBP) Circular Local Binary Patterns; (PCA) Principal Component Analysis; (LDA) Linear
Discriminant Analysis; (LPM) Light Propagation Modeling; (LMM) Linear Mixture Model; (ICA) Independent
Component Analysis; (RDFS) Recursive Divergence Feature Selection; (DI) Dependence of Information; (MDC)
Minimum Distance Classifiers; (TPCR) Total Principal Component Regression; (RF) Random Forest; (SAM)
Spectral Angle Mapper; (SPA) Successive Projection Algorithm; (LBP) Local Binary Pattern; (ANNs) Artificial
Neural Networks.
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6. Discussion
Although HSI technology has shown its potential to be used as a diagnostic tool, the roadmap for
a new generation of HS medical devices is not clear yet. One of the most relevant challenges holds
in the acquisition system. The most appropriate technology to be used in the GI tract is not clear.
Although most of the state-of-art studies employ systems based on LCTF, acquisition systems based on
push-broom or tunable light sources have also been successfully employed to this end. Despite the fact
that higher spectral resolution is achieved using push-broom cameras, the spatial scanning required
to obtain an HS cube makes difficult the integration of such kind of cameras with standard medical
instrumentation, such as gastroscopes, colonoscopes, and laparoscopes. For this reason, LCTF can be
regarded as the most extended technology for the GI tract. On the other hand, a novel study has been
recently performed to identify in-vivo esophageal squamous neoplasia in human patients by using
a RGB-HSI combined system [65]. In this study, authors developed a system capable of artificially
generating an in-vivo HS image in the visual range by merging the information of a RGB endoscopic
image with the spectral information obtained from a 30 Macbeth color checker tile measured with
a spectrometer.
Concerning the optimal spectral range for GI diagnosis, the answer is still unclear. Although most
of the studies in the state-of-art use images in the VNIR spectral range, there are several research works
reporting successful detection of diseases using a spectral range beyond 1000 nm. In the upcoming
years, the research community should assess the optimal spectral range for diagnostic applications.
Depending on this spectral range, the directions on medical HS acquisition systems will possibly vary.
On the one hand, if the VNIR spectral range is optimal for disease detection in the GI tract, the future
medical HS images will be probably based on LCTF or snapshot cameras, that provide lower spectral
resolution and a limited spectral range compared with push-broom cameras, but they are easily
adapted to conventional medical instrumentation. On the other hand, if the spectral range increases
beyond 1000 nm, the identification of diseases will probably improve due to the richer amount of
available spectral information. However, push-broom cameras have to be used, and the engineering
challenge will be the adaptation of the push-broom cameras to conventional medical instrumentation.
Recently, pioneering HSI-enabled flexible endoscopes and concept capsule endoscopes have been
proposed [47,91,92], indicating the feasibility of incorporating HSI in clinical practice for colorectal
cancer detection. Future challenges of HSI in gastrointestinal endoscopy are mainly associated with its
application for the detection and characterization of various different kinds of abnormalities.
There are other interesting applications of MSI/HSI that are closely related to gastroenterology,
but they are out of the scope of this manuscript. For example, in a recent study performed
by Bhutiani et al. [93], the authors studied the in-vivo detection of AF-680 dye encapsulated PLA
(Polylactic Acid) using an MSI laparoscope. The exploitation of such type of information has a
potential use for in-vivo characterization of drug delivery.
Besides, on a recent review regarding current trends in endoscopic imaging, Joshi et al. [94]
mentioned two novel applications of MSI that are relevant to be mentioned in this review. The first
application is related to the use of dual-channel fluorescence images from in-vivo cross sections
using a confocal microendoscope [95]. This research points out that in-vivo cross section images
can be captured with a similar orientation as the corresponding histological sample. The same
methodology could be applied with MSI/HSI instead of fluorescence. The second application presented
by Joshi et al. [96] used a multispectral endoscope to simultaneously collect three fluorescence images
(DEAC, 6-TAMRA and CF633). They were able to acquire images from colonic adenoma stained with
two different peptides at the same time, providing sharp visualization of the lesion margins.
Structured light and MSI were used to simultaneously extract information about reflectance
and surface structure of tissue during small bowel surgery [97]. Although this research was just a
proof-of-concept, the incorporation of an additional spatial dimension to MSI/HSI can lead to better
discrimination among different tissues.
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Other spectral technologies based on Raman spectroscopy and Quantum Cascade Lasers (QCL)
have been applied to assist pathological analysis. First, Raman spectroscopy has been employed to
detect alterations in the biomedical composition of intestinal tissue biopsies, which can reveal coeliac
disease [98]. Although more research is needed to confirm the hypothesis, Raman spectroscopy is
also presented as a promising alternative for coeliac disease detection. Furthermore, several research
works have been performed in the literature with the goal of diagnosing histological slides without
requiring stains using QCL acquisition systems. These systems are able to acquire hyperspectral images
beyond five microns. Firstly, in [99], Kröger-Lui et al. had the goal of detecting goblet cell regions in
colonic epithelium using unstained histological sections, instead of conventional H&E stained samples.
They demonstrated a strong correlation between the contents obtained with HS unstained images
and the corresponding stained section using H&E. Secondly, in [100], Petersen et al. presented a
proof-of-concept following a similar methodology, demonstrating that the mid-infrared information
could be also useful for diagnosis purposes. In this pilot study, the authors found valuable information
about protein rich amide regions of colonic crypts, the musin secretions and the surface epithelium
walls that could be extracted from unstained colon sections using this spectral range (beyond 2500 nm).
As far as the data analysis techniques are concerned, there is not a generalized framework for
processing HS data. Table 1 summarizes the data analysis methods currently used in GI HS applications.
Actually, most techniques aim to get an enhanced visualization of tissues, with dimensional reduction
techniques, such as PCA, LDA or ICA, being the most popular HS data processing methods. Another
interesting trend is the definition of some normalized difference indexes to retrieve some characteristics
of tissues, such as the proposed Normalized Difference Ischemia Index (NDII) or the Normalized
Difference Cancer Index (NDCI). Although the use of such types of indices is handy, their use is still
limited. As far as classification methods are concerned, in contrast to other HSI applications (such as
precision agriculture or food quality analysis) the classification approaches used in the context of GI
endoscopy imaging are limited, mainly based on SVMs. Maybe the slow raise of HS data classifiers for
GI HS data is motivated by the difficulties to collect sufficiently large labeled datasets, allowing the
generation and evaluation of reliable classification models. A relevant challenge for the analysis of
medical HS data would be to investigate adaptation or enhancements of the current state-of-art HS
data classification approaches (mainly coming from the Remote Sensing community) for the analysis
of GI endoscopy data.
7. Conclusions
This survey is intended to provide a useful introduction to HSI in the medical field, paying special
attention to the applications in gastroenterology. HSI has been limitedly explored for clinical purposes
in GI endoscopy; moreover, the study of the literature indicates that it is a novel imaging modality with
a high potential to improve several current medical procedures. For instance, HSI can contribute to
make gastric surgical procedures safer by avoiding bile duct injury or ureteral injuries. Furthermore, it
can contribute in a more accurate determination of tumor boundaries, facilitating a complete resection
of the tumor tissue. Detection of malignant tissue, beyond the limitations of the contemporary white
light imaging remains an area where properly employed HSI could lead to precision diagnosis. Further
use of HSI technology has to face limitations of space and applicability [101].
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Abstract: The central nervous system (CNS) and the human gastrointestinal (GI) tract communicate
through the gut-brain axis (GBA). Such communication is bi-directional and involves neuronal,
endocrine, and immunological mechanisms. There is mounting data that gut microbiota is the
source of a number of neuroactive and immunocompetent substances, which shape the structure
and function of brain regions involved in the control of emotions, cognition, and physical activity.
Most GI diseases are associated with altered transmission within the GBA that are influenced by
both genetic and environmental factors. Current treatment protocols for GI and non-GI disorders
may positively or adversely affect the composition of intestinal microbiota with a diverse impact on
therapeutic outcome(s). Alterations of gut microbiota have been associated with mood and depressive
disorders. Moreover, mental health is frequently affected in GI and non-GI diseases. Deregulation
of the GBA may constitute a grip point for the development of diagnostic tools and personalized
microbiota-based therapy. For example, next generation sequencing (NGS) offers detailed analysis
of microbiome footprints in patients with mental and GI disorders. Elucidating the role of stem
cell–host microbiome cross talks in tissues in GBA disorders might lead to the development of next
generation diagnostics and therapeutics. Psychobiotics are a new class of beneficial bacteria with
documented efficacy for the treatment of GBA disorders. Novel therapies interfering with small
molecules involved in adult stem cell trafficking are on the horizon.
Keywords: gut brain axis; microbiota; functional gastrointestinal disorders; inflammatory bowel
disease (IBD); adult stem cells
1. Introduction
Recently, a new United Nation’s (UN) Commission goals on global mental health and sustainable
development has been published [1]. This Commission is in line with other UN General Assembly
and High-Level Meeting report and explores the issues of mental health from those with mental
disorders to whole populations [2]. Accordingly, good mental health is viewed as fundamental to
individual’s well-being and overall health. In addition, efforts are being focused on systemic and
global changes in order to align mental health across all medical specialties [3,4]. In the context of the
previously mentioned documents, the relationship between gut microbiota and mental health seems to
be very interesting.
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Intestinal microbiota represent one of the richest ecosystems in nature. Professor Rob Knight of
the University of California, San Diego [5] reported that more than half of all cells in the human body
are microorganisms, which are mainly bacteria as well as fungi and viruses. Until recently, the general
belief was that intestinal microbes were mainly involved in digestive processes. With the advent of
new molecular techniques and bioinformatics, in-depth research has unraveled the role of intestinal
microbiota in a number of physiological processes [6,7]. The topic of global microbial diversity is so
crucial and important to human health and wellbeing that scientists from Rutgers University-New
Brunswick—In a recent issue of Science—Called for the creation of a global microbiota vault to protect
humanity’s long-term health [8].
The role of the gut microbiome on human health is very diverse and implicated in the
pathophysiology of various diseases. Its role in metabolism and obesity development has been
clearly documented [9]. More recently, gut microbes have been implicated in the pathogenesis of
cancer and microbial contribution in cancer treatment [10]. The pathogenesis and natural history of
chronic GI, non-communicable diseases e.g., non-alcoholic steatohepatitis (NASH) [11], functional
gastrointestinal disorders (FGIDs) [12], and non-GI disorders e.g., cardiovascular disease (CVD) [13]
have been linked to GI tract microbes. The alterations of gut microbiota have been associated with
neurodegenerative diseases as well as mood disturbance and depression [14–16]. In fact, mental health
alterations are frequently observed in many GI diseases [17–20].
2. Paradigm Changer—Rome IV Criteria and FGIDs
For years, FGIDs were viewed as purely functional disorders with no scientific confirmation of a
clear pathogenetic mechanism. According to Rome IV criteria, the phenotype of FGIDs results from
an altered transmission of nerve and biochemical signals within the gut-brain-microbiota axis with
mechanisms controlled by both genetic and environmental factors [21]. Additionally, few studies
conducted in patients suffering from functional dyspepsia (FD) and irritable bowel syndrome (IBS)
found alterations in small bowel microbiota. Zhong et al. [22] showed that Actinomyces, Atopobium,
Leptotrichia, Prevotella, and Veilonella counts differ between FD and control patients. The finding was
preceded by an observation that, in FD patients, gut barrier integrity is impaired and expressed as
lowered transepithelial resistance, diminished expression of proteins of tight junctions, and, lastly,
elevated levels of mast cells, eosinophils, and interstitial lymphocytes [23]. Giamarellos-Bourboulis
reported a significant reduction in the diversity of small-bowel microbiota and the number of
species [24]. Furthermore, Martinez et al. reported that the proportion of dilated junctions and
intercellular distance between enterocytes in their apical part was elevated [25]. They also found that
higher tryptase mRNA expression leads to overactive bowel movements and looser stool as per Bristol
stool scale. Importantly, the degranulation of mast cells was found to positively affect the firing of
visceral-nociceptive sensory neurons in IBS [26]. According to the new ROME IV criteria, the following
factors contribute to the pathogenesis of FGIDs: (i) motility disturbance, (ii) visceral hypersensitivity,
(iii) altered mucosal and immune function, (iv) altered gut microbiota, and (v) altered central nervous
system (CNS). All of them are also associated with the concept of the microbiota-gut-brain axis.
The overlap of FGIDs and CNS disorders has been discussed in a few studies. It has
been demonstrated that approximately one third of IBS patients suffer from depression [27].
More recently, Batmaz et al. [28] reviewed patients referred either directly to psychiatric clinics or from
gastroenterology wards to psychiatrists and concluded that these patients were complaining of both
GI and psychiatric symptoms. Furthermore, patients of the latter group complained more frequently
of constipation, abdominal pain, and bloating and were more frequently diagnosed with psychotic
disorders in comparison to those directly referred to psychiatric clinics. It is estimated that psychiatric
symptoms occur in at least 36.5% of FGIDs patients [17]. Stasi et al. found that the highest prevalence
of mental or spectrum disorders is in patients with functional constipation (60%) as compared to
patients diagnosed with FD (52.4%) and/or functional bloating (47.6%). The most prevalent psychiatric
disorder observed in FGIDs were the general anxiety disorder and panic diagnosis [17]. Furthermore,
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Wilder-smith et al. [29] identified both GI and CNS symptom profiles secondary to fructose or
lactose ingestion.
3. The Emerging Role of the Microbiota-Gut-Brain Axis
Studies in animal models have shown that microbiota play an essential role in shaping the
structure and function of the CNS [30]. Using sophisticated strategies for manipulating the microbiome,
researchers observed the consequences of these changes one the brain and behavior. For example,
it has been found out that the thickness of the myelin sheath, the length of dendrites, and the density
of dendritic spines are controlled by microbiota [31,32]. A recent study by Lu et al. [33] conducted
in humanized germ-free mice demonstrated that slow-growing mice presented skewed neuron and
oligodendrocyte development as well as evident signs of neuro-inflammation. Social competences
and repetitive behaviors are, at least in part, a reflection of the composition of intestinal bacteria [34].
These dependencies result directly from the existence of a physical and functional connection between
the human digestive tract and the CNS. This concept called the gut-brain axis (GBA) with the
participation of neural and biochemical mechanisms can be exploited for the development of new
therapies for mental health disorders.
The CNS utilizes neural and endocrine pathways to cooperate with the gut. The sympathetic part
of the autonomic nervous system and the hypothalamus-pituitary-adrenal axis (HPA) co-modulate
the secretion, motility, and blood flow affecting intestinal permeability and influencing various GI
disorders [35]. Gut neural signals are passed through the enteric nervous system (ENS) and the vagus
nerve [36]. Biochemical information is carried out by cytokines, chemokines, neurotransmitters,
and micro-vesicles [37] as well as directly by-products of gut microbiota metabolic activity, i.e.,
short chain fatty acids (SCFAs). Eventually, once in the circulation, these molecules influence HPA and
GBA [38]. An elevated stress response may impair the psychosomatic well-being [39]. With pioneering
work, Sudo et al. [40] demonstrated that gut microbiota is essential to proper stress hormones release
and the restoration of intestinal ecosystem may reverse abnormal stress response. More recently,
in vivo experimentation has demonstrated that stress mediators and their receptors’ expression are
reduced in pathogen-free animals [41].
4. How the Gut/Brain Talks to the Brain/Gut
Intestinal microbiota as an integral part of the intestinal barrier controls the transport of antigens
through the peri-cellular route to the lamina propria where the gut associated lymphoid tissue (GALT)
is located [42]. The composition of intestinal microbiota can, therefore, influence intestinal barrier
permeability, which guarantees the flow of molecules through the peri-cellular route to blood vessels.
Gut microbes permanently train GALT to create immunity against commensal bacteria and food
antigens but also to provide defense against pathogenic microorganisms [43]. During dysbiosis,
due to GALT activation, effector cells and inflammatory mediators disrupt gut barrier integrity and
result in elevated intestinal permeability [44]. The interaction of the intestinal barrier elements, thus,
provides a physiologic and selective ability to absorb and secrete specific substances while inhibiting
the translocation of microorganisms and the penetration of toxins and other harmful antigens [45,46].
The effects of increased intestinal permeability may manifest locally—In the GI tract—As well as
extra-intestinally. For example, the concentration of zonulin—A protein that activates the intracellular
signaling pathway leading to tight junctions [47] modulation and a marker of intestinal permeability
increases in people with inflammatory and autoimmune diseases [48]. Of importance, the gut barrier
resembles in structure and function the blood brain barrier (BBB) [49]. Both barriers are composed
of epithelial and endothelial cells laced with lymphatic vessels, macrophages, and cellular tight
junctions. It has already been suggested that both IBS and pseudomembranous colitis [50,51] are
consequences of microbiota and intestinal barrier dysfunctions and these entities frequently coexist
with depression [52,53].
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5. Microbiota-Gut-Brain Axis and Susceptibility to Neuropsychiatric and Gastrointestinal
Disease and Response to Therapy
The structure of intestinal microbiota is strongly influenced by diet and environmental stressors
such as drugs. It seems that these factors dominate over the impact of genotype on the gut flora
composition [54]. Consequently, it has been recognized that it may be the optimal marker of
susceptibility to express certain clinical phenotypes and, thus, the response to pharmacotherapy [55].
Since the concept of bidirectional signaling between the gut and the brain started to evolve, scientists
have made attempts to discover microbial fingerprints in neurology and psychiatry. Emerging
research suggested that gut-brain axis dysfunction may be involved in the etiology of depression
and anxiety, schizophrenia, addiction, and neurodevelopmental and neurodegenerative diseases as
well as age-related cognitive decline [14,56–59]. Major microbiota-related alterations in particular
neuropsychiatric conditions are summarized in Table 1.
Table 1. Microbiota and its metabolites alterations in various psychiatric conditions.
The Disease Microbiota-Related Fingerprint Reference
Depression
↑ Bacteroidetes, Proteobacteria, Actinobacteria,
Enterobacteriaceae, Alistipes, propionic, isobutyric,
and isovaleric acids [60–63]
↓ Faecalibacterium, Bifidobacterium, Lactobacillus; serotonin,
noradrenalin, SCFAs, kynurenic acid, kynurenine
Schizophrenia
↑ Corinobacteriaceae, Prevotella, Succinivibrio, Collinsella,
Megasphaera, Klebsiella, Methanobrevibacter, Clostridium [64,65]
↓ Blautia, Coprococcus, Roseburia,
Bipolar disorder ↑ Bacteroides, Actinobacteria, Coriobacteria [66,67]↓ Faecalibacterium, Roseburia, Alistipes,
Parkinson’s disease
↑ Bacteroides, Roseburia
[68]↓ Blautia, Coprococcus, Dorea, Oscillospira, Akkermansia
Autism Spectrum Disorder
↑ Streptococcus, Clostridiales, Comamonadaceae,
Akkermansia, Rhosococcus, Oscillospira, Desulvibrio,
Burkholderia, Collinsella, Corynebacterium, Dorea, and
Lactobacillus; acetic and propionic acid,
p-cresol, Glutamate, [69–73]
↓ Firmicutes, Faecalibacterium, Ruminococcus, Proteobacteria,
Fuscobacteria, Verrumicrobia, Bifidobacterium, Neisseria,
Alistipes, Bilophila, Dialister, Parabacteroides, and Veillonella,
butyric acid, tryptophan, kynurenic acid,
Attention-Deficit Hyperactivity Disorder ↑ Actinobacteria (Bifidobacterium genus) [74]↓ Firmicutes (Clostridiales order)
Alzheimer’s disease
↑ Blautia, Phascolarctobacterium, Gemella, E.coli, Shigella,
Ps. aueruginosa
[75,76]↓ Ruminococcaceae, Turicibacteraceae, Peptostreptococcaceae,
Clostridiaceae, Mogibacteriaceae, and the genera SMB53
(family, Clostridiaceae) Dialister, Clostridium, Turicibacter,
and cc115 (family Erysipelotrichaceae)
Multiple sclerosis ↑ Akkermansia muciniphila, Acinetobacter calcoaceticus [77]↓ Parabacteroides distasonis
Anorexia nervosa ↑ Methanobrevibacter smithii [78]
Nevertheless, uninterrupted stress regulation is pivotal to mental health and altered stress
response has been implicated in the origin of psychiatric diseases [58]. Numerous studies conducted
in animals and humans have demonstrated that both acute and chronic stress interfere with intestinal
barrier integrity and induce adverse alterations in intestinal microbiota composition. This has been
confirmed in models of early-life [79] stress and prenatal stress [80]. Yarandi et al. [81] showed that
water and ion in the gut might be reduced and elevated, respectively, under stressful conditions. This,
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in turn, impairs the physical protection of the gut barrier against both pathogenic microorganisms
and nociceptive molecules. Furthermore, HPA activation, in particular corticotropin-releasing factor
(CRF), showed a causative role in gut integrity disruption [82]. Elevated intestinal permeability was
also found to be linked to stress-induced hypersensitivity of the rectum in animals, which were
studied by means of partial restraint stress [83]. Winter et al. merged microbiome data from both
animals and humans and selected bacterial genera that were either over-represented or appeared in
a reduced number following stressor exposure. The first group included: Desulfovibrio, Eggerthella,
Holdemania, Turicibacter, Clostridium, Blautia, Anaerofilum and Roseburia whereas those found in reduced
numbers were: Prevotella, Bacteroides, Mucispirillum, Dialister, Allobaculum, Faecalibacterium, Oscillospira,
Ruminococcus, Dorea, Coprococcus, and Pseudobytyrivibrio [84].
Emerging New Concepts in the Development of Neurodegenerative and GI Disease—Gut Microbes, Innate
Immunity, and Bone Marrow Stem Cells as Partners in Crime
Mood and psychiatric disorders as well as numerous GI disorders are related to chronic
inflammation [85]. For example, post-infectious IBS alters GI tract motility and behavior [86]. A similar
effect appears in patients with FD [87]. Behavioral alterations predominate in chronic GI inflammatory
disorders [88]. Chronic inflammation of the ENS can easily affect the CNS. However, knowledge on
mechanisms behind this phenomenon is still scarce. For decades, inflammation in the brain, which were
recently implicated in the pathogenesis of psychiatric diseases, has been considered “sterile.” However,
recent reports reveal the presence of the gut-vascular barrier (GVB), which, in structure and function,
resembles the blood brain barier (BBB) and their communication is mediated via blood and bone
marrow systems [89]. GVB controls the dissemination of bacteria from the gut into the bloodstream
and the Salmonella typhimirum infection has been shown to decrease the Wnt/β catenin-inducible gene
Axin2 (a marker of stem cell renewal) in the gut endothelium.
Importantly, the Wnt/β catenin signaling pathway is universally involved in trafficking
(mobilization and proliferation) of stem cells deposited in adult tissues [90] including those located
in GI tract [91]. Wnt/β catenin system has also been involved in the developmental control of BBB
formation [92]. It has been demonstrated that various types of bone marrow-derived stem cells are
mobilized into peripheral blood in patients and experimental animals in response to tissue/organ
injury [93]. Examples include myocardial infarction [94], stroke [95], deep skin burns [96], and gut
inflammation [97]. It has been previously shown that circulating peripheral bone marrow mononuclear
cells (PBMNCs) were enriched with cells expressing mRNA of leucine-rich repeat-containing G-protein
coupled receptor 5 (lgr-5), Achaete-scute complex homolog 2 (Ascl-2), Doublecortin Like Kinase
1 (Dclk-1), Male-specific lethal 1 homolog (MSL1), and B lymphoma Mo-MLV insertion region
1 homolog (BML-1). These markers are involved in the development of early intestinal lineage [97].
These circulating in PB cells could potentially be involved in reparatory mechanisms of peripheral
tissues including the brain [98].
In fact, the release of very small embryonic-like stem cells (VSELs) and more differentiated
neural stem cells (NSCs) from bone marrow into the peripheral blood in response to brain injury in
rodents [99] and humans [95] has been well documented. Recent research indicates the involvement of
other factors such as small bioactive lipids that may direct mobilization and trafficking of stem cells to
injured organs [100]. Notably, release of sphingiosine-1-phosphate (S1P) correlates with the activation
of the complement cascade and formation of the C5b-C9 membrane attack complex (MAC). Activation
of proteolytic and fibrynolitis complement cascades. The release of cleavage fragments (e.g., C5a and
desArgC5a fragments) could enhance the mobilization of stem cells from their niche in the bone
marrow [101]. Moreover, these stem cells can be attracted from the bone marrow and from the intestinal
epithelium in response to tumor or injured tissue derived plasma chemo-atractants such as stromal
derived factor-1 (SDF-1), vascular endothelial growth factor (VEGF), zonulin, hepatocyte growth factor
(HGF) or shphingosine-1-phosphate (S1P), ceramides, and extracellular nucleotides [102,103]. On the
other hand, stem cells may secrete their own growth factors, cytokines, or even membrane-derived
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micro-vesicles that accelerate the regeneration process [104]. The previously mentioned factors have
been frequently implicated in the pathogenesis of gastrointestinal and psychiatric disorders [89,105].
We envision that stem cells together with the GI microbiome are mutually involved in the
pathogenesis of disorders of GBA by employing different mechanisms (e.g., autocrine, paracrine,
or hormonal effects, immunomodulatory effects, replacement of damaged cells, cytotoxic effects, and
neurotoxic effects) in distant tissues and organs. Further studies are needed to assess more accurately
the mechanisms of cell-host-microbe interactions (Figure 1). Knowledge around these mechanisms
already allows the design of novel treatments targeting GBA. For example, structural analog of S1P
—Fingolimod and Ozanimod, functional antagonists of S1P receptors have already been applied in
the treatment of relapsing forms of multiple sclerosis [106] as well as ulcerative colitis [107]. Similarly,
supplementation with multi-species probiotics (Ecologic® Barrier, Amsterdam, The Netherlands) in a
12-week, placebo-controlled, randomized clinical study, which favorably modified both functional and
biochemical markers (e.g., VEGF) of vascular dysfunction in obese postmenopausal women [108].
Figure 1. The bidirectional signaling within the GBA with the involvement of sterile inflammation of
the brain and actions of microbiota and circulating adult stem cells. For details, see the text.
Emerging scientific data show that rapid changes in diet and lifestyle significantly contribute to
the weakening of old evolutionary cell door-keeping mechanisms (e.g., Wnt/β catenin system) in the
gut and the brain. The notion that even minor and subclinical stimuli to the gut mucosal and vascular
barrier (e.g., infection) can result in significant, though delayed, consequences that may seriously affect
the health of an individual is attractive [109], it still requires further detailed studies.
6. Drug-Microbiome Interactions—Still Neglected Problem in Clinical Medicine
Although microbiota alterations play—At least in part—A role in the etiology of neuropsychiatric
diseases. Paradoxically, the treatment of these conditions may adversely affect the composition of
intestinal microbiota. In fact, multiple drugs were found to be involved in dysbiosis origin [110–112].
Recently, Maier [113] reported that approximately one-fourth of about 10,000 non-antibiotic drugs
were found to be able to reduce the in vitro growth of particular bacteria strain. Among these,
the psychiatric drugs were predominant. In fact, certain pharmaceuticals utilized in neurology
and psychiatry, which are predominantly antidepressants and antipsychotics, were historically
characterized for being antibacterial agents. Evidence gathered mostly from animal studies but
also in humans suggests that second-generation antipsychotics (SGA), which are mainly olanzapine
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and risperidone, change the composition of intestinal bacteria toward bacterial species promoting
obesity. As demonstrated by several authors, the administration of these psychotropic drugs may
increase the Firmicutes/Bacteroidetes ratio [114–118] previously found to be a microbiota profile of the
obese [119].
The majority of studies aimed to look for the link between antipsychotic-induced metabolic
malfunctions and microbiota dysbiosis were in vivo models. In rats treated with olanzapine (OLZ)
and mice fed with a high fat diet and administered with OLZ, the microbiome diversity was found
to be reduced [115,118]. When treated with another neuroleptic agent, namely risperidone (RIS),
fewer operational taxonomy units (OTUs) were found in female mice [117]. Davey et al. demonstrated
gender-dependent elevation of Firmicutes abundance and a decrease of Bacteroidetes [115,116].
Antipsychotic-driven dysbiosis in rodents resulted in decreased counts of beneficial Actinobacteria
and Proteobacteria [115]. The OLZ regimen introduced higher abundance of Erysipelotrichia and
Gammaproteobacteria and lower abundance of Bacteroidia. Lastly, OLZ suppressed the growth of
anaerobic bacteria [117] and Escherichia coli NC101 [118].
In parallel, very few studies in humans explored the alterations of the gut microbiome following
SGA treatment. Skewed intestinal microbiota following the psychotropic pharmacotherapy in humans
expressed as elevated phylogenetic diversity and evaluated by means of PcoA of unweighted UniFrac
distances [120] and reduced Simpson diversity in females [121] have been reported. Chronic use of RIS
in children elevated the levels of Clostridium, Lactobacillus, Ralstonia, and Eubacterium. This occurred
only in patients with a significant gain in BMI [120]. Flowers et al. conducted gut microbiota analyses
in adult patients diagnosed with bipolar disorder and demonstrated that psychotropic treatment
increased concentration of family Lachnospiraceae in the whole cohort of patients treated with SGA and
a group of obese subjects. In addition, lowered counts of Akkermansia genera were noticed in the whole
cohort of patients receiving treatment [121]. Yuan et al. lowered the levels of Clostridium coccoides
Kaneuchi and Lactobacillus spp. and elevated the numbers of Escherichia coli Castellani and Chalmers
in adult schizophrenia patients since six weeks of RIS treatment, which demonstrated that these
variations may have induced body weight gain and increased fasting plasma glucose, homeostasis
model assessment of insulin resistance (HOMA-IR), and low density lipoprotein (LDL) cholesterol
concentration [122]. As far as metabolic disturbances are concerned, studies by Bahr et al. [120] and
Flowers et al. [121] microbiota alteration during psychotropic treatment may correlate with weight gain.
We previously demonstrated that SGA-induced dysbiosis may potentially result in body weight
and metabolic disturbances with low-level inflammation and decreased energy expenditure involved
in the mechanism. However, since the majority of studies were conducted in rodent models with a
high number of unclear risk of bias assessments, these findings need to be considered cautiously and
may not be fully replicated in humans [123]. More studies regarding the involvement of psychiatric
medications on gut microbiota composition in humans are warranted and, ccurrently, our research
team undertook this effort.
The first antidepressant—Iproniazid—Via producing isonicotinoyl radicals may interrupt the
bacterial cell cycle and inhibit their growth [124,125]. Tricyclic antidepressants were found to possess
anti-plasmid activity and inhibit the growth of Escherichia coli Castellani and Chalmers, Yersinia
enterocolitica Schleifstein & Coleman [126] and Giardia lamblia Kofoid & Christiansen [127] by means of
decreasing the activity of DNA gyrase [128]. Tricyclic antidepressants are active relative to Plasmodium
falciparum [129] and Leishmania spp. [130]. Selective serotonin re-uptake inhibitors may inhibit
the growth of Staphylococcus, Enterococcus [131–133], Citrobacter spp, Pseudomonas aeruginosa Migula,
Klebsiella pneumoniae Trevisan, Morganella morganii Brenner et al., Clostridium perfringens Hauduroy
et al., and Clostridium difficile Prevot [131,134]. Efflux pump inhibition may be involved in these
properties [135]. Ketamine may control the growth of Staphylococcus aureus Rosenbach, Staphylococcus
epidermidis Evans, Entercoccus faecalis Schleifer and Kilpper-Bälz, Streptococcus pyogenes Rosenbach,
Pseudomonas aeruginosa Migula and Candida albicans (C.P.Robin) Berkhout [134,136].
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7. Modulation of Microbiota-Gut-Brain Axis as a Promising Tool to Manage Gastrointestinal and
Mental Health
Mood disorders and depression are associated frequently with other GI conditions such as
liver disease, inflammatory bowel disease (IBD), food intolerance, enteropathies (e.g., celiac disease),
and cancer. Recently, Felice and O’Mahony [137] explained the origin of the high coincidence between
stress-related psychiatric conditions and GI symptoms. Dysbiotic gut microbiota via synthesizing
neuroactive metabolites are able to counteract secretion, motility, and blood flow within the GI tract
and, additionally, transfer neural signals through vagus nerve and spinal cord routes. Therefore,
the modulation of microbiota-gut-brain pathways opens up new avenues for the management of
chronic diseases both of psychiatric and organic origin [12,138–143].
The new treatment avenues could be addressed through the modulation of the microbiota-
gut-brain axis by means of prebiotic and probiotic administration. The World Gastroenterology
Organization (WGO) recently issued a Global Guideline on Prebiotics and Probiotics use by healthcare
professionals [144]. Among probiotics, those are recommended in the management of disorders
of gut-brain interaction commonly known as FGIDs: Lactobacillus plantarum Bergey et al. 299V,
Bifidobacterium infantis Reuter 35624, Bifidobacterium animalis Scardovi and Trovatelli DN-173 010,
and Saccharomyces boullardii Henri Boulard CNCM I-745.
Psychobiotics—New Kid on the Block
Psychobiotics are a new class of probiotics which, when ingested, confer mental health benefits
through interactions with the microbiota-gut-brain axis [145]. This term should also include prebiotics,
which favorably influence the growth of beneficial gut bacteria [146]. Some of the properties of
probiotics are prevalent among different strains, e.g., improvement of the intestinal epithelium renewal
while the others are strain-specific, e.g., modulation of the CNS function [147]. Misra et al. noted that
psychobiotic strains may be involved in the neuroactive substances synthesis, activate directly neural
pathways, modulate neurotrophic factors, protect microbiota against stress, and others [148].
The action of psychobiotics was confirmed in mechanistic studies. For example, Ait-Belgnaoui et
al. [149] demonstrated that psychobiotics may significantly reduce stress-induced neuronal activation
in three brain regions i.e., hypothalamus, amygdala, and hippocampus, and promote the development
of dendrites in the cingulate cortex-center of neurogenesis. Another study confirmed that psychobiotics
decreased visceral hypersensitivity intensity and such an action correlated with the concentration
of stress hormones (noradrenaline, adrenaline, corticosterone) and was possibly regulated by
glucocorticoid receptors [150]. In vivo studies also reported that ingestion of psychobiotics improved
GI function through the modulation of GBA in animals experiencing maternal separation [151] and
Citrobacter rodentium infection [152].
Lately, the importance of psychobiotic use in humans has been acknowledged. Diop et al.
was the first to demonstrate that probiotic supplementation reduces symptoms of GI disorders
caused by stress in healthy people [153]. Messaoudi et al. showed that psychobiotic strains
impact positively psychological stress exponents and reduce urinary free cortisol concentration [154].
Steenbergen et al. [155] demonstrated that, after 4 weeks of probiotic supplementation,
a statistically significant improvement of aggression and rumination compared to placebo was found.
Allen et al. [156] tested the psychobiotic strain to find that it may improve memory and reduce stress
while Kato-Katoka [157] who analyzed a group of students during the exam session reported that the
incidence of abdominal pain and cold as vegetative stress symptoms was significantly lowered in the
group of students receiving probiotics compared to the placebo group. A recent study by Lv et al. [158]
summarized that psychobiotics improve the function of the GI tract in patients with schizophrenia.
In addition, meta-analyses have shown that probiotic intervention may positively affect the
mood in healthy persons as well as depressive patients [159]. McKean et al. [160] found that
probiotic consumption may diminish the symptoms of depression, anxiety, and stress. Surprisingly,
the latest meta-analysis concluded that such an intervention may significantly improve the mood
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of patients with mild to moderate depression but not the mood of healthy individuals [161].
Consequently, psychobiotics and neurobiotics, which are capable of GBA and HPA modulation,
could be advocated in the management of patients endangered with iatrogenic complications associated
with pharmacotherapy and polypharmacy. However, more studies—Especially of the highest evidence
level—Are necessary to elucidate the psychobiotic potential to improve GBA function.
The use of these new probiotic compounds could be of great use in the daily management of stress
and depression in FGIDs patients but also with other GI and extra-intestinal complaints associated
with mental or mood alterations [162,163]. The data supporting their use are already strong and new
studies that shall create even more evidence to medical societies as well as governmental agencies
to help them evaluate the microbiota-gut-brain axis therapeutics in the management of stress in
contemporary medicine [164,165]. Table 2 includes examples of psychobiotic strains and their clinical
applications [144,148,166]. Since a few probiotic strains were found to be effective to counteract
mood disorders and FGIDs, there is still limited data in individuals with ASD, Parkinson’s disease,
and Alzheimer’s disease. There is an urgent need for a great investment in clinical trials in these
entities [167–171].
Table 2. Probiotics strains with documented efficacy in gut-brain axis disorders [144,148,166,172].
Condition Strain
Anxiety and depression
Lactobacillus fermentum NS8 and NS9, Lactobacillus casei Shirota, Lactobacillus
gasseri OLL2809, Lactobacillus rhamnosus JB-1, Lactobacillus helveticus Rosell -52,
Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactococcus lactis W19 and
W58, Bifidobacterium longum Rosell-175, Bifidobacterium longum NCC3001,
Bifidobacterium longum 1714, Bifidobacterium bifidum W23, Bifidobacterium lactis
W52, Lactobacillus plantarum 299v
Stress Lactobacillus casei Shirota, Lactobacillus helveticus Rosell -52, Lactobacillusplantarum PS128, Bifidobacterium longum Rosell-175, Lactobacillus gasseri CP230 *
FGIDs
Lactobacillus plantarum 299v (DSM 9843), Escherichia coli DSM17252,
Bifidobacterium animalis DN-173, Saccharomyces boulardii CNCM I-745
Bifidobacterium infantis 35624, Lactobacillus rhamnosus NCIMB 30174, Lactobacillus
plantarum NCIMB 30173, Lactobacillus acidophilus NCIMB 30175, Enterococcus
faecium NCIMB 30176
* Para-psychobiotic-heat inactivated strain.
8. Conclusions
Our review suggests some involvements of GBA deregulation in the origin of disorders of the
brain and gut. We hypothesize that stem cell-host microbiome cross talk is potentially involved
in GBA disorders. Consequently, molecules mediating GBA signaling may constitute a grip point
for the development of diagnostic tools and personalized microbiota-based therapies. In addition,
novel treatment protocols based on new compounds interfering with gut derived metabolites as
well as small molecules and bioactive lipids playing roles in adult stem cell trafficking are awaiting
further developments.
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